U.S. patent application number 13/269882 was filed with the patent office on 2012-02-23 for renin inhibitors.
This patent application is currently assigned to Merck Frosst Canada Ltd.. Invention is credited to CHRISTOPHER I. BAYLY, Austin C. Chen, Daniel Dube, Laurence Dube, Michel Gallant, Erich L. Grimm, Patrick Lacombe, Dwight MacDonald, Daniel McKay, David A. Powell.
Application Number | 20120046293 13/269882 |
Document ID | / |
Family ID | 37668406 |
Filed Date | 2012-02-23 |
United States Patent
Application |
20120046293 |
Kind Code |
A1 |
BAYLY; CHRISTOPHER I. ; et
al. |
February 23, 2012 |
RENIN INHIBITORS
Abstract
The present invention relates to renin inhibitor compounds
having the structure ##STR00001## and their use in treating
cardiovascular events and renal insufficiency.
Inventors: |
BAYLY; CHRISTOPHER I.;
(Beaconsfield, CA) ; Chen; Austin C.; (San Diego,
CA) ; Dube; Daniel; (St. Lazare, CA) ; Dube;
Laurence; (Laval, CA) ; Gallant; Michel;
(Kirkland, CA) ; Lacombe; Patrick; (Montreal,
CA) ; MacDonald; Dwight; (L'lle Bizard, CA) ;
McKay; Daniel; (Milton, MA) ; Powell; David A.;
(Lansdale, PA) ; Grimm; Erich L.; (Baie d'Urfe,
CA) |
Assignee: |
Merck Frosst Canada Ltd.
Kirkland
CA
|
Family ID: |
37668406 |
Appl. No.: |
13/269882 |
Filed: |
October 10, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11988437 |
Jan 7, 2008 |
8063105 |
|
|
PCT/CA2006/001196 |
Jul 20, 2006 |
|
|
|
13269882 |
|
|
|
|
60702026 |
Jul 22, 2005 |
|
|
|
Current U.S.
Class: |
514/237.5 ;
514/255.01; 514/357; 514/506; 514/531; 514/563; 514/620; 514/622;
544/171; 544/176; 544/389; 546/337; 560/160; 560/45; 562/455;
564/161; 564/165; 564/174 |
Current CPC
Class: |
A61P 17/00 20180101;
C07D 207/27 20130101; C07C 323/12 20130101; A61P 25/00 20180101;
A61P 5/42 20180101; C07C 2601/04 20170501; C07D 213/56 20130101;
C07D 215/12 20130101; C07C 269/06 20130101; C07D 213/30 20130101;
A61P 25/28 20180101; A61P 9/04 20180101; C07C 317/18 20130101; C07C
317/22 20130101; C07C 317/28 20130101; A61P 9/12 20180101; A61P
15/10 20180101; A61P 25/22 20180101; C07D 213/64 20130101; A61P
9/00 20180101; A61P 27/06 20180101; A61P 9/10 20180101; A61P 11/00
20180101; A61P 43/00 20180101; C07C 2601/02 20170501; C07D 213/40
20130101; C07D 401/06 20130101; A61P 13/12 20180101; C07C 269/06
20130101; C07C 271/22 20130101 |
Class at
Publication: |
514/237.5 ;
564/174; 514/622; 564/161; 544/176; 562/455; 514/563; 560/45;
514/531; 546/337; 514/357; 560/160; 514/506; 544/389; 514/255.01;
544/171; 564/165; 514/620 |
International
Class: |
A61K 31/165 20060101
A61K031/165; C07D 295/192 20060101 C07D295/192; A61K 31/5375
20060101 A61K031/5375; A61K 31/196 20060101 A61K031/196; A61K
31/216 20060101 A61K031/216; C07D 213/56 20060101 C07D213/56; A61K
31/4425 20060101 A61K031/4425; A61K 31/4402 20060101 A61K031/4402;
C07C 271/48 20060101 C07C271/48; A61K 31/27 20060101 A61K031/27;
A61K 31/495 20060101 A61K031/495; C07D 295/205 20060101
C07D295/205; C07C 237/20 20060101 C07C237/20; A61P 9/12 20060101
A61P009/12; A61P 9/00 20060101 A61P009/00; A61P 9/10 20060101
A61P009/10; A61P 27/06 20060101 A61P027/06; A61P 25/00 20060101
A61P025/00; A61P 25/22 20060101 A61P025/22; A61P 15/10 20060101
A61P015/10; C07C 235/36 20060101 C07C235/36 |
Claims
1. A compound of formula I, or a pharmaceutically acceptable salt
thereof, or an optical isomer thereof, having the formula I
##STR00208## wherein, m is 1 or 2; n, in each instance in which it
occurs, is independently 0, 1 or 2; p, in each instance in which it
occurs, is independently 0, 1 or 2; X and X.sup.1 are each
independently selected from the group consisting of CH.sub.2, O,
and S(O).sub.p, provided that when both X and X.sup.1 are each
independently O or S(O).sub.p, m is 2; Y is selected from the group
consisting of N(R.sup.a), CH(R.sup.a), O, and S(O).sub.p; R.sup.1,
R.sup.3, and R.sup.a are each independently selected from the group
consisting of H, C.sub.1-C.sub.6alkyl and C.sub.2-C.sub.6alkenyl,
wherein the alkyl and alkenyl group is unsubstituted or substituted
with one, two, three or four substituents independently selected
from: 1) OH, 2) CN, 3) CF.sub.3, 4) COOH, 5) C.sub.1-C.sub.6alkoxy,
6) C(O)R.sup.b, 7) C(O)N(R.sup.c).sub.2, 8)
S(O).sub.pC.sub.1-C.sub.6alkyl, 9) SO.sub.2N(R.sup.c).sub.2, 10)
N(R.sup.c).sub.2, 11) NHC(O)R.sup.b, 12) NHC(O)NHR.sup.d, 13)
NHC(S)NHR.sup.d, 14) NH(NR.sup.c)NHR.sup.c, 15) tetrazolyl, and 16)
--(CH.sub.2).sub.1-2R.sup.e; R.sup.4 is selected from the group
consisting of H, C.sub.1-C.sub.6alkyl and C.sub.2-C.sub.6alkenyl,
wherein the alkyl and alkenyl group is unsubstituted or substituted
with one, two, three or four substituents independently selected
from: 1) OH, 2) CN, 3) CF.sub.3, 4) COOH, 5) C.sub.1-C.sub.6alkoxy,
6) C(O)R.sup.b, 7) C(O)N(R.sup.c).sub.2, 8)
S(O).sub.pC.sub.1-C.sub.6alkyl, 9) SO.sub.2N(R.sup.c).sub.2, 10)
N(R.sup.c).sub.2, 11) NHC(O)R.sup.b, 12) NHC(O)NHR.sup.d, 13)
NHC(S)NHR.sup.d, 14) NH(NR.sup.c)NHR.sup.c, and 15) tetrazolyl, or
R.sup.4, together with R.sup.5, forms a 5- or 6-membered
heterocyclic ring which is unsubstituted or mono- or di-substituted
with a substituent selected from the group consisting of .dbd.O and
C.sub.1-C.sub.6 alkyl; R.sup.5 is selected from the group
consisting of hydrogen and --C(NH(NH.sub.2), or R.sup.5, together
with R.sup.4, forms a 5- or 6-membered heterocyclic ring which is
unsubstituted or mono- or di-substituted with a substituent
selected from the group consisting of .dbd.O and C.sub.1-C.sub.6
alkyl; R.sup.2 and R.sup.b are independently selected from the
group consisting of H, C.sub.1-C.sub.6alkyl,
C.sub.2-C.sub.6alkenyl, C.sub.1-C.sub.6alkoxy, CF.sub.3 and
CH.sub.2CF.sub.3; R.sup.c is selected from the group consisting of
H, C.sub.1-C.sub.6alkyl and CH.sub.2CF.sub.3; R.sup.d is selected
from the group consisting of H and C.sub.1-C.sub.6alkyl, wherein
the alkyl group is unsubstituted or substituted with one, two,
three or four substituents selected from the group consisting of:
1) OH, 2) CN, 3) CF.sub.3, 4) COOH, and 5) C(O)NHR.sup.c, and 6)
tetrazolyl; R.sup.c is a 5- or 6-membered heteroaryl ring having 1
or 2 nitrogen atoms; Ar.sup.1 is an unsubstituted or substituted
aryl ring or an unsubstituted or substituted 5- or 6-membered
heteroaryl ring containing 1 to 3 heteroatoms selected from O, S
and N, wherein the substituted aryl ring and substituted heteroaryl
ring are substituted with one, two three or four substituents
independently selected from the group consisting of: 1) OH, 2) CN,
3) halogen, 4) N.sub.3, 5) NO.sub.2, 6) COOH, 7) OCF.sub.2H, 8)
CF.sub.3, 9) C.sub.1-C.sub.6alkyl, 10) C.sub.2-C.sub.6alkenyl, 11)
C.sub.1-C.sub.6alkoxy, 12) C(O)C.sub.1-C.sub.6alkyl, and 13)
S(O).sub.pC.sub.1-C.sub.6alkyl, wherein substituents (9)-(13) are
unsubstituted or substituted with one, two three or four
substituents independently selected from the group consisting of:
a) OH, b) COOH, c) CN, d) CF.sub.3, e) C.sub.1-C.sub.6alkoxy, f)
S(O).sub.pC.sub.1-C.sub.6alkyl; Ar.sup.2 is independently selected
from the group consisting of Ar.sup.1 and a 9- or 10-membered fused
bicyclic aryl or heteroaryl ring, wherein the fused bicyclic
heteroaryl contains 1 to 4 heteroatoms selected from O, S and N,
wherein the fused bicyclic aryl and heteroaryl are each
unsubstituted or substituted with one, two, three or four
substituents independently selected from the group consisting of:
1) OH, 2) CN, 3) halogen, 4) N.sub.3, 5) NO.sub.2, 6) COOH, 7)
OCF.sub.2H, 8) CF.sub.3, 9) C.sub.1-C.sub.6alkyl, unsubstituted or
substituted with Ar.sup.3, 10) C.sub.1-C.sub.6alkyl, 11)
C.sub.2-C.sub.6alkenyl, 12) C.sub.1-C.sub.6alkoxy, 13)
C(O)C.sub.1-C.sub.6alkyl, 14) S(O).sub.pC.sub.1-C.sub.6alkyl, 15)
--O(CH.sub.2).sub.1-2Ar.sup.3, 16) --O(CH.sub.2).sub.1-2D, 17)
--OC(O)D, 18) --OC(O)NH(C.sub.1-C.sub.6alkylene)C(O)NH.sub.2, and
19) --OC(O)NH(C.sub.1-C.sub.6alkylene)(OH)R.sup.d; wherein
substituents (10)-(14) are unsubstituted or substituted with one,
two three or four substituents independently selected from the
group consisting of: a) OH, b) COOR.sup.d, c) CN, d) CF.sub.3, e)
C.sub.1-C.sub.6alkoxy, f) S(O).sub.pC.sub.1-C.sub.6alkyl, g)
tetrazolyl h) --C(O)NH.sub.2, i) --COONa, j) --NR.sup.dR.sup.d, and
k) --NR.sup.dC(O)R.sup.d; Ar.sup.3 is an unsubstituted or
substituted aryl ring or an unsubstituted or substituted 5- or
6-membered heteroaryl ring containing 1 to 3 heteroatoms selected
from O, S and N, wherein the substituted aryl ring and substituted
heteroaryl ring are substituted with one, two three or four
substituents independently selected from the group consisting of:
1) OH, 2) CN, 3) OCF.sub.2H, 4) CF.sub.3, 5) C j 6)
C.sub.1-C.sub.3alkoxy, and 7) --SO.sub.2R.sup.d; and D is a 5- or
6-membered saturated heterocyclic ring having 1 or 2 nitrogen atoms
and 0 or 1 oxygen atoms, wherein the ring may be unsubstituted or
substituted with C.sub.1-C.sub.6alkyl.
2. A compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein Y is CH(R.sup.a) and R.sup.1 is H.
3. A compound of claim 2, or a pharmaceutically acceptable salt
thereof, wherein Y is CH(R.sup.a), R.sup.1 is H, and n is 1.
4. A compound of claim 3, or a pharmaceutically acceptable salt
thereof, wherein Y is CH.sub.2 or CH(CH.sub.2Ar.sup.3) and R.sup.2
is C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 alkenyl.
5. A compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 alkenyl.
6. A compound of claim 5, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is C.sub.3-C.sub.6cycloalkyl.
7. A compound of claim 1, or a pharmaceutically acceptable salt
thereof, selected from the group consisting of:
N-{3-[(Acetyl-methyl-amino)-methyl]-benzyl}-2-aminomethyl-N-cyclopropyl-3-
-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propionamide,
2-Aminomethyl-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethox-
y]-phenyl}-N-(1,2,3,4-tetrahydro-quinolin-8-ylmethyl)-propionamide,
2-Aminomethyl-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethox-
y]-phenyl}-N-quinolin-4-ylmethyl-propionamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-ben-
zyl}-N-(2,3-dimethyl-benzyl)-propionamide,
2-Aminomethyl-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethox-
y]-phenyl}-N-[3-(2-methanesulfonyl-ethyl)-benzyl]-propionamide,
5-(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-dichloro--
4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-pentanoic acid
methyl ester,
6-(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-di-
chloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-hexanoic
acid,
6-(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-dichloro--
4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-hexanoic acid methyl
ester,
N-Cyclopropyl-N-(2,3-dichloro-benzyl)-3-{4-[2-(2,6-dichloro-4-methyl-phen-
oxy)-ethoxy]-phenyl}-2-[(2,2,2-trifluoro-ethylamino)-methyl]-propionamide,
2-Aminomethyl-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethox-
y]-phenyl}-N-[3-(3-methoxy-propyl)-benzyl]-propionamide,
2-Aminomethyl-N-[2-chloro-5-(3-methoxy-propyl)-benzyl]-N-cyclopropyl-3-{4-
-[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propionamide,
2-[(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-dichloro-
-4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-methyl]-cyclopropanecarbox-
ylic acid,
2-[(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,-
6-dichloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-methyl]-cyclopro-
panecarboxylic acid ethyl ester,
2-Aminomethyl-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-c-
yclopropyl-N-[3-(3-methoxy-propyl)-benzyl]-propionamide,
2-Aminomethyl-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-[-
2-chloro-5-(3-methoxy-propyl)-benzyl]-N-cyclopropyl-propionamide,
3-Amino-N-cyclopropyl-N-(2,3-dichloro-benzyl)-2-{4-[2-(2,6-dichloro-4-met-
hyl-phenoxy)-ethyl]-benzyl}-propionamide,
2-Aminomethyl-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-c-
yclopropyl-N-(2,3-dichloro-benzyl)-2-methyl-propionamide,
3-Amino-N-cyclopropyl-N-(2,3-dichloro-benzyl)-2-{4-[2-(2,6-dichloro-4-met-
hyl-phenoxy)-ethoxy]-benzyl}-propionamide,
2-Aminomethyl-N-cyclopropyl-N-(2,3-dichloro-benzyl)-3-{4-[3-(2,6-dichloro-
-4-methyl-phenoxy)-propyl]-phenyl}-propionamide,
3-{4-[3-(2-Chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-cyclopropyl-N-(-
2,3-dichloro-benzyl)-2-methylaminomethyl-propionamide,
2-(Benzylamino-methyl)-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-ph-
enyl}-N-cyclopropyl-N-(2,3-dichloro-benzyl)-propionamide,
2-Aminomethyl-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-c-
yclopropyl-N-(2,3-dichloro-benzyl)-propionamide,
2-Aminomethyl-N-[2-chloro-5-(2-methoxy-ethyl)-benzyl]-N-cyclopropyl-3-{4--
[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propionamide,
Methyl
(2R)-2-{2-[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-[2-(2,6-dich-
loro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]ethyl}-3-methylbutan-
oate,
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethoxy]benzyl}-3-[(3R)-3-isopropyl-2-oxopyrrolidin-1-yl]propanamide-
, Methyl
(2S)-2-{2-[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{-4-[2-[2--
(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]ethyl}-3-me-
thylbutanoate,
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenox-
y)ethoxy]benzyl}-3-{[2-(2-napthyl)ethyl]amino}propanamide,
2-(Aminomethyl)-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethox-
y]phenyl}-N-(2,3-dimethylbenzyl)-4-pyridin-2-ylbutanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}butanamide,
3-Amino-N-[2-chloro-5-(3-hydroxypropyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-
-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethoxy)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-
-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{[6-(pyridin-4-ylmethyl)quinoline-8-yl]methyl}propanamide,
3-Amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-
-dichloro-4-methylphenoxy)ethyl]benzyl}propanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethyl]benzyl}propanamide,
3-Amino-N-{2-chloro-5-[3-(dimethylamino)propyl)benzyl}-N-cyclopropyl-2-{4-
-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-N-[2,3-dichloro-5-[3-methoxypropyl)benzyl}-2-{4-[2--
(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-N-[2,3-dichloro-5-[3-methoxypropyl)benzyl}-2-{4-[2--
(2,6-dichloro-4-methylphenoxy)ethyl]benzyl}propanamide,
3-Amino-N-{[6-(cyanomethyl)quinoline-8-yl]methyl}-N-cyclopropyl]-2-{4-[2--
(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{[2-(3-methoxypropyl)quinoline-4-yl]methyl}propanamide,
3-Amino-N-[2-chloro-5-(2-cyano
ethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]-
benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[5-(3-methoxypropyl)-2-methylbenzyl]propanamide,
3-Amino-N-[2-chloro-5-(2-cyanomethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-d-
ichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[5-(3-methoxyethyl)-2-methylbenzyl]propanamide,
3-Amino-N-[2,5-bis(trifluoromethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-dic-
hloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-{[6-(1-cyano-1-methylethyl)quinoline-8-yl]methyl}-N-cyclopropyl-
-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-(1-phenylethyl)propanamide,
3-Amino-N-benzyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-m-
ethylpropanamide,
3-Amino-N-benzyl-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)etho-
xy]benzyl}propanamide,
3-Amino-N-benzyl-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)etho-
xy]benzyl}-N-(2-phenylethyl)propanamide,
3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-methyl-N-(-
2-phenylethyl)propanamide,
3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-methyl-N-(-
1-phenylethyl)propanamide,
3-Amino-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy)etho-
xy]benzyl}-N-(2,2,2-trifluoroethyl)propanamide,
3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-methyl-N-(-
1-methyl-1-phenylethyl)propanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-(cyclopropyl)methyl)-2-{4-
-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-2-{4-[2-(2,6-dichloro-4-met-
hylphenoxy)ethoxy]benzyl}-N-methylpropanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-(cyclobutylmethyl)-2-{4-[-
2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-2-{4-[2-(2,6-dichloro-4-met-
hylphenoxy)ethoxy]benzyl}-N-isopropylpropanamide,
N-Allyl-3-amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-2-{4-[2-(2,6-dichlo-
ro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-cyclobutyl-2-{4-[2-(2,6-d-
ichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-2-{4-[2-(2,6-dichloro-4-met-
hylphenoxy)ethoxy]benzyl}-N-ethylpropanamide,
3-{[Amino(imino)methyl]amino}-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cy-
clopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
2-{[Amino(imino)methyl]amino}-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-{4-[-
2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
2-Amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-3-{4-[2-(2,6-
-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
2-{[Amino(imino)methyl]amino}-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cy-
clopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[3-hydroxy-5-(3-methoxypropyl)benzyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[3-(3-methoxypropyl)-5-(2-pyrrolidin-1-ylethoxy)benzyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[3-(3-methoxypropyl)-5-(pyridin-2-ylmethoxy)benzyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl]propanamide,
3-Amino-N-[3-(3-cyanopropoxy)-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2--
{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{3-(3-methoxypropyl)-5-[(3-methylthio)propoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{3-(3-methoxypropyl)-5-[(3-methylsulfonyl)propoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[3-(3-methoxypropyl)-5-(pyridin-3-ylmethoxy)benzyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[3-(3-methoxypropyl)-5-(pyridin-4-ylmethoxy)benzyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{3-(3-methoxypropyl)-5-[(1-oxidopyridin-2-yl)methoxy]benzyl}propanamid-
e,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benz-
yl}-N-{3-(3-methoxypropyl)-5-[(1-oxidopyridin-3-yl)methoxy]benzyl}propanam-
ide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]be-
nzyl}-N-{3-(3-methoxypropyl)-5-[(1-oxidopyridin-4-yl)methoxy]benzyl}propan-
amide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]-
benzyl}-N-[3-(3-methoxypropyl)-5-(2-pyridin-2-ylethoxy)benzyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{3-(3-methoxypropyl)-5-[2-(1-oxidopyridin-2-yl)ethoxy]benzyl}propanami-
de,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]ben-
zyl}-N-[3-(3-methoxypropyl)-5-(2-morpholin-4-ylmethoxy)benzyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[3-(3-methoxypropyl)-5-{[4-(methylsulfonyl)benzyl]oxy}benzyl)propanami-
de, Ethyl
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]be-
nzyl}propanoyl)
(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclopropane-
carboxylate, Sodium
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}prop-
anoyl)
(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclop-
ropanecarboxylate, Ethyl
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}prop-
anoyl)
(cyclopropyl)amino]methyl}-2-chloro-5-(3-methoxypropyl)phenoxy]meth-
yl}cyclopropanecarboxylate, Sodium
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}prop-
anoyl)
(cyclopropyl)amino]methyl}-2-chloro-5-(3-methoxypropyl)phenoxy]meth-
yl}cyclopropanecarboxylate, Ethyl
2-[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
noyl)
(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]-2-methylpropa-
noate, Sodium
2-[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
noyl)
(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]-2-methylpropa-
noate,
3-Amino-N-[3,5-bis(2-methoxyethoxy)benzyl]-N-cyclopropyl-2-{4-[2-(2-
,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-[3,5-bis(4,4,4-trifluorobutoxy)benzyl]-N-cyclopropyl-2-{4-[2-(2-
,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{3-(3-methoxypropyl)-5-[3-(1H-tetrazol-5-yl)propoxy]benzyl}propanamide-
,
3-Amino-N-{[5-chloro-2-(3-methoxypropyl)pyridin-4-yl]methyl}-N-cycloprop-
yl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-{[5-chloro-2-(3-methoxypropyl)-1-oxidopyridin-4-yl]methyl}-N-cy-
clopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{[2-methoxy-6-(3-methoxypropyl)pyridin-4-yl]methyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{[2-hydroxy-6-(3-methoxypropyl)pyridin-4-yl]methyl}propanamide,
3-Amino-N-{[2,6-bis(3-methoxypropyl)pyridin-4-yl]methyl}-N-cyclopropyl-2--
{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-({2-(3-methoxypropyl)-6-[3-(methylthio)propoxy]pyridin-4-yl}methyl}pro-
panamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)etho-
xy]benzyl}-N-({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]pyridin-4--
yl}methyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]-1-oxidopyridin-4-y-
l}methyl}propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-{[2-(3-methoxypropyl)-6-(2-morpholin-4-ylethoxy)pyridin-4-yl}methyl}pr-
opanamide,
3-Amino-N-[3-(2-amino-2-oxoethoxy)-5-(3-methoxypropyl)benzyl]-N-
-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanami-
de,
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
noyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
ethylcarbamate,
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoy-
l)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
morpholine-4-carboxylate,
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoy-
l)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)pheny
4-methylpiperazine-1-carboxylate,
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoy-
l)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
(3-amino-2,2-dimethyl-3-oxopropyl)carbamate,
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoy-
l)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
(2-hydroxypropyl)carbamate,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-(pyridin-4-ylmethyl)propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-(pyridin-3-ylmethyl)propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-(pyridin-2-ylmethyl)propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[(1-oxidopyridin-4-yl)methyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[(1-oxidopyridin-3-yl)methyl]propanamide,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[(1-oxidopyridin-2-yl)methyl]propanamide, Ethyl
3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoy-
l)(cyclopropyl)amino]methyl}-2-bromophenoxy)acetate, Ethyl
3-(3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
noyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)propanoate, Ethyl
5-(3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
noyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)pentanoate, Sodium
3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoy-
l)(cyclopropyl)amino]methyl}-2-bromophenoxy)acetate, Sodium
5-(3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
noyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)pentanoate,
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}-N-[3-(3-methoxypropyl)-5-(2-morpholin-4-yl-2-oxoethoxy)benzyl]propanamid-
e,
2-{4-[2-(4-Allyl-2,6-dichlorophenoxy)ethoxy]benzyl}-3-amino-N-2-chloro--
5-(3-methoxypropyl)benzyl]-N-cyclopropanamide, and
3-Amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2-(4-{2-[2,6-
-dichloro-4-(3-hydroxypropyl)phenoxy]ethoxy}benzyl}propanamide.
8. A pharmaceutical composition comprising an effective amount of a
compound according to claim 1, or a pharmaceutically acceptable
salt thereof, and a pharmaceutically acceptable carrier.
9. Use of a compound according to claim 1, or a composition
according to claim 8, for the manufacture of a medicament for the
treatment or prophylaxis of diseases which are related to
hypertension, congestive heart failure, pulmonary hypertension,
renal insufficiency, renal ischemia, renal failure, renal fibrosis,
cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis,
myocardial ischemia, cardiomyopathy, glomerulonephritis, renal
colic, complications resulting from diabetes such as nephropathy,
vasculopathy and neuropathy, glaucoma, elevated intra-ocular
pressure, atherosclerosis, restenosis post angioplasty,
complications following vascular or cardiac surgery, erectile
dysfunction, hyperaldosteronism, lung fibrosis, scleroderma,
anxiety, cognitive disorders, complications of treatments with
immunosuppressive agents, and other diseases known to be related to
the renin-angiotensin system.
10. A method for the treatment or prophylaxis of diseases which are
related to hypertension, congestive heart failure, pulmonary
hypertension, renal insufficiency, renal ischemia, renal failure,
renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac
fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis,
renal colic, complications resulting from diabetes such as
nephropathy, vasculopathy and neuropathy, glaucoma, elevated
intra-ocular pressure, atherosclerosis, restenosis post
angioplasty, complications following vascular or cardiac surgery,
erectile dysfunction, hyperaldosteronism, lung fibrosis,
scleroderma, anxiety, cognitive disorders, complications of
treatments with immunosuppressive agents, and other diseases known
to be related to the renin-angiotensin system, comprising the
administration to a patient of a pharmaceutically active amount of
a compound according to claim 1.
Description
JOINT RESEARCH AGREEMENT
[0001] The claimed invention was made as a result of activities
undertaken within the scope of a joint research agreement between
Merck & Co., Inc. and Actelion Pharmaceuticals Ltd. The
agreement was executed on Dec. 4, 2003. The field of the invention
is described below.
FIELD OF THE INVENTION
[0002] The invention relates to novel renin inhibitors of the
general formula (I). The invention also concerns related aspects
including processes for the preparation of the compounds,
pharmaceutical compositions containing one or more compounds of
formula (I) and especially their use as renin inhibitors in
cardiovascular events and renal insufficiency.
BACKGROUND OF THE INVENTION
[0003] In the renin-angiotensin system (RAS) the biologically
active angiotensin II (Ang II) is generated by a two-step
mechanism. The highly specific enzyme renin cleaves angiotensinogen
to angiotensin I (Ang I), which is then further processed to Ang II
by the less specific angiotensin-converting enzyme (ACE). Ang II is
known to work on at least two receptor subtypes called AT.sub.1 and
AT.sub.2. Whereas AT.sub.1 seems to transmit most of the known
functions of Ang II, the role of AT.sub.2 is still unknown.
[0004] Modulation of the RAS represents a major advance in the
treatment of cardiovascular diseases. ACE inhibitors and AT.sub.1
blockers have been accepted to treat hypertension (Waeber B. et
al., "The renin-angiotensin system: role in experimental and human
hypertension", in Birkenhager W. H., Reid J. L. (eds):
Hypertension, Amsterdam, Elsevier Science Publishing Co, 1986,
489-519; Weber M. A., Am. J. Hypertens., 1992, 5, 247S). In
addition, ACE inhibitors are used for renal protection (Rosenberg
M. E. et al., Kidney International, 1994, 45, 403; Breyer J. A. et
al., Kidney International, 1994, 45, S156), in the prevention of
congestive heart failure (Vaughan D. E. et al., Cardiovasc. Res.,
1994, 28, 159; Fouad-Tarazi F. et al., Am. J. Med., 1988, 84
(Suppl. 3A), 83) and myocardial infarction (Pfeffer M. A. et al.,
N. Engl. J. Med., 1992, 327, 669).
[0005] The rationale to develop renin inhibitors is the specificity
of renin (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The
only substrate known for renin is angiotensinogen, which can only
be processed (under physiological conditions) by renin. In
contrast, ACE can also cleave bradykinin besides Ang I and can be
by-passed by chymase, a serine protease (Husain A., J. Hypertens.,
1993, 11, 1155). In patients inhibition of ACE thus leads to
bradykinin accumulation causing cough (5-20%) and potentially
life-threatening angioneurotic edema (0.1-0.2%) (Israili Z. H. et
al., Annals of Internal Medicine, 1992, 117, 234). Chymase is not
inhibited by ACE inhibitors. Therefore, the formation of Ang II is
still possible in patients treated with ACE inhibitors. Blockade of
the AT.sub.1 receptor (e.g. by losartan) on the other hand
overexposes other AT-receptor subtypes (e.g. AT.sub.2) to Ang II,
whose concentration is significantly increased by the blockade of
AT.sub.1 receptors. In summary, renin inhibitors are expected to
demonstrate a different pharmaceutical profile than ACE inhibitors
and AT.sub.1 blockers with regard to efficacy in blocking the RAS
and in safety aspects.
[0006] Only limited clinical experience (Azizi M. et al., J.
Hypertens., 1994, 12, 419; Neutel J. M. et al., Am. Heart, 1991,
122, 1094) has been created with renin inhibitors because of their
insufficient oral activity due to their peptidomimetic character
(Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The clinical
development of several compounds has been stopped because of this
problem together with the high cost of goods. Only one compound
containing four chiral centers has entered clinical trials (Rahuel
J. et al., Chem. Biol., 2000, 7, 493; Mealy N. E., Drugs of the
Future, 2001, 26, 1139). Thus, renin inhibitors with good oral
bioavailability and long duration of action are required. Recently,
the first non-peptide renin inhibitors were described which show
high in vitro activity (Oether C. et al., Chem. Biol., 1999, 6,
127; Patent Application WO97/09311; Marki H. P. et al., Il Farmaco,
2001, 56, 21). However, the development status of these compounds
is not known.
[0007] The present invention relates to the identification of renin
inhibitors of a non-peptidic nature and of low molecular weight.
Described are orally active renin inhibitors of long duration of
action which are active in indications beyond blood pressure
regulation where the tissular renin-chymase system may be activated
leading to pathophysiologically altered local functions such as
renal, cardiac and vascular remodeling, atherosclerosis, and
possibly restenosis. So, the present invention describes these
non-peptidic renin inhibitors.
[0008] The compounds described in this invention represent a novel
structural class of renin inhibitors.
SUMMARY OF THE INVENTION
[0009] The present invention is directed to certain compounds and
their use in the inhibition of the renin enzyme, including
treatment of conditions known to be associated with the renin
system. The invention includes compounds of Formula I and
pharmaceutically acceptable salts thereof, or an optical isomer
thereof:
##STR00002##
wherein, [0010] m is 1 or 2; [0011] n, in each instance in which it
occurs, is independently 0, 1 or 2; [0012] p, in each instance in
which it occurs, is independently 0, 1 or 2; [0013] X and X.sup.1
are each independently selected from the group consisting of
CH.sub.2, O, and S(O).sub.p, provided that when both X and X.sup.1
are each independently O or S(O).sub.p, m is 2; [0014] Y is
selected from the group consisting of N(R.sup.a), CH(R.sup.a), O,
and S(O).sub.p; [0015] R.sup.1, R.sup.3, and R.sup.a are each
independently selected from the group consisting of H,
C.sub.1-C.sub.6alkyl and C.sub.2-C.sub.6alkenyl, wherein the alkyl
and alkenyl group is unsubstituted or substituted with one, two,
three or four substituents independently selected from: [0016] 1)
OH, [0017] 2) CN, [0018] 3) CF.sub.3, [0019] 4) COOH, [0020] 5)
C.sub.1-C.sub.6alkoxy, [0021] 6) C(O)R.sup.b, [0022] 7)
C(O)N(R.sup.c).sub.2, [0023] 8) S(O).sub.pC.sub.1-C.sub.6alkyl,
[0024] 9) SO.sub.2N(R.sup.c).sub.2, [0025] 10) N(R.sup.c).sub.2,
[0026] 11) NHC(O)R.sup.b, [0027] 12) NHC(O)NHR.sup.d, [0028] 13)
NHC(S)NHR.sup.d, [0029] 14) NH(NRC)NHR.sup.c, [0030] 15)
tetrazolyl, and [0031] 16) --(CH.sub.2).sub.1-2R.sup.e; [0032]
R.sup.4 is selected from the group consisting of H,
C.sub.1-C.sub.6alkyl and C.sub.2-C.sub.6alkenyl, wherein the alkyl
and alkenyl group is unsubstituted or substituted with one, two,
three or four substituents independently selected from: [0033] 1)
OH, [0034] 2) CN, [0035] 3) CF.sub.3, [0036] 4) COOH, [0037] 5)
C.sub.1-C.sub.6alkoxy, [0038] 6) C(O)R.sup.b, [0039] 7)
C(O)N(R.sup.c).sub.2, [0040] 8) S(O).sub.pC.sub.1-C.sub.6alkyl,
[0041] 9) SO.sub.2N(R.sup.c).sub.2, [0042] 10) N(R.sup.c).sub.2,
[0043] 11) NHC(O)R.sup.b, [0044] 12) NHC(O)NHR.sup.d, [0045] 13)
NHC(S)NHR.sup.d, [0046] 14) NH(NRC)NHR.sup.c, and [0047] 15)
tetrazolyl, or R.sup.4, together with R.sup.5, forms a 5- or
6-membered heterocyclic ring which is unsubstituted or mono- or
di-substituted with a substituent selected from the group
consisting of .dbd.O and C.sub.1-C.sub.6 alkyl; [0048] R.sup.5 is
selected from the group consisting of hydrogen and
--C(NH(NH.sub.2), or R.sup.5, together with R.sup.4, forms a 5- or
6-membered heterocyclic ring which is unsubstituted or mono- or
di-substituted with a substituent selected from the group
consisting of .dbd.O and C.sub.1-C.sub.6 alkyl; [0049] R.sup.2 and
R.sup.b are independently selected from the group consisting of H,
C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl,
C.sub.1-C.sub.6alkoxy, CF.sub.3 and CH.sub.2CF.sub.3; [0050]
R.sup.c is selected from the group consisting of H,
C.sub.1-C.sub.6alkyl and CH.sub.2CF.sub.3; [0051] R.sup.d is
selected from the group consisting of H and C.sub.1-C.sub.6alkyl,
wherein the alkyl group is unsubstituted or substituted with one,
two, three or four substituents selected from the group consisting
of: [0052] 1) OH, [0053] 2) CN, [0054] 3) CF.sub.3, [0055] 4) COOH,
and [0056] 5) C(O)NHR.sup.c, and [0057] 6) tetrazolyl; [0058]
R.sup.c is a 5- or 6-membered heteroaryl ring having 1 or 2
nitrogen atoms; [0059] Ar.sup.1 is an unsubstituted or substituted
aryl ring or an unsubstituted or substituted 5- or 6-membered
heteroaryl ring containing 1 to 3 heteroatoms selected from O, S
and N, wherein the substituted aryl ring and substituted heteroaryl
ring are substituted with one, two three or four substituents
independently selected from the group consisting of: [0060] 1) OH,
[0061] 2) CN, [0062] 3) halogen, [0063] 4) N.sub.3, [0064] 5)
NO.sub.2, [0065] 6) COOH, [0066] 7) OCF.sub.2H, [0067] 8) CF.sub.3,
[0068] 9) C.sub.1-C.sub.6alkyl, [0069] 10) C.sub.2-C.sub.6alkenyl,
[0070] 11) C.sub.1-C.sub.6alkoxy, [0071] 12)
C(O)C.sub.1-C.sub.6alkyl, and [0072] 13)
S(O).sub.pC.sub.1-C.sub.6alkyl, [0073] wherein substituents
(9)-(13) are unsubstituted or substituted with one, two three or
four substituents independently selected from the group consisting
of: [0074] a) OH, [0075] b) COOH, [0076] c) CN, [0077] d) CF.sub.3,
[0078] e) C.sub.1-C.sub.6alkoxy, [0079] f)
S(O).sub.pC.sub.1-C.sub.6alkyl; [0080] Ar.sup.2 is independently
selected from the group consisting of Ar.sup.1 and a 9- or 10
membered fused bicyclic aryl or heteroaryl ring, wherein the fused
bicyclic heteroaryl contains 1 to 4 heteroatoms selected from O, S
and N, wherein the fused bicyclic aryl and heteroaryl are each
unsubstituted or substituted with one, two, three or four
substituents independently selected from the group consisting of:
[0081] 1) OH, [0082] 2) CN, [0083] 3) halogen, [0084] 4) N.sub.3,
[0085] 5) NO.sub.2, [0086] 6) COOH, [0087] 7) OCF.sub.2H, [0088] 8)
CF.sub.3, [0089] 9) C.sub.1-C.sub.6alkyl, unsubstituted or
substituted with Ar.sup.3, [0090] 10) C.sub.1-C.sub.6alkyl, [0091]
11) C.sub.2-C.sub.6alkenyl, [0092] 12) C.sub.1-C.sub.6alkoxy,
[0093] 13) C(O)C.sub.1-C.sub.6alkyl, [0094] 14)
S(O).sub.pC.sub.1-C.sub.6alkyl, [0095] 15)
--O(CH.sub.2).sub.1-2Ar.sup.3, [0096] 16) --O(CH.sub.2).sub.1-2D,
[0097] 17) --OC(O)D, [0098] 18)
--OC(O)NH(C.sub.1-C.sub.6alkylene)C(O)NH.sub.2, and [0099] 19)
--OC(O)NH(C.sub.1-C.sub.6alkylene)(OH)R.sup.d; [0100] wherein
substituents (10)-(14) are unsubstituted or substituted with one,
two three or four substituents independently selected from the
group consisting of: [0101] a) OH, [0102] b) COOR.sup.d, [0103] c)
CN, [0104] d) CF.sub.3, [0105] e) C.sub.1-C.sub.6alkoxy, [0106] f)
S(O).sub.pC.sub.1-C.sub.6alkyl, [0107] g) tetrazolyl [0108] h)
--C(O)NH.sub.2, [0109] i) --COONa, [0110] j) --NR.sup.dR.sup.d, and
[0111] k) --NR.sup.dC(O)R.sup.d; [0112] Ar.sup.3 is an
unsubstituted or substituted aryl ring or an unsubstituted or
substituted 5- or 6-membered heteroaryl ring containing 1 to 3
heteroatoms selected from O, S and N, wherein the substituted aryl
ring and substituted heteroaryl ring are substituted with one, two
three or four substituents independently selected from the group
consisting of: [0113] 1) OH, [0114] 2) CN, [0115] 3) OCF.sub.2H,
[0116] 4) CF.sub.3, [0117] 5) C.sub.1-C.sub.3alkyl, [0118] 6)
C.sub.1-C.sub.3alkoxy, and [0119] 7) --SO.sub.2R.sup.d; and D is a
5- or 6-membered saturated heterocyclic ring having 1 or 2 nitrogen
atoms and 0 or 1 oxygen atoms, wherein the ring may be
unsubstituted or substituted with C.sub.1-C.sub.6alkyl.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0120] The compounds of Formula I above, and pharmaceutically
acceptable salts thereof, are renin inhibitors. The compounds are
useful for inhibiting renin and treating conditions such as
hypertension.
[0121] One embodiment of the invention relates to compounds of
Formula I, or a pharmaceutically acceptable salt thereof, wherein Y
is CH(R.sup.a), wherein R.sup.a is as originally defined. Within
this subset, all other variables are as originally defined.
[0122] Another embodiment of the invention relates to compounds of
Formula I, or a pharmaceutically acceptable salt thereof, wherein
R.sup.1 is H. Within this subset, all other variables are as
originally defined. Within another subset of this embodiment Y is
CH(R.sup.a), wherein R.sup.a is as originally defined and all other
variables are as originally defined.
[0123] Another embodiment of the invention relates to compounds of
Formula I, or a pharmaceutically acceptable salt thereof, wherein n
is 1. Within this subset, all other variables are as originally
defined. Within another subset of this embodiment Y is CH(R.sup.a),
wherein R.sup.a is as originally defined and all other variables
are as originally defined. Within another subset of this embodiment
Y is CH(R.sup.a), wherein R.sup.a is as originally defined, R.sup.1
is H and all other variables are as originally defined. Within
another subset of this embodiment R.sup.1 is H, Y is CH.sub.2 or
--CH(CH.sub.2Ar.sup.3), R.sup.2 is C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 alkenyl, and all other variables are as originally
defined Another embodiment of the invention relates to compounds of
Formula I, or a pharmaceutically acceptable salt thereof, wherein
R.sup.2 is C.sub.1-C.sub.6alkyl. Within this subset, all other
variables are as originally defined.
[0124] Another embodiment of the invention relates to compounds of
Formula I, or a pharmaceutically acceptable salt thereof, wherein
R.sup.2 is C.sub.3-C.sub.6cycloalkyl. Within this subset, all other
variables are as originally defined.
[0125] Specific examples of compounds of formula I, and
pharmaceutically acceptable salts thereof, include
[0126] The compounds represented by the structures shown above have
the following names: [0127] (i)
N-{3-[(Acetyl-methyl-amino)-methyl]-benzyl}-2-aminomethyl-N-cyclopropyl-3-
-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propionamide,
[0128] (ii)
2-Aminomethyl-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethox-
y]-phenyl}-N-(1,2,3,4-tetrahydro-quinolin-8-ylmethyl)-propionamide,
[0129] (iii)
2-Aminomethyl-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-
-ethoxy]-phenyl}-N-quinolin-4-ylmethyl-propionamide, [0130] (iv)
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-ben-
zyl}-N-(2,3-dimethyl-benzyl)-propionamide, [0131] (v)
2-Aminomethyl-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethox-
y]-phenyl}-N-[3-(2-methanesulfonyl-ethyl)-benzyl]-propionamide,
[0132] (vi)
5-(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-dich-
loro-4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-pentanoic acid
methyl ester, [0133] (vii)
6-(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-dichloro--
4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-hexanoic acid,
[0134] (viii)
6-(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-di-
chloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-hexanoic acid
methyl ester, [0135] (ix)
N-Cyclopropyl-N-(2,3-dichloro-benzyl)-3-{4-[2-(2,6-dichloro-4-methyl-phen-
oxy)-ethoxy]-phenyl}-2-[(2,2,2-trifluoro-ethylamino)-methyl]-propionamide,
[0136] (x)
2-Aminomethyl-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methyl-phenoxy)-ethox-
y]-phenyl}-N-[3-(3-methoxy-propyl)-benzyl]-propionamide, [0137]
(xi)
2-Aminomethyl-N-[2-chloro-5-(3-methoxy-propyl)-benzyl]-N-cyclopropyl-3-{4-
-[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propionamide,
[0138] (xii)
2-[(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-di-
chloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-methyl]-cyclopropane-
carboxylic acid, [0139] (xiii)
2-[(2-[Cyclopropyl-(2,3-dichloro-benzyl)-carbamoyl]-3-{4-[2-(2,6-dichloro-
-4-methyl-phenoxy)-ethoxy]-phenyl}-propylamino)-methyl]-cyclopropanecarbox-
ylic acid ethyl ester, [0140] (xiv)
2-Aminomethyl-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-c-
yclopropyl-N-[3-(3-methoxy-propyl)-benzyl]-propionamide, [0141]
(xv)
2-Aminomethyl-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-[-
2-chloro-5-(3-methoxy-propyl)-benzyl]-N-cyclopropyl-propionamide,
[0142] (xvi)
3-Amino-N-cyclopropyl-N-(2,3-dichloro-benzyl)-2-{4-[2-(2,6-dichloro-
-4-methyl-phenoxy)-ethyl]-benzyl}-propionamide, [0143] (xvii)
2-Aminomethyl-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-c-
yclopropyl-N-(2,3-dichloro-benzyl)-2-methyl-propionamide, [0144]
(xxiii)
3-Amino-N-cyclopropyl-N-(2,3-dichloro-benzyl)-2-{4-[2-(2,6-dichloro-4-met-
hyl-phenoxy)-ethoxy]-benzyl}-propionamide, [0145] (ixx)
2-Aminomethyl-N-cyclopropyl-N-(2,3-dichloro-benzyl)-3-{4-[3-(2,6-dichloro-
-4-methyl-phenoxy)-propyl]-phenyl}-propionamide, [0146] (xx)
3-{4-[3-(2-Chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-cyclopropyl-N-(-
2,3-dichloro-benzyl)-2-methylaminomethyl-propionamide, [0147] (xxi)
2-(Benzylamino-methyl)-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-ph-
enyl}-N-cyclopropyl-N-(2,3-dichloro-benzyl)-propionamide, [0148]
(xxii)
2-Aminomethyl-3-{4-[3-(2-chloro-3,6-difluoro-phenoxy)-propyl]-phenyl}-N-c-
yclopropyl-N-(2,3-dichloro-benzyl)-propionamide, and [0149] (xxiii)
2-Aminomethyl-N-[2-chloro-5-(2-methoxy-ethyl)-benzyl]-N-cyclopropyl-3-{4--
[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-phenyl}-propionamide.
[0150] The present invention also encompasses a pharmaceutical
formulation comprising a pharmaceutically acceptable carrier and
the compound of Formula I or a pharmaceutically acceptable crystal
form or hydrate thereof. A preferred embodiment is a pharmaceutical
composition of the compound of Formula I, comprising, in addition,
a second agent.
[0151] The compounds of the present invention may have chiral
centers, e.g. one chiral center (providing for two stereoisomers,
(R) and (S)), or two chiral centers (providing for up to four
stereoisomers, (R,R), (S,S), (R,S), and (S,R)). This invention
includes all of the optical isomers and mixtures thereof. Unless
specifically mentioned otherwise, reference to one isomer applies
to any of the possible isomers. Whenever the isomeric composition
is unspecified, all possible isomers are included.
[0152] Tautomers of compounds defined in Formula I are also
included within the scope of the present invention. For example,
compounds including carbonyl --CH.sub.2C(O)-- groups (keto forms)
may undergo tautomerism to form hydroxyl --CH.dbd.C(OH)-- groups
(enol forms). Both keto and enol forms are included within the
scope of the present invention.
[0153] In addition compounds with carbon-carbon double bonds may
occur in Z- and E-forms with all isomeric forms of the compounds
being included in the present invention.
LIST OF ABBREVIATIONS
[0154] ABTS 2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic Acid)
2NH.sub.3 [0155] Ac acetyl [0156] ADDP
1,1'-(azodicarbonyl)-dipiperidine [0157] AIBN
2,2'-azobis(2-methylpropionitrile) [0158] Boc t-butyloxycarbonyl
[0159] BSA bovine serum albumin [0160] DIBAL diisobutylaluminum
hydride [0161] DME dimethoxyethane [0162] DMF dimethylformamide
[0163] DMP Dess-Martin periodinane [0164] DMSO dimethylsulfoxide
[0165] EDTA ethylenediaminetetraacetic acid [0166] EIA enzyme
immunoassay [0167] HATU
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate [0168] LAH lithium aluminum hydride [0169] PBS
phosphate-buffered saline [0170] TBAF tetra-n-butylammonium
fluoride [0171] TBS tert-butyldimethylsilyl [0172] THF
tetrahydrofuran [0173] TBSO tert-butyldimethylsilyloxy
[0174] Embodiments of the method of the present invention include
those in which the compound of Formula I administered to the
subject is as defined in the compound embodiments, classes and
sub-classes set forth above.
[0175] As used herein except where noted, "alkyl" is intended to
include both branched- and straight-chain saturated aliphatic
hydrocarbon groups, and is intended to include the cyclic group
cycloalkyl, including all isomers, having the specified number of
carbon atoms. The term "cycloalkyl" means carbocycles containing no
heteroatoms. Examples of cycloalkyl include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl. Commonly used abbreviations
for alkyl groups are used throughout the specification, e.g. methyl
may be represented by "Me" or CH.sub.3, ethyl may be represented by
"Et" or CH.sub.2CH.sub.3, propyl may be represented by "Pr" or
CH.sub.2CH.sub.2CH.sub.3, butyl may be represented by "Bu" or
CH.sub.2CH.sub.2CH.sub.2CH.sub.3, etc. "C.sub.1-6 alkyl" (or
"C.sub.1-C.sub.6 alkyl") for example, means linear or branched
chain alkyl groups, including all isomers, having the specified
number of carbon atoms. C.sub.1-6 alkyl includes all of the hexyl
alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and
t-butyl, n- and isopropyl, ethyl and methyl. "C.sub.1-4 alkyl"
means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and
methyl. The term "alkylene" refers to both branched- and
straight-chain saturated aliphatic hydrocarbon groups, including
all isomers, having the specified number of carbons, and having two
terminal end chain attachments. For illustration, the term
"unsubstituted A-C.sub.4alkylene-B" represents
A-CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--B. The term "alkoxy"
represents a linear or branched alkyl group of indicated number of
carbon atoms attached through an oxygen bridge.
[0176] The term "alkenyl" includes both branched and straight chain
unsaturated hydrocarbon groups containing at least two carbon atoms
joined by a double bond. The alkene ethylene is represented, for
example, by "CH.sub.2CH.sub.2" or alternatively, by
"H.sub.2C.dbd.CH.sub.2". "C.sub.2-5 alkenyl" (or "C.sub.2-C.sub.5
alkenyl") for example, means linear or branched chain alkenyl
groups having from 2 to 5 carbon atoms and includes all of the
pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl,
1-propenyl, 2-propenyl, and ethenyl (or ethylenyl). Similar terms
such as "C.sub.2-3 alkenyl" have an analogous meaning.
[0177] Unless otherwise specifically noted as only "unsubstituted"
or only "substituted", alkyl, cycloalkyl, alkylene, alkoxy, and
alkenyl groups are unsubstituted or substituted with 1 to 3
substituents on each carbon atom, with halo, C.sub.1-C.sub.20
alkyl, CF.sub.3, NH.sub.2, N(C.sub.1-C.sub.6 alkyl).sub.2,
NO.sub.2, oxo, CN, N.sub.3, --OH, --O(C.sub.1-C.sub.6 alkyl),
C.sub.3-C.sub.10 cycloalkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, (C.sub.0-C.sub.6 alkyl) S(O).sub.0-2--,
(C.sub.0-C.sub.6 alkyl)S(O).sub.0-2(C.sub.0-C.sub.6 alkyl)-,
(C.sub.0-C.sub.6 alkyl)C(O)NH--, H.sub.2N--C(NH)--,
--O(C.sub.1-C.sub.6 alkyl)CF.sub.3, (C.sub.0-C.sub.6 alkyl)C(O)--,
(C.sub.0-C.sub.6 alkyl)OC(O)--, (C.sub.0-C.sub.6
alkyl)O(C.sub.1-C.sub.6 alkyl)-, (C.sub.0-C.sub.6
alkyl)C(O).sub.1-2(C.sub.0-C.sub.6 alkyl)-, (C.sub.0-C.sub.6
alkyl)OC(O)NH--, --NH(C.sub.1-C.sub.6
alkyl)NHC(O)NH(C.sub.1-C.sub.6 alkyl), --NHSO.sub.2NH.sub.2,
--NH(C.sub.1-C.sub.6 alkyl)NHSO.sub.2(C.sub.1-C.sub.6 alkyl),
--(C.sub.0-C.sub.6 alkyl)NHSO.sub.2(C.sub.1-C.sub.6 alkyl),
tetrazolyl, aryl, aralkyl, heterocycle, heterocyclylalkyl,
halo-aryl, halo-aralkyl, halo-heterocycle, halo-heterocyclylalkyl,
cyano-aryl, cyano-aralkyl, cyano-heterocycle and
cyano-heterocyclylalkyl.
[0178] The term "C.sub.0" as employed in expressions such as
"C.sub.0-6 alkyl" means a direct covalent bond. Similarly, when an
integer defining the presence of a certain number of atoms in a
group is equal to zero, it means that the atoms adjacent thereto
are connected directly by a bond. For example, in the structure
##STR00003##
wherein s is an integer equal to zero, 1 or 2, the structure is
##STR00004##
when s is zero.
[0179] The term "C.sub.3-8 cycloalkyl" (or "C.sub.3-C.sub.8
cycloalkyl") means a cyclic ring of an alkane having three to eight
total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, or cyclooctyl). The terms "C.sub.3-7
cycloalkyl", "C.sub.3-6 cycloalkyl", "C.sub.5-7 cycloalkyl" and the
like have analogous meanings.
[0180] The term "halogen" (or "halo") refers to fluorine, chlorine,
bromine and iodine (alternatively referred to as fluoro (F), chloro
(Cl), bromo (Br), and iodo (I)).
[0181] The term "C.sub.1-6 haloalkyl" (which may alternatively be
referred to as "C.sub.1-C.sub.6 haloalkyl" or "halogenated
C.sub.1-C.sub.6 alkyl") means a C.sub.1 to C.sub.6 linear or
branched alkyl group as defined above with one or more halogen
substituents. The term "C.sub.1-4 haloalkyl" has an analogous
meaning. The term "C.sub.1-6 fluoroalkyl" has an analogous meaning
except that the halogen substituents are restricted to fluoro.
Suitable fluoroalkyls include the series (CH.sub.2).sub.0-4CF.sub.3
(i.e., trifluoromethyl, 2,2,2-trifluoroethyl,
3,3,3-trifluoro-n-propyl, etc.).
[0182] The term "carbocycle" (and variations thereof such as
"carbocyclic" or "carbocyclyl") as used herein, unless otherwise
indicated, refers to (i) a C.sub.3 to C.sub.8 monocyclic, saturated
or unsaturated ring or (ii) a C.sub.7 to C.sub.12 bicyclic
saturated or unsaturated ring system. Each ring in (ii) is either
independent of, or fused to, the other ring, and each ring is
saturated or unsaturated. The carbocycle may be attached to the
rest of the molecule at any carbon atom which results in a stable
compound. The fused bicyclic carbocycles are a subset of the
carbocycles; i.e., the term "fused bicyclic carbocycle" generally
refers to a C.sub.7 to C.sub.10 bicyclic ring system in which each
ring is saturated or unsaturated and two adjacent carbon atoms are
shared by each of the rings in the ring system. A fused bicyclic
carbocycle in which one ring is saturated and the other is
saturated is a saturated bicyclic ring system. A fused bicyclic
carbocycle in which one ring is benzene and the other is saturated
is an unsaturated bicyclic ring system. A fused bicyclic carbocycle
in which one ring is benzene and the other is unsaturated is an
unsaturated ring system. Saturated carbocyclic rings are also
referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl,
etc. Unless otherwise noted, carbocycle is unsubstituted or
substituted with C.sub.1-6 alkyl, C.sub.1-6 alkenyl, C.sub.1-6
alkynyl, aryl, halogen, NH.sub.2 or OH. A subset of the fused
bicyclic unsaturated carbocycles are those bicyclic carbocycles in
which one ring is a benzene ring and the other ring is saturated or
unsaturated, with attachment via any carbon atom that results in a
stable compound. Representative examples of this subset include the
following:
##STR00005##
[0183] The term "aryl" refers to aromatic mono- and
poly-carbocyclic ring systems, wherein the individual carbocyclic
rings in the polyring systems are fused or attached to each other
via a single bond. Suitable aryl groups include phenyl, naphthyl,
and biphenylenyl.
[0184] The term "heterocycle" (and variations thereof such as
"heterocyclic" or "heterocyclyl") broadly refers to (i) a stable 4-
to 8-membered, saturated or unsaturated monocyclic ring, or (ii) a
stable 7- to 12-membered bicyclic ring system, wherein each ring in
(ii) is independent of, or fused to, the other ring or rings and
each ring is saturated or unsaturated, and the monocyclic ring or
bicyclic ring system contains one or more heteroatoms (e.g., from 1
to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O
and S and a balance of carbon atoms (the monocyclic ring typically
contains at least one carbon atom and the ring systems typically
contain at least two carbon atoms); and wherein any one or more of
the nitrogen and sulfur heteroatoms is optionally oxidized, and any
one or more of the nitrogen heteroatoms is optionally quaternized.
Unless otherwise specified, the heterocyclic ring may be attached
at any heteroatom or carbon atom, provided that attachment results
in the creation of a stable structure. Unless otherwise specified,
when the heterocyclic ring has substituents, it is understood that
the substituents may be attached to any atom in the ring, whether a
heteroatom or a carbon atom, provided that a stable chemical
structure results.
[0185] Unless otherwise specifically noted as only "unsubstituted"
or only "substituted", cycloalkyl, aryl and heterocycle groups are
unsubstituted or substituted. As used herein, the terms
"substituted C.sub.3-8 cycloalkyl", "substituted aryl" and
"substituted heterocycle" are intended to include the cyclic group
containing from 1 to 3 substituents in addition to the point of
attachment to the rest of the compound. Preferably, the
substituents are selected from the group which includes, but is not
limited to, halo, C.sub.1-C.sub.20 alkyl, CF.sub.3, NH.sub.2,
N(C.sub.1-C.sub.6 alkyl).sub.2, NO.sub.2, oxo, CN, N.sub.3, --OH,
--O(C.sub.1-C.sub.6 alkyl), C.sub.3-C.sub.10 cycloalkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, (C.sub.0-C.sub.6
alkyl) S(O).sub.0-2--, aryl-S(O).sub.0-2--, (C.sub.0-C.sub.6
alkyl)S(O).sub.0-2(C.sub.0-C.sub.6 alkyl)-, (C.sub.0-C.sub.6
alkyl)C(O)NH--, H.sub.2N--C(NH)--, --O(C.sub.1-C.sub.6
alkyl)CF.sub.3, (C.sub.0-C.sub.6 alkyl)C(O)--, (C.sub.0-C.sub.6
alkyl)OC(O)--, (C.sub.0-C.sub.6alkyl)O(C.sub.1-C.sub.6
alkyl)C(O).sub.1-2(C.sub.0-C.sub.6 (C.sub.0-C.sub.6
alkyl)OC(O)NH--, aryl, aralkyl, heteroaryl, heterocyclylalkyl,
halo-aryl, halo-aralkyl, halo-heterocycle, halo-heterocyclylalkyl,
cyano-aryl, cyano-aralkyl, cyano-heterocycle and
cyano-heterocyclylalkyl.
[0186] Saturated heterocyclics form a subset of the heterocycles;
i.e., the term "saturated heterocyclic" generally refers to a
heterocycle as defined above in which the entire ring system
(whether mono- or poly-cyclic) is saturated. The term "saturated
heterocyclic ring" refers to a 4- to 8-membered saturated
monocyclic ring or a stable 7- to 12-membered bicyclic ring system
which consists of carbon atoms and one or more heteroatoms selected
from N, O and S. Representative examples include piperidinyl,
piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl,
oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl,
thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or
tetrahydrofuranyl).
[0187] Heteroaromatics form another subset of the heterocycles;
i.e., the term "heteroaromatic" (alternatively "heteroaryl")
generally refers to a heterocycle as defined above in which the
entire ring system (whether mono- or poly-cyclic) is an aromatic
ring system. The term "heteroaromatic ring" refers a 5- or
6-membered monocyclic aromatic ring or a 7- to 12-membered bicyclic
which consists of carbon atoms and one or more heteroatoms selected
from N, O and S. In the case of substituted heteroaryl rings
containing at least one nitrogen atom (e.g., pyridine), such
substitutions can be those resulting in N-oxide formation.
Representative examples of heteroaromatic rings include pyridyl,
pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or
thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl,
tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl,
isothiazolyl, and thiadiazolyl.
[0188] Representative examples of bicyclic heterocycles include
benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl,
isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl,
isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoon
inolinyl isoquinolinyl, 2,3-dihydrobenzofuranyl,
2,3-dihydrobenzo-1,4-dioxinyl (i.e.,
##STR00006##
imidazo(2,1-b)(1,3)thiazole, (i.e.,
##STR00007##
and benzo-1,3-dioxolyl (i.e.,
##STR00008##
In certain contexts herein,
##STR00009##
is alternatively referred to as phenyl having as a substituent
methylenedioxy attached to two adjacent carbon atoms.
[0189] Unless expressly stated to the contrary, an "unsaturated"
ring is a partially or fully unsaturated ring. For example, an
"unsaturated monocyclic C.sub.6 carbocycle" refers to cyclohexene,
cyclohexadiene, and benzene.
[0190] Unless expressly stated to the contrary, all ranges cited
herein are inclusive. For example, a heterocycle described as
containing from "1 to 4 heteroatoms" means the heterocycle can
contain 1, 2, 3 or 4 heteroatoms.
[0191] When any variable occurs more than one time in any
constituent or in any formula depicting and describing compounds of
the invention, its definition on each occurrence is independent of
its definition at every other occurrence. Also, combinations of
substituents and/or variables are permissible only if such
combinations result in stable compounds.
[0192] The term "substituted" (e.g., as in "aryl which is
optionally substituted with one or more substituents . . . ")
includes mono- and poly-substitution by a named substituent to the
extent such single and multiple substitution (including multiple
substitution at the same site) is chemically allowed.
[0193] The term "hydrate" as used herein means a compound of the
invention or a salt thereof, that further includes a stoichiometric
or non-stoichiometric amount of water bound by non-covalent
intermolecular forces.
[0194] The term "clathrate" as used herein means a compound of the
invention or a salt thereof in the form of a crystal lattice that
contains spaces (e.g., channels) that have a guest molecule (e.g.,
a solvent or water) trapped within.
[0195] In compounds of the invention having pyridyl N-oxide
moieties, the pyridyl-N-oxide portion is structurally depicted
using conventional representations such as
##STR00010##
which have equivalent meanings.
[0196] For variable definitions containing terms having repeated
terms, e.g., (CR.sup.iR.sup.j).sub.r, where r is the integer 2,
R.sup.i is a defined variable, and R.sup.j is a defined variable,
the value of R.sup.i may differ in each instance in which it
occurs, and the value of R.sup.j may differ in each instance in
which it occurs. For example, if R.sup.i and R.sup.j are
independently selected from the group consisting of methyl, ethyl,
propyl and butyl, then (CR.sup.iR.sup.j).sub.2 can be
##STR00011##
[0197] Pharmaceutically acceptable salts include both the metallic
(inorganic) salts and organic salts; a list of which is given in
Remington's Pharmaceutical Sciences, 17th Edition, pg. 1418 (1985).
It is well known to one skilled in the art that an appropriate salt
form is chosen based on physical and chemical stability,
flowability, hydro-scopicity and solubility. As will be understood
by those skilled in the art, pharmaceutically acceptable salts
include, but are not limited to salts of inorganic acids such as
hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and
nitrate or salts of an organic acid such as malate, maleate,
fumarate, tartrate, succinate, citrate, acetate, lactate,
methanesulfonate, p-toluenesulfonate or palmoate, salicylate and
stearate. Similarly pharmaceutically acceptable cations include,
but are not limited to sodium, potassium, calcium, aluminum,
lithium and ammonium (especially ammonium salts with secondary
amines). Preferred salts of this invention for the reasons cited
above include potassium, sodium, calcium and ammonium salts. Also
included within the scope of this invention are crystal forms,
hydrates and solvates of the compounds of Formula I.
[0198] The compounds of Formula I can be administered in the form
of pharmaceutically acceptable salts. The term "pharmaceutically
acceptable salt" refers to a salt which possesses the effectiveness
of the parent compound and which is not biologically or otherwise
undesirable (e.g., is neither toxic nor otherwise deleterious to
the recipient thereof). Suitable salts include acid addition salts
which may, for example, be formed by mixing a solution of the
compound of the present invention with a solution of a
pharmaceutically acceptable acid such as hydrochloric acid,
sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
Certain of the compounds employed in the present invention carry an
acidic moiety (e.g., --COOH or a phenolic group), in which case
suitable pharmaceutically acceptable salts thereof can include
alkali metal salts (e.g., sodium or potassium salts), alkaline
earth metal salts (e.g., calcium or magnesium salts), and salts
formed with suitable organic ligands such as quaternary ammonium
salts. Also, in the case of an acid (--COOH) or alcohol group being
present, pharmaceutically acceptable esters can be employed to
modify the solubility or hydrolysis characteristics of the
compound.
[0199] The invention relates to a method for the treatment and/or
prophylaxis of diseases which are related to hypertension,
congestive heart failure, pulmonary hypertension, systolic
hypertension, renal insufficiency, renal ischemia, renal failure,
renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac
fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis,
renal colic, complications resulting from diabetes such as
nephropathy, vasculopathy and neuropathy, glaucoma, elevated
intra-ocular pressure, atherosclerosis, restenosis post
angioplasty, complications following vascular or cardiac surgery,
erectile dysfunction, hyperaldosteronism, lung fibrosis,
scleroderma, anxiety, cognitive disorders, complications of
treatments with immunosuppressive agents, and other diseases known
to be related to the renin-angiotensin system, which method
comprises administrating a compound as defined above to a human
being or animal.
[0200] In another embodiment, the invention relates to a method for
the treatment and/or prophylaxis of diseases which are related to
hypertension, congestive heart failure, pulmonary hypertension,
renal insufficiency, renal ischemia, renal failure, renal fibrosis,
cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis,
myocardial ischemia, cardiomyopathy, complications resulting from
diabetes such as nephropathy, vasculopathy and neuropathy.
[0201] In another embodiment, the invention relates to a method for
the treatment and/or prophylaxis of diseases, which are associated
with a dysregulation of the renin-angiotensin system as well as for
the treatment of the above-mentioned diseases.
[0202] The invention also relates to the use of compounds of
formula (I) for the preparation of a medicament for the treatment
and/or prophylaxis of the above-mentioned diseases.
[0203] Compounds of formula (I) or the above-mentioned
pharmaceutical compositions are also of use in combination with
other pharmacologically active compounds comprising ACE-inhibitors,
neutral endopeptidase inhibitors, angiotensin II receptor
antagonists, endothelin receptors antagonists, vasodilators,
calcium antagonists, potassium activators, diuretics,
sympatholitics, beta-adrenergic antagonists, alpha-adrenergic
antagonists or with other drugs beneficial for the prevention or
the treatment of the above-mentioned diseases.
[0204] The term "administration" and variants thereof (e.g.,
"administering" a compound) in reference to a compound of Formula I
mean providing the compound or a prodrug of the compound to the
individual in need of treatment or prophylaxis. When a compound of
the invention or a prodrug thereof is provided in combination with
one or more other active agents (e.g., an agent such as
anangiotensin II receptor antagonist, ACE inhibitor, or other
active agent which is known to reduce blood pressure),
"administration" and its variants are each understood to include
provision of the compound or prodrug and other agents at the same
time or at different times. When the agents of a combination are
administered at the same time, they can be administered together in
a single composition or they can be administered separately.
[0205] As used herein, the term "composition" is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combining the specified ingredients in the
specified amounts.
[0206] By "pharmaceutically acceptable" is meant that the
ingredients of the pharmaceutical composition must be compatible
with each other and not deleterious to the recipient thereof.
[0207] The term "subject" as used herein refers to an animal,
preferably a mammal, most preferably a human, who has been the
object of treatment, observation or experiment.
[0208] The term "effective amount" as used herein means that amount
of active compound or pharmaceutical agent that elicits the
biological or medicinal response in a tissue, system, animal or
human that is being sought by a researcher, veterinarian, medical
doctor or other clinician. In one embodiment, the effective amount
is a "therapeutically effective amount" for the alleviation of the
symptoms of the disease or condition being treated. In another
embodiment, the effective amount is a "prophylactically effective
amount" for prophylaxis of the symptoms of the disease or condition
being prevented. The term also includes herein the amount of active
compound sufficient to inhibit renin and thereby elicit the
response being sought (i.e., an "inhibition effective amount").
When the active compound (i.e., active ingredient) is administered
as the salt, references to the amount of active ingredient are to
the free form (i.e., the non-salt form) of the compound.
[0209] In a preferred embodiment, this amount is comprised between
1 mg and 1000 mg per day. In a particularly preferred embodiment,
this amount is comprised between 1 mg and 500 mg per day. In a more
particularly preferred embodiment, this amount is comprised between
1 mg and 200 mg per day.
[0210] In the method of the present invention (i.e., inhibiting
renin), the compounds of Formula I, optionally in the form of a
salt, can be administered by any means that produces contact of the
active agent with the agent's site of action. They can be
administered by any conventional means available for use in
conjunction with pharmaceuticals, either as individual therapeutic
agents or in a combination of therapeutic agents. They can be
administered alone, but typically are administered with a
pharmaceutical carrier selected on the basis of the chosen route of
administration and standard pharmaceutical practice. The compounds
of the invention can, for example, be administered orally,
parenterally (including subcutaneous injections, intravenous,
intramuscular, intrasternal injection or infusion techniques), by
inhalation spray, or rectally, in the form of a unit dosage of a
pharmaceutical composition containing an effective amount of the
compound and conventional non-toxic pharmaceutically-acceptable
carriers, adjuvants and vehicles. Liquid preparations suitable for
oral administration (e.g., suspensions, syrups, elixirs and the
like) can be prepared according to techniques known in the art and
can employ any of the usual media such as water, glycols, oils,
alcohols and the like. Solid preparations suitable for oral
administration (e.g., powders, pills, capsules and tablets) can be
prepared according to techniques known in the art and can employ
such solid excipients as starches, sugars, kaolin, lubricants,
binders, disintegrating agents and the like. Parenteral
compositions can be prepared according to techniques known in the
art and typically employ sterile water as a carrier and optionally
other ingredients, such as a solubility aid. Injectable solutions
can be prepared according to methods known in the art wherein the
carrier comprises a saline solution, a glucose solution or a
solution containing a mixture of saline and glucose. Further
description of methods suitable for use in preparing pharmaceutical
compositions for use in the present invention and of ingredients
suitable for use in said compositions is provided in Remington's
Pharmaceutical Sciences, 18.sup.th edition, edited by A. R.
Gennaro, Mack Publishing Co., 1990.
Assays Demonstrating Biological Activity
Inhibition of Human Recombinant Renin
[0211] The enzymatic in vitro assay was performed in 384-well
polypropylene plates (Nunc). The assay buffer consisted of PBS
(Gibco BRL) including 1 mM EDTA and 0.1% BSA. The reaction mixture
were composed of 47.5 .mu.L per well of an enzyme mix and 2.5 .mu.L
of renin inhibitors in DMSO. The enzyme mix was premixed at
4.degree. C. and consists of the following components: [0212] human
recombinant renin (40 pM) [0213] synthetic human angiotensin(1-14)
(0.5 .mu.M) [0214] hydroxyquinoline sulfate (1 mM) The mixtures
were then incubated at 37.degree. C. for 3 h. The enzyme reaction
was stopped by placing the reaction plate on wet ice.
[0215] To determine the enzymatic activity and its inhibition, the
accumulated Ang I was detected by an enzyme immunoassay (EIA) in
384-well plates (Nunc). 5 .mu.L of the reaction mixture or
standards were transferred to immuno plates which were previously
coated with a covalent complex of Ang I and bovine serum albumin
(Ang I-BSA). 75 .mu.L of Ang I-antibodies in assay buffer above
including 0.01% Tween 20 were added and the plates were incubated
at 4.degree. C. overnight.
[0216] An alternative protocol could be used by stopping the
enzymatic reaction with 0.02N final concentration of HCl. 5 .mu.L
of the reaction mixture or standards were transferred to immuno
plates and 75 .mu.L of Ang I-antibodies in assay buffer above
including 0.01% Tween 20 were added and the plates were incubate at
RT for 4 h.
[0217] The plates were washed 3 times with PBS including 0.01%
Tween 20, and then incubated for 2 h at RT with an anti
rabbit-peroxidase coupled antibody (WA 934, Amersham). After
washing the plates 3 times, the peroxidase substrate ABTS
((2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic Acid) 2NH.sub.3)
was added and the plates incubated for 60 min at RT. The plate was
evaluated in a microplate reader at 405 nm. The percentage of
inhibition was calculated for each concentration point and the
concentration of renin inhibition was determined that inhibited the
enzyme activity by 50% (IC.sub.50). The IC.sub.50-values of all
compounds tested were below 1 .mu.M.
Inhibition of Renin in Human Plasma
[0218] The enzymatic in vitro assay was performed in 384-well
polypropylene plates (Nunc). The assay buffer consisted of PBS
(Gibco BRL) including 1 mM EDTA and 0.1% BSA. The reaction mixture
was composed of 80 .mu.L per well of human plasma, enzyme, Ang
I-antibodies mix and 5 .mu.L of renin inhibitors in DMSO. The human
plasma mix was premixed at 4.degree. C. and consists of [0219]
human plasma from 10 normal donors [0220] human recombinant renin
(3 .mu.M) [0221] Ang I-antibodies. The mixtures were then incubated
at 37.degree. C. for 2 h.
[0222] To determine the enzymatic activity and its inhibition, the
accumulated Ang I was detected by an enzyme immunoassay (EIA) in
384-well plates (Nunc). 10 .mu.L of the reaction mixture or
standards were transferred to immuno plates which were previously
coated with a covalent complex of Ang I and bovine serum albumin
(Ang I-BSA). 70 pt assay buffer were added and the plates were
incubated at 4.degree. C. overnight. The plates were washed 3 times
with PBS including 0.01% Tween 20, and then incubated for 2 h at RT
with an anti rabbit-peroxidase coupled antibody (WA 934, Amersham).
After washing the plates 3 times, the peroxidase substrate ABTS
((2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic Acid) 2NH.sub.3)
was added and the plates incubated for 60 min at RT. The plate was
evaluated in a microplate reader at 405 nm. The percentage of
inhibition was calculated of each concentration point and the
concentration of renin inhibition was determined that inhibited the
enzyme activity by 50% (IC.sub.50). The IC.sub.50-values of all
compounds tested were below 10 .mu.M.
[0223] In vivo animal model--Female double transgenic rats were
purchased from RCC Ltd, Fullingsdorf, Switzerland. All animals were
maintained under identical conditions and had free access to normal
pelleted rat chow and water. Rats were initially treated with
enalapril (1 mg/kg/day) during 2 months. After approximately two
weeks following cessation of enalapril treatment the double
transgenic rats become hypertensive and reach mean arterial blood
pressures in the range of 160-170 mmHg.
[0224] Transmitter implantation--The rats were anaesthetised with a
mixture of 90 mg/kg Ketamin-HCl (Ketavet, Parke-Davis, Berlin FRG)
and 10 mg/kg xylazin (Rompun, Bayer, Leverkusen, FRG) i.p. The
pressure transmitter was implanted under aseptic conditions into
the peritoneal cavity with the sensing catheter placed in the
descending aorta below the renal arteries pointing upstream. The
transmitter was sutured to the abdominal musculature and the skin
closed.
[0225] Telemetry-System--Telemetry units were obtained from Data
Sciences (St. Paul, Minn.). The implanted sensor consisted of a
fluid-filled catheter (0.7 mm diameter, 8 cm long; model
TA11PA-C40) connected to a highly stable low-conductance
strain-gauge pressure transducer, which measured the absolute
arterial pressure relative to a vacuum, and a radio-frequency
transmitter. The tip of the catheter was filled with a viscous gel
that prevents blood reflux and was coated with an antithrombogenic
film to inhibit thrombus formation. The implants (length=2.5 cm,
diameter=1.2 cm) weighted 9 g and have a typical battery life of 6
months. A receiver platform (RPC-1, Data Sciences) connected the
radio signal to digitized input that was sent to a dedicated
personal computer (Compaq, deskpro). Arterial pressures were
calibrated by using an input from an ambient-pressure reference
(APR-1, Data Sciences). Systolic, mean and diastolic blood pressure
was expressed in millimeter of mercury (mmHg).
[0226] Hemodynamic measurements--Double transgenic rats with
implanted pressure transmitters were dosed by oral gavage with
vehicle or 10 mg/kg of the test substance (n=6 per group) and the
mean arterial blood pressure was continuously monitored. The effect
of the test substance is expressed as maximal decrease of mean
arterial pressure (MAP) in the treated group versus the control
group.
Methods of Synthesis
[0227] Compounds of the present invention can be made by a variety
of methods depicted in the illustrative synthetic reaction schemes
shown and described below. The starting materials and reagents used
in preparing these compounds generally are either available from
commercial suppliers, such as Aldrich Chemical Co., or are prepared
by methods known to those skilled in the art following procedures
set forth in references such as Fieser and Fieser's Reagents for
Organic Synthesis; Wiley & Sons: New York, Volumes 1-21; R. C.
LaRock, Comprehensive Organic Transformations, 2.sup.nd edition
Wiley-VCH, New York 1999; Comprehensive Organic Synthesis, B. Trost
and I. Fleming (Eds.) vol. 1-9 Pergamon, Oxford, 1991;
Comprehensive Heterocyclic Chemistry, A. R. Katritzky and C. W.
Rees (Eds) Pergamon, Oxford 1984, vol. 1-9; Comprehensive
Heterocyclic Chemistry II, A. R. Katritzky and C. W. Rees (Eds)
Pergamon, Oxford 1996, vol. 1-11; and Organic Reactions, Wiley
& Sons: New York, 1991, Volumes 1-40. The following synthetic
reaction schemes and examples are merely illustrative of some
methods by which the compounds of the present invention can be
synthesized, and various modifications to these synthetic reaction
schemes can be made and will be suggested to one skilled in the art
having referred to the disclosure contained in this
application.
[0228] The starting materials and the intermediates of the
synthetic reaction schemes can be isolated and purified if desired
using conventional techniques, including but not limited to,
filtration, distillation, crystallization, chromatography, and the
like. Such materials can be characterized using conventional means,
including physical constants and spectral data.
[0229] Unless specifically stated otherwise, the experimental
procedures were performed under the following conditions.
Evaporation of solvent was carried out using a rotary evaporator
under reduced pressure (600-4000 pascals: 4.5-30 mm Hg) with a bath
temperature of up to 60.degree. C. Reactions are typically run
under nitrogen atmosphere at ambient temperature if not otherwise
mentioned. Anhydrous solvent such as THF, DMF, Et.sub.2O, DME and
Toluene are commercial grade. Reagents are commercial grade and
were used without further purification. Flash chromatography is run
on silica gel (230-400 mesh). The course of the reaction was
followed by either thin layer chromatography (TLC) or nuclear
magnetic resonance (NMR) spectrometry and reaction times given are
for illustration only. The structure and purity of all final
products were ascertained by TLC, mass spectrometry, .sup.1H NMR
and high-pressure liquid chromatography (HPLC). Chemical symbols
have their usual meanings. The following abbreviations have also
been used: v (volume), w (weight), b.p. (boiling point), m.p.
(melting point), L (liter(s)), mL (milliliter(s)), g (gram(s)), mg
(milligram(s)), mol (mole(s)), mmol (millimole(s)), eq.
(equivalent(s)). Unless otherwise specified, all variables
mentioned below have the meanings as provided above.
[0230] Compounds of the present invention can be prepared according
to the following general methods as exemplified in Scheme I-II. For
example a Knoevenagel type condensation between cyanoacetate II and
appropriately substituted aldehyde III can provide
.alpha.,.beta.-unsaturated ester IV. Concomitant reduction of the
alkene and the cyano groups in IV can be accomplished stepwise or
in one step using hydrogenation or with reducing agents such as
CoCl.sub.2--NaBH.sub.4. The resulting saturated amine can be better
isolated after protection with for example an N--BOC to give
derivative V. Saponification of ester V and coupling of the
resulting acid with amine VI will provide protected aminoamide VII.
Finally, removal of the protecting group can provide the desired
aminoamide VIII. (Scheme 1).
##STR00012##
[0231] Alternatively, the sequence can be modified with the initial
coupling of amine VI with cyanoacetic acid IX to give amide
precursor X (Scheme 2). Subsequent Knoevenagel condensation with
substituted aldehyde III can deliver the .alpha.,.beta.-unsaturated
amide XI. Reduction of the double bond and nitrile group can be
accomplished using for example the CoCl.sub.2--NaBH.sub.4 reagent.
The resulting saturated amine is most conveniently isolated as the
N--BOC derivative VII. Finally, removal of the BOC protecting group
under acidic conditions furnishes the desired aminoamide VIII
##STR00013##
[0232] It is also possible to obtain the title compounds by
alkylation of cyanoamide X using a base such as potassium
hexamethyldisilazide with an appropriately substituted benzyl
halide XII (Scheme 3). The resulting cyanoamide can be further
alkylated with, for example, an alkyl halide to give the
corresponding disubstituted analog XIV.
##STR00014##
[0233] The 3-amino amide XXI can be built from the corresponding
3-pentenoate XVI by alkylation using a strong base and an
appropriate benzyl halide XII as described in Scheme 4. After the
amide formation, the double bond in XVIII can be cleaved by
ozonolysis followed by reduction to the primary alcohol XIX. The
latter could be transformed to the azide XX by, for example,
displacement of the corresponding mesylate. Reduction of azide
group to amine will then provide the desired product XXI.
##STR00015## ##STR00016##
[0234] The alpha-amino amide homologue XXIV can be built from
commercially available amino acid derivatives using standard
chemistry for alkylation of phenol and amide formation as
exemplified in Scheme 5.
##STR00017##
[0235] N-alkylation of aminoamide VIII, to afford the secondary
amine XXV, and the secondary amine precursors VI used in the amide
formation could be readily achieved via the reductive amination of
the corresponding aldehydes (Scheme 6).
##STR00018##
[0236] Conversion of the amine such as VIII into its corresponding
guanidine analogue XXVII could be affected through the use of
diimidothiotricarbonate XXVI (Scheme 7) followed by acid-promoted
deprotection.
##STR00019##
[0237] Introduction of a f3-substituent (i.e. XXIX) can be readily
accomplished, for example, via reaction of an organocuprate with
.alpha.,.beta.-unsaturated amide XI (Scheme 8). Subsequent
reduction of XXVIII using, for example the CoCl.sub.2--NaBH.sub.4
reagent, would afford the desired product XXIX.
##STR00020##
[0238] Inhibitors possessing a substituent a to the amino group
(i.e. XXXIII) can be accessed by alkylation of .beta.-ketoester XXX
(Scheme 9) with an appropriately substituted benzyl halide XII in
the presence of a base such as potassium hexamethyldisilazide.
Conversion of the resulting ester XXXI intoo .beta.-ketoamide XXXII
and its subsequent reductive amination with ammonium acetate is one
way of synthesizing the desired aminoamide XXXIII.
##STR00021##
[0239] The aldehydes used in the preparation of VI can be obtained
from the corresponding bromobenzoate XXXV (Scheme 10). Suzuki type
coupling of XXXV with for example borane XXXIV can afford ester
XXXVI. The desired aldehydes XXXVII can be obtained by direct
reduction of the ester using DIBAL or via a two-step sequence, for
example a reduction with LAH followed by oxidation with Dess-Martin
periodinane (DMP).
##STR00022##
[0240] Aldehyde of type XL with a methoxyethyl chain can also be
prepared from the corresponding bromobenzoate XXXV (Scheme 11). For
example, a copper mediated Grignard displacement with allylbromide
can furnish alkene XXXVIII. Its ozonolysis followed by a reductive
workup can provide alcohol XXXIX. Subsequent methylation with
iodomethane and reduction of the ester with LAH and then oxidation
can deliver the desired aldehyde XL.
##STR00023##
[0241] Alternatively, the aldehydes like XLIII can be prepared from
the corresponding iodo or bromo phenyl using palladium-catalyzed
carbonylation (Scheme 12). In this example, the nucleophilic
displacement of iodobenzyl bromide XLI by methylsulfone salt
provides the methylsulfone XLII. Subsequent reductive
palladium-catalyzed carbonylation with carbon monoxide affords the
desired aldehyde XLIII.
##STR00024##
[0242] Formylation using DMF from lithium halogen exchange of a
bromo or iodo phenyl analog is another strategy for the synthesis
of, for example, aldehyde XLV or XLVII (Scheme 13). Starting with
dibromophenyl analogue such as XLVI would allow for
palladium-mediated elaboration of the aryl bromide obtained
following formylation to give, for example, XLVIII.
##STR00025##
[0243] Radical bromination of a benzyl analog such as XLIX followed
by oxidation would constitute another approach to the synthesis of
the desired aldehyde LI (Scheme 14).
##STR00026##
[0244] The requisite benzyl amine VI can also be prepared in two
steps from the corresponding acid or acid chloride (Scheme 15). The
intermediate amide LII is readily reduced to the amine using for
example, a reagent such as borane.
##STR00027##
[0245] The aryl aldehydes LV, can be assembled as depicted in
Scheme 16. The substituted phenol can be heated neat at 150.degree.
C. with ethylene carbonate and imidazole to deliver the alcohol
LIII. Subsequent coupling with 4-hydroxybenzaldehyde under typical
Mitsunobu type conditions then can afford aldehyde LV.
Alternatively, the requisite aldehydes can be obtained via
sequential etherification and palladium-catalyzed reductive
carbonylation of alcohol LIV.
##STR00028##
[0246] The cyclopropylamine building blocks in Table 1 were
synthesized as follows.
TABLE-US-00001 TABLE 1 Compound Structure Amine 1 ##STR00029##
Amine 2 ##STR00030## Amine 3 ##STR00031## Amine 4 ##STR00032##
Amine 5 ##STR00033## Amine 6 ##STR00034## Amine 7 ##STR00035##
Amine 8 ##STR00036## Amine 9 ##STR00037## Amine 10 ##STR00038##
Amine 11 ##STR00039## Amine 12 ##STR00040## Amine 13 ##STR00041##
Amine 14 ##STR00042## Amine 15 ##STR00043## Amine 16 ##STR00044##
Amine 17 ##STR00045## Amine 18 ##STR00046## Amine 19 ##STR00047##
Amine 20 ##STR00048## Amine 21 ##STR00049## Amine 22 ##STR00050##
Amine 23 ##STR00051## Amine 24 ##STR00052## Amine 25 ##STR00053##
Amine 26 ##STR00054## Amine 27 ##STR00055## Amine 28 ##STR00056##
Amine 29 ##STR00057## Amine 30 ##STR00058## Amine 31 ##STR00059##
Amine 32 ##STR00060## Amine 33 ##STR00061## Amine 34 ##STR00062##
Amine 35 ##STR00063## Amine 36 ##STR00064## Amine 37 ##STR00065##
Amine 38 ##STR00066## Amine 39 ##STR00067## Amine 40 ##STR00068##
Amine 41 ##STR00069## Amine 42 ##STR00070## Amine 43 ##STR00071##
Amine 44 ##STR00072## Amine 45 ##STR00073## Amine 46 ##STR00074##
Amine 47 ##STR00075## Amine48 ##STR00076## Amine 49 ##STR00077##
Amine 50 ##STR00078## Amine 51 ##STR00079##
Amine 1
N-(2,3-Dimethylbenzyl)cyclopropanamine
[0247] A mixture of 2,3-dimethylbenzaldehyde (1 eq.),
cyclopropylamine (1.2 eq.) and sodium bicarbonate (1.5 eq.) were
heated at reflux in MeOH (0.5 M) for 1 h. The reaction mixture was
then cooled in ice and sodium borohydride (1.2 eq.) was introduced
portionwise. Following the completion of addition, the reaction
mixture was warmed to RT and stirred at RT for 1 h. The volatiles
were then removed in vacuo and the resulting residue was
partitioned between H.sub.2O and CH.sub.2Cl.sub.2. The organic
layer was separated, washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded the title
compound as a light yellow oil.
Amine 2
N-(2,3-Dichlorobenzyl)cyclopropanamine
[0248] Amine 2 was prepared according to the procedure described in
Amine 1, but using instead 2,3-dichlorobenzaldehyde as the starting
aldehyde. Purification of the crude product by way of flash
chromatography (SiO.sub.2, 98:2.fwdarw.1:1 (v/v) Hex:EtOAc)
afforded the title compound as a colorless oil.
Amine 3
N-(Quinolin-4-ylmethyl)cyclopropanamine
[0249] A mixture of 4-quinolinecarboxaldehyde (1 eq.),
cyclopropylamine (1 eq.) and sodium cyanoborohydride (1.5 eq.) were
combined in MeOH (0.2 M). At 0.degree. C., acetic acid (3 eq.) was
added dropwise and the reaction mixture was slowly warmed to RT
over 16 h. The reaction mixture was then diluted with ether and
quenched with 1N aq. NaOH. The aqueous layer was separated and
back-extracted with ether. The combined organic extracts were then
washed with water and brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded a purple residue.
Purification of the crude product thus obtained by way of flash
chromatography (SiO.sub.2, 98:2 (v/v) CH.sub.2Cl.sub.2: 2 M
NH.sub.3 in MeOH) afforded the title compound as a viscous, yellow
oil.
Amine 4
N-(Quinolin-8-ylmethyl)cyclopropanamine
[0250] Amine 4 was prepared according to the procedure described in
Amine 3, but using instead 8-quinolinecarboxaldehyde as the
starting material. The title compound was isolated as a viscous,
yellow oil.
Amine 5
N-[3-(3-Methoxypropyl)benzyl]cyclopropanamine
Step 1: Ethyl 3-(3-methoxypropyl)benzoate
[0251] To a THF solution (0.1 M) of allyl methyl ether (1.4 eq.)
was added, at 0.degree. C., 9-borabicyclo[3.3.1]nonane (2.4 eq.)
over a period of 30 min. The solution was stirred at 0.degree. C.
for 1 h and then warmed slowly to RT over 16 h. To the resulting
clear solution was then added sodium methoxide (2.4 eq.),
Cl.sub.2Pd(dppf)-dichloromethane complex (5% loading) and ethyl
3-bromobenzoate (1 eq.). The now brown suspension was heated to
reflux for 16 h. The reaction mixture was cooled to RT, quenched
with sat. aq. NH.sub.4Cl and extracted with ether. The combined
organic extracts were washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded a brown
oil. Purification of the crude product thus obtained by way of
flash chromatography (SiO.sub.2, Hex.fwdarw.4:1 (v/v) Hex:EtOAc)
afforded the title compound as a light yellow oil.
Step 2: [3-(3-Methoxypropyl)phenyl]methanol
[0252] To a THF solution (0.2 M) of ethyl
3-(3-methoxypropyl)benzoate from the previous step (1 eq.) was
added lithium aluminum hydride (1.0 M THF solution, 5 eq.) at
0.degree. C. over a period of 20 min. The resulting suspension was
stirred at 0.degree. C. for 1 h and then at RT for 1 h. The
reaction was quenched, at 0.degree. C., with the dropwise addition
of H.sub.2O and then 1 N aq. NaOH. The biphasic mixture was allowed
to stir at RT for 10 min, poured into H.sub.2O and extracted with
ether. The combined organic extracts were washed with brine, dried
over MgSO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded a cloudy oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 7:3 (v/v)
Hex:EtOAc) afforded the title compound as a colorless oil.
Step 3: 3-(3-Methoxypropyl)benzaldehyde
[0253] To a CH.sub.2Cl.sub.2 solution (0.3 M) of
[3-(3-methoxypropyl)phenyl]methanol from the previous step (1 eq.)
was added Dess-Martin periodinane (1.2 eq.). The resulting
suspension was stirred at RT for 2 h. The reaction was quenched
with sat. aq. NaHCO.sub.3 and 2 N aq. Na.sub.2S.sub.2O.sub.3. The
biphasic mixture was allowed to stir at RT for 20 min, poured into
sat. aq. NaHCO.sub.3 and extracted with CH.sub.2Cl.sub.2. The
combined organic extracts were washed with brine, dried over
MgSO.sub.4 and filtered. Concentration of the filtrate in vacuo
afforded a cloudy oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, Hex.fwdarw.7:3
(v/v) Hex:EtOAc) afforded the title compound as a colorless
oil.
Step 4
Amine 5
[0254] Amine 5 was prepared according to the procedure described in
Amine 3, but using instead 3-(methoxypropyl)benzaldehyde from the
previous step as the starting material. The title compound was
isolated as a colorless oil.
Amine 6
N-[2-Chloro-5-(3-methoxypropyl)benzyl]cyclopropanamine
[0255] Amine 6 was prepared according to the reaction sequence
described for Amine 5, but using instead ethyl
5-bromo-2-chlorobenzoate as the starting material. The title
compound was isolated as a colorless oil.
Amine 7
N-[2-Chloro-5-(2-methoxyethyl)benzyl]cyclopropanamine
Step 1: tert-Butyl 5-bromo-2-chlorobenzoate
[0256] 5-bromo-2-chlorobenzoic acid (1 eq.) and anhydrous DMF (1.2
eq.) was taken up in toluene (0.9 M). To this was then added,
dropwise over 5 min, oxalyl chloride (1.2 eq.) and the reaction
mixture was stirred at RT for 1 h. The volatiles were then removed
in vacuo and the resulting residue was taken up in toluene (0.9 M).
At 0.degree. C., potassium tert-butoxide (2.5 eq.) was added and
the reaction mixture was stirred at RT for 1 h. The reaction
mixture was poured into H.sub.2O and extracted with ether. The
combined organic extracts were washed with brine, dried over
MgSO.sub.4 and filtered. Concentration of the filtrate in vacuo
afforded a pale yellow oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2,
Hex.fwdarw.85:15 (v/v) Hex:EtOAc) afforded the title compound as a
light yellow oil.
Step 2: tert-Butyl 5-allyl-2-chlorobenzoate
[0257] At 0.degree. C., isobutylmagnesium bromide (2.0 M ether
solution, 1.2 eq.) and n-butyl lithium (2.5 M hexane solution, 2.4
eq.) were added to anhydrous THF (0.3 M). After stirring at
0.degree. C. for 30 min, the reaction mixture was cooled to
-40.degree. C. and tert-butyl 5-bromo-2-chlorobenzoate from the
previous step (1 eq.) was added over 15 min. The now red solution
was stirred at -40.degree. C. for 1 h before copper (I) cyanide
(30% loading) was added. The resulting suspension was stirred at
-40.degree. C. for 15 min and then added allyl bromide (3 eq.).
After stirring at -40.degree. C. for another 2 h, the reaction
mixture was quenched with sat. aq. NH.sub.4Cl and warmed to RT. The
biphasic mixture was poured into more sat. aq. NH.sub.4Cl and
extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4 and filtered. Concentration of
the filtrate in vacuo afforded a brown oil. Purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.19:1 (v/v) Hex:ether) afforded the title
compound as a light yellow oil.
Step 3: tert-Butyl 2-chloro-5-(2-hydroxyethyl)benzoate
[0258] To a solution of tert-butyl 5-allyl-2-chlorobenzoate from
the previous step (1 eq.) in CH.sub.2Cl.sub.2 (0.4 M) was bubbled,
at -78.degree. C., freshly generated ozone until a persistent blue
color was obtained. The reaction solution was stirred at
-78.degree. C. for a further 1 h before sodium borohydride (2 eq.)
in (0.4 M) MeOH was added. The resulting mixture was warmed to RT
and stirred at RT for 1 h. The reaction mixture was diluted with
sat. aq. NaHCO.sub.3 and extracted with ether. The combined organic
extracts were washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded a
colorless oil. Purification of the crude product thus obtained by
way of flash chromatography (SiO.sub.2, 4:1.fwdarw.1:1 (v/v)
Hex:EtOAc) afforded the title compound as a colorless oil.
Step 4: tert-Butyl 2-chloro-5-(2-methoxyethyl)benzoate
[0259] To a suspension of sodium hydride (60% w/w dispersion in
oil, 2 eq.) in anhydrous THF (0.23 M) was added tert-butyl
2-chloro-5-(2-hydroxyethyl)benzoate from the previous step (1 eq.).
The reaction mixture was heated at reflux for 30 min before
iodomethane (7.9 eq.) was added. After carefully quenching with
sat. aq. NaHCO.sub.3, the resulting mixture was extracted with
ether. The combined organic extracts were washed with brine, dried
over MgSO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded a cloudy oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2,
Hex.fwdarw.85:15 (v/v) Hex:EtOAc) afforded the title compound as a
colorless oil.
Step 5: [2-Chloro-5-(2-methoxyethyl)phenyl]methanol
[0260] To a solution of tert-butyl
2-chloro-5-(2-methoxyethyl)benzoate from the previous step (1 eq.)
in anhydrous THF (0.26 M) was added, at 0.degree. C., lithium
aluminum hydride (1.0 M THF solution, 3 eq.). The resulting
suspension was stirred at 0.degree. C. for 1 h and then at RT for 1
h. After carefully quenching with EtOAc and H.sub.2O, sat. aq.
sodium potassium tartrate was added. The resulting biphasic mixture
was vigorously stirred at RT for 30 min and then extracted with
ether. The combined organic extracts were washed with brine, dried
over MgSO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded a cloudy oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2,
90:10.fwdarw.70:30 (v/v) Hex:EtOAc) afforded the title compound as
a colorless oil.
Step 6: 2-Chloro-5-(2-methoxyethyl)benzaldehyde
[0261] To a solution of [2-chloro-5-(2-methoxyethyl)phenyl]methanol
from the previous step (1 eq.) in CH.sub.2Cl.sub.2 (0.4 M) was
added Dess-Martin periodinane (1.2 eq.) portionwise. The resulting
suspension was stirred at RT for 2 h. The reaction was quenched
with sat. aq. NaHCO.sub.3 and sat. aq. NaHSO.sub.3. The biphasic
mixture was allowed to stir at RT for 20 min before it was
extracted with CH.sub.2Cl.sub.2. The combined organic extracts were
washed with brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded a colorless oil.
Purification of the crude product thus obtained by way of flash
chromatography (SiO.sub.2, Hex.fwdarw.9:1 (v/v) Hex:EtOAc) afforded
the title compound as a colorless oil.
Step 7
Amine 7
[0262] Amine 7 was prepared according to the procedure described in
Amine 3, but using instead 2-chloro-5-(2-methoxyethyl)benzaldehyde
from the previous step as the starting material. The title compound
was isolated as a colorless oil.
Amine 8
N-{3-[2-(Methylsulfonyl)ethyl]benzyl}cyclopropanamine
Step 1: 2-(3-Iodophenyl)ethyl methyl sulfone
[0263] To a solution of dimethyl sulfone (1 eq.) in 60 mL of
anhydrous THF (0.2 M) was added, at -78.degree. C., n-butyl lithium
(1.6 M hexane solution, 1.2 eq.) over a period of 10 min. The
resulting mixture was stirred at -78.degree. C. for 1 h. To the now
yellow solution was added, at -78.degree. C., 3-iodobenzyl bromide
(1 eq.). The reaction mixture was then slowly warmed to RT over 16
h. The reaction was carefully quenched with 10% aq. HCl and
extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4 and filtered. Concentration of
the filtrate in vacuo afforded a viscous oil. Purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.1:1 (v/v) Hex:EtOAc) followed by trituration
with hexanes afforded the title compound as a white crystalline
solid.
Step 2: 3-[2-(Methylsulfonyl)ethyl]benzaldehyde
[0264] To a solution of 2-(3-iodophenyl)ethyl methyl sulfone from
the previous step (1 eq.) in anhydrous, deoxygenated DMF (0.5 M)
was added freshly-dried sodium formate (1.5 eq.) and
Pd(PPh.sub.3)Cl.sub.2 (2% loading). Through the resulting yellow
suspension, was bubbled CO and then reaction was heated to
95.degree. C. for 6 h. The now black reaction suspension was cooled
to RT, diluted with water, and extracted with ether. The combined
organic extracts were washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded an orange
semi-solid. Purification of the crude product thus obtained by way
of flash chromatography (SiO.sub.2, 1:1 (v/v) Hex:EtOAc) afforded
the title compound as a colorless oil.
Step 3: Amine 8
[0265] Amine 8 was prepared according to the procedure described in
Amine 3, but using instead 3-[2-(methylsulfonyl)ethyl]benzaldehyde
from the previous step as the starting material. The title compound
was isolated as a colorless oil.
Amine 9
N-{3-[(Cyclopropylamino)methyl]benzyl}-N-methylacetamide
Step 1: N-(3-Bromobenzyl)-N-methylacetamide
[0266] To a DMF (0.1 M) solution of 3-bromo-N-methylbenzylamine (1
eq.), Hunig's base (3 eq) and 4-(dimethylamino)pyridine (5%
loading) was added acetyl chloride (1.5 eq). The resulting reaction
mixture was stirred at RT for 16 h. After quenching the reaction
with sat. aq. NaHCO.sub.3, the mixture was extracted with EtOAc.
The organic extract was washed with 10% aq. HCl, sat. aq.
NaHCO.sub.3, and brine. Drying over Na.sub.2SO.sub.4, filtration
and concentration of the filtrate in vacuo afforded the crude
product as a yellow oil. Purification by way of flash
chromatography (SiO.sub.2, 4:1 (v/v) Hex:EtOAc.fwdarw.EtOAc)
afforded the title compound as a yellow oil.
Step 2: N-(3-Formylbenzyl)-N-methylacetamide
[0267] To a solution of N-(3-bromobenzyl)-N-methylacetamide from
the previous step (1 eq.) in anhydrous, deoxygenated DMF (0.5 M)
was added freshly-dried sodium formate (1.5 eq.) and
Pd(PPh.sub.3)Cl.sub.2 (5% loading). Through the resulting yellow
suspension was bubbled CO and then the reaction was heated to
80.degree. C. for 16 h. The now black reaction suspension was
cooled to RT, diluted with water and extracted with ether. The
combined organic extracts were washed with brine, dried over
Na.sub.2SO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded an orange semi-solid. Purification of the crude
product thus obtained by way of flash chromatography (SiO.sub.2,
7:3 (v/v) Hex:EtOAc) afforded the title compound as a light yellow
oil.
Step 3
Amine 9
[0268] Amine 9 was prepared according to the procedure described in
Amine 3, but using instead N-(3-formylbenzyl)-N-methylacetamide
from the previous step as the starting material. The title compound
was isolated as a colorless oil.
Amine 10
N-{4-Chloro-3-[(cyclopropylamino)methyl]benzyl)-N-methylacetamide
Step 1: (5-Bromo-2-chlorophenyl)methanol
[0269] To a solution of ethyl 5-bromo-2-chlorobenzoate (1 eq.) in
THF (0.03 M) was added, at -78.degree. C., DIBAL (2.5 eq). The
reaction was stirred at -78.degree. C. for 1 h and then warmed
slowly to RT over 1 h. The reaction mixture was then diluted with
ether and carefully quenched with aq. 6 M HCl. The organic layer
was separated and the aqueous layer was back extracted with ether.
The combined organic extracts were washed with sat. aq. NaHCO.sub.3
and brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded a white semi-solid. Purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, 3:1 (v/v) Hex:EtOAc) afforded the title compound as a
light yellow oil.
Step 2: [(5-Bromo-2-chlorobenzyl)oxy](tert-butyl)dimethylsilane
[0270] To a solution of (5-bromo-2-chlorophenyl)methanol from the
previous step (1 eq.) in DMF (0.25 M) was added imidazole (1.2 eq.)
and tert-butyldimethylsilyl chloride (1.1 eq.). The resulting
solution was stirred at RT for 3 h. The reaction mixture was
quenched with sat. aq. NH.sub.4Cl and extracted with ether. The
combined organic extracts were washed further with aq. 10% HCl,
sat. aq. NaHCO.sub.3, and brine. Concentration of the organic
extracts in vacuo afforded an orange oil. Purification of the crude
product thus obtained by way of flash chromatography (SiO.sub.2,
9:1 (v/v) Hex:EtOAc) afforded the title compound as a light yellow
oil.
Step 3:
3-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-4-chlorobenzaldehyde
[0271] To a solution of
[(5-bromo-2-chlorobenzyl)oxy](tert-butyl)dimethylsilane from the
previous step (1 eq.) in THF (0.08 M) was added, at -78.degree. C.,
n-butyl lithium (2.5 M hexane solution, 1.1 eq) dropwise over 15
min. The reaction mixture was stirred at -78.degree. C. for a
further 30 min before DMF (2 eq.) was slowly added. The resulting
solution was allowed to warm to RT over 3 h and then quenched with
H.sub.2O. The organic layer was separated and the aqueous layer was
back-extracted with EtOAc. The combined organic extracts were
washed with sat. aq. NaHCO.sub.3 and brine, dried over
Na.sub.2SO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded an orange oil. Purification of the crude product
thus obtained by way of flash chromatography (SiO.sub.2, 9:1 (v/v)
Hex:EtOAc) afforded the title compound as a yellow oil.
Step 4:
[3-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-4-chlorobenzyl]methyla-
mine
[0272] To a solution of
3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorobenzaldehyde
from the previous step (1 eq.) in THF (0.3 M) was added methylamine
(2.0 M THF solution, 5 eq.) and freshly-activated 3A molecular
sieves. The resulting mixture was stirred at RT for 16 h. The
molecular sieves were then filtered off and the filtrate was
evaporated in vacuo. The resulting residue was taken up in ethanol
(0.25 M) and added sodium borohydride (3 eq.). After 3 h of
stirring at RT, the reaction was quenched by the addition of 1 N
aq. HCl and then basified with 1 N aq. NaOH. This was extracted
with EtOAc. The combined organic extracts were washed with brine,
dried over Na.sub.2SO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded a cloudy oil. Purification of the crude
product thus obtained by way of flash chromatography (SiO.sub.2,
19:1 (v/v) CH.sub.2Cl.sub.2: 2 M NH.sub.3 in MeOH) afforded the
title compound as a pale yellow oil.
Step 5:
N-[3-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-4-chlorobenzyl]-N-me-
thylacetamide
[0273] To a solution of
[3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorobenzyl]methylamine
from the previous step (1 eq.) in pyridine (0.09 M) was added
acetic anhydride (1.1 eq.) The resulting reaction mixture was
stirred at RT for 3 h. After quenching the reaction with H.sub.2O,
the mixture was extracted with EtOAc. The combined organic extracts
were washed with 10% aq. HCl, sat. aq. NaHCO.sub.3, and brine.
Drying over Na.sub.2SO.sub.4, filtration and concentration of the
filtrate in vacuo afforded the crude product as a brown oil.
Purification by way of flash chromatography (SiO.sub.2, 7:3 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a pale
yellow oil.
Step 6: N-[4-Chloro-3-(hydroxymethyl)benzyl]-N-methylacetamide
[0274] To a solution of
N-[3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorobenzyl]-N-methylace-
tamide from the previous step (1 eq.) in THF (0.8M) was added
tetrabutylammonium fluoride (1.0 M THF solution, 1.5 eq.). The
resulting reaction mixture was stirred at RT for 1 h. After
quenching the reaction with 10% aq. HCl, the mixture was extracted
with EtOAc. The combined organic extracts were washed with sat. aq.
NaHCO.sub.3 and brine, dried over Na.sub.2SO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded a pale yellow oil.
Purification of the crude product thus obtained by way of flash
chromatography (SiO.sub.2, 9:1 (v/v) CH.sub.2Cl.sub.2:MeOH)
afforded the title compound as a light yellow oil.
Step 7: N-(4-Chloro-3-formylbenzyl)-N-methylacetamide
[0275] To a solution of
N-[4-chloro-3-(hydroxymethyl)benzyl]-N-methylacetamide from the
previous step (1 eq.) in CH.sub.2Cl.sub.2 (0.8 M) was added
Dess-Martin periodinane (1.2 eq.) portionwise. The resulting
suspension was stirred at RT for 3 h. The reaction was quenched
with MeOH and H.sub.2O. The organic layer was separated and the
aqueous layer was back-extracted with EtOAc. The combined organic
extracts were washed sat. aq. NaHCO.sub.3 and brine, dried over
Na.sub.2SO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded a pale yellow oil. Purification of the crude product
thus obtained by way of flash chromatography (SiO.sub.2, EtOAc)
afforded the title compound as a pale yellow oil.
Step 8
Amine 10
[0276] To a solution of
N-(4-chloro-3-formylbenzyl)-N-methylacetamide from the previous
step (1 eq.) in THF (0.08 M) was added cyclopropylamine (2 eq.) and
freshly activated 3A molecular sieves. The resulting mixture was
stirred at RT for 48 h. The molecular sieves were then filtered off
and the filtrate was evaporated in vacuo. The resulting residue was
taken up in methanol (0.07 M) and added sodium borohydride (2 eq.).
After 2 h of stirring at RT, the reaction was quenched by the
addition of 1 N aq. HCl. The volatiles were removed in vacuo and
the resulting residue was partitioned between EtOAc and H.sub.2O.
The organic layer was separated and the aqueous layer was back
extracted with EtOAc. The combined organic extracts were washed
with brine, dried over Na.sub.2SO.sub.4 and filtered. Concentration
of the filtrate in vacuo afforded the title compound as a colorless
oil.
Amine 11
3-{4-Chloro-3-[(cyclopropylamino)methyl]phenyl}propan-1-ol
[0277] Amine 6 (1 eq.) in chloroform (0.3 M) was added
iodotrimethylsilane (9 eq.). The resulting solution was stirred at
RT for 8 h. The reaction was then quenched with MeOH before the
volatiles were removed in vacuo. The resulting reddish-orange oil
was taken up in dichloromethane and washed sequentially with 1 N
aq. NaOH, water and brine. The organic layer was separated, dried
over MgSO.sub.4, filtered and the filtrate concentrated in vacuo to
afford a pale yellow oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 95:5 (v/v)
CH.sub.2Cl.sub.2: 2 M NH.sub.3 in MeOH) afforded the title compound
as a viscous, pale yellow oil.
Amine 12
N-[2-Chloro-5-(2-methoxyethoxy)benzyl]cyclopropanamine
Step 1: 1-Chloro-4-(2-methoxyethoxy)-2-methylbenzene
[0278] To a solution of ethyl 4-chloro-3-methylphenol (1 eq.) in
acetone (0.2 M) was added potassium carbonate (5 eq.) and
1-bromo-2-methoxyethane (1.3 eq.). The resulting suspension was
refluxed for 25 h. The insolubles were removed via filtration and
the filtrate was concentrated in vacuo to furnish the title
compound.
Step 2: 2-(Bromomethyl)-1-chloro-4-(2-methoxyethoxy)benzene
[0279] To a solution of
1-chloro-4-(2-methoxyethoxy)-2-methylbenzene from the previous step
(1 eq.) in carbon tetrachloride (0.02 M) was added
N-bromosuccinimide (1 eq.) and a few crystals of AIBN (1.1 eq.).
The resulting mixture was irradiated with sunlamp at reflux for 1
h. The insolubles were removed via filtration and the filtrate was
concentrated in vacuo to furnish the title compound.
Step 3: 2-Chloro-5-(2-methoxyethoxy)benzaldehyde
[0280] To a solution of
2-(bromomethyl)-1-chloro-4-(2-methoxyethoxy)benzene from the
previous step (1 eq.) in dioxane (0.2 M) was added
4-methylmorpholine N-oxide (3 eq.). The reaction mixture was heated
at 80.degree. C. The resulting solution was allowed to cool to RT,
poured into brine and then extracted with EtOAc. The combined
organic extracts were dried over MgSO.sub.4, filtered and the
filtrate concentrated in vacuo. Purification of the crude product
thus obtained by way of flash chromatography (SiO.sub.2,
Hex.fwdarw.2:1 (v/v) Hex:EtOAc) afforded the title compound as a
pale yellow oil.
Step 4
Amine 12
[0281] Amine 7 was prepared according to the procedure described in
Amine 3, but using instead 2-chloro-5-(2-methoxyethoxy)benzaldehyde
from the previous step as the starting material. The title compound
was isolated as a colorless oil.
Amine 13
N-{[6-(pyridine-4-ylmethyl)quinoline-8-yl]methyl}cyclopropanamine
Step 1: 6-(Pyridine-4-ylmethyl)quinoline-8-carbaldehyde
[0282] To a solution of 8-bromo-6-(pyridine-4-ylmethyl)quinoline (1
eq.) in THF (0.13 M) was added, at -78.degree. C., n-butyl lithium
(2.5 M hexane solution, 1.1 eq) dropwise over 15 min. The reaction
mixture was stirred at -78.degree. C. for a further 30 min before
DMF (1.5 eq.) was slowly added. The resulting solution was allowed
to warm to RT over 3 h and then quenched with H.sub.2O. The organic
layer was separated and the aqueous layer was back-extracted with
EtOAc. The combined organic extracts were washed with sat. aq.
NaHCO.sub.3 and brine, dried over Na.sub.2SO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded a brown oil.
Purification of the crude product thus obtained by way of flash
chromatography (SiO.sub.2, 7:3 (v/v) Hex:EtOAc.fwdarw.EtOAc)
afforded the title compound.
Step 2
Amine 13
[0283] To a solution of
6-(pyridine-4-ylmethyl)quinoline-8-carbaldehyde from the previous
step (1 eq.) in THF (0.07 M) was added cyclopropylamine (2 eq.) and
freshly activated 3A molecular sieves. The resulting mixture was
stirred at RT for 18 h. The molecular sieves were then filtered off
and the filtrate was evaporated in vacuo. The resulting residue was
taken up in methanol (0.07 M) and added sodium borohydride (1 eq.).
After 2 h of stirring at RT, the reaction was quenched by the
addition of water. The volatiles were removed in vacuo and the
resulting residue was partitioned between EtOAc and H.sub.2O. The
organic layer was separated and the aqueous layer was back
extracted with EtOAc. The combined organic extracts were washed
with sat. aq. NaHCO.sub.3, dried over Na.sub.2SO.sub.4 and
filtered. The filtrate was concentrated in vacuo to afford the
title compound as a pale yellow oil.
Amine 14
N-{2-Chloro-5-[3-(dimethylamino)propyl]benzyl}cyclopropanamine
Step 1: 5-Bromo-2-chloro-N-cyclopropylbenzamide
[0284] To a toluene solution (1 M) of 5-bromo-2-chlorobenzoic acid
(1 eq.) and DMF (1.2 eq.) was added at 0.degree. C. oxalyl chloride
(1.2 eq.) dropwise over 1 h. The resulting solution was stirred at
0.degree. C. for 2 h before the volatiles were removed in vacuo.
The resulting residue was taken up in dichloromethane (1 M), cooled
to 0.degree. C. and added sequentially cyclopropylamine (1.5 eq.)
and Hunig's base (2 eq.) dropwise over 1 h. The resulting
suspension was stirred at RT for 18 h. The reaction was quenched
with 1 N HCl and extracted with dichloromethane. The combined
organic extracts were dried over MgSO.sub.4, filtered and the
filtrate concentrated in vacuo to .about.1/3 in volume. The
resulting white suspension was added an equivalent volume of
hexanes and the title compound was isolated via vacuum
filtration.
Step 2: N-(5-Bromo-2-chlorobenzyl)cyclopropanamine
[0285] At 0.degree. C., a suspension of
5-bromo-2-chloro-N-cyclopropylbenzamide from the previous step (1
eq.) in THF (0.4 M) was added borane (1 M THF solution, 3 eq.). The
resulting suspension was warmed to RT over 1 h and then heated at
reflux for 1 h. The now pale yellow solution was re-cooled to
0.degree. C. and carefully quenched with 1 N aq. HCl. The resulting
mixture was heated at reflux for 1 h to ensure complete breakdown
of the amine-borane complex. Following careful neutralization with
1 N aq. NaOH, the aqueous layer was separated and back extracted
with EtOAc. The combined organic extracts were washed with brine,
dried over MgSO.sub.4 and filtered. The filtrate was concentrated
in vacuo and the crude product thus obtained was purified further
by way of column chromatography (SiO.sub.2, Hex.fwdarw.80:20 (v/v)
Hex:Et.sub.2O) to reveal the title compound as a colorless oil.
Step 3: tert-Butyl (5-bromo-2-chlorobenzyl)cyclopropylcarbamate
[0286] A THF solution (0.3 M) of
N-(5-bromo-2-chlorobenzyl)cyclopropanamine from the previous step
(1 eq.) was added at -78.degree. C. potassium hexamethyldisilazide
(0.5 M in toluene, 1.2 eq.). After 1 h of stirring at -78.degree.
C., di-tert-butyl dicarbonate was added and the resulting mixture
was slowly warmed to RT over 2 h. The reaction was quenched with
sat. aq. NH.sub.4Cl and then extracted with ether. The combined
organic extracts were washed with brine, dried over MgSO.sub.4,
filtered and the filtrate concentrated in vacuo. Further
purification by way of column chromatography (SiO.sub.2,
Hex.fwdarw.80:20 (v/v) Hex:Et.sub.2O) to reveal the title compound
as a pale yellow oil.
Step 4: tert-Butyl (5-allyl-2-chlorobenzyl)cyclopropylcarbamate
[0287] A THF solution (0.13 M) of tert-butyl
(5-bromo-2-chlorobenzyl)cyclopropylcarbamate from the previous step
(1 eq.), Pd(PCy.sub.3).sub.2 (0.05 eq.) and cesium fluoride (2.0
eq.) was added allyl tributylstannane (1.2 eq.). The resulting
brown solution was heated at reflux for 8 h and then filtered
through a pad of SiO.sub.2. The insolubles were rinsed further with
ether and the filtrate was concentrated in vacuo to afford a brown
semisolid. Purification of the crude product thus obtained by way
of column chromatography (SiO.sub.2, Hex.fwdarw.90:10 (v/v)
Hex:Et.sub.2O) afforded the title compound as a colorless oil.
Step 5:
tert-Butyl[2-chloro-5-(3-(hydroxypropropyl)benzyl]cyclopropylcarba-
mate
[0288] To a solution of tert-butyl
(5-allyl-2-chlorobenzyl)cyclopropylcarbamate from the previous step
(1 eq.) in THF (0.3 M) was added dropwise at 0.degree. C.
BH.sub.3.SMe.sub.2 complex (1.1 eq.) over 20 min. The resulting
solution was stirred at 0.degree. C. for 1 h and then at RT for
another 2 h. The reaction was then quenched at 0.degree. C. with
NaOH (1 N aqueous solution, 4 eq.) and H.sub.2O.sub.2 (30% w/w
aqueous solution, 4 eq.). The biphasic mixture was slowly warmed to
RT and stirred at RT for 2 h. The aqueous layer then was separated
and back extracted with ether. The combined organic extracts were
washed with brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded the title compound
which can be purified further by way of column chromatography
(SiO.sub.2, 90:10 (v:v) Hex:EtOAc.fwdarw.40:60 (v/v)
Hex:EtOAc).
Step 6: tert-Butyl
{2-chloro-5-[3-(dimethylamino)propyl]benzyl}cyclopropylcarbamate
[0289] To a solution of
tert-butyl[2-chloro-5-(3-(hydroxypropropyl)benzyl]cyclopropylcarbamate
from the previous step (1 eq.) in dichloromethane (0.1 M) was added
Dess-Martin periodinane (1.2 eq.). The resulting suspension was
stirred at RT for 2 h. The reaction was then quenched with sat. aq.
NaHSO.sub.3 and extracted with dichloromethane. The combined
organic extracts were washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded the crude
aldehyde as a pale yellow oil. This was then taken up in MeOH (0.15
M) and added, sequentially, sodium cyanoborohydride (1.3 eq.),
dimethylamine (2 M THF solution, 2.5 eq.) and acetic acid (2.5
eq.). After 18 h of stirring at RT, the reaction was concentrated
in vacuo and partitioned between ether and sat. aq. NaHCO.sub.3.
The aqueous layer was separated and back extracted with ether. The
combined organic extracts were washed with brine, dried over
MgSO.sub.4 and filtered. Concentration of the filtrate in vacuo
afforded the crude product as a yellow oil. Further purification by
way of column chromatography (SiO.sub.2, 79:19:2 (v:v:v)
Hex:EtOAc:NEt.sub.3.fwdarw.98:2 (v/v) EtOAc:NEt.sub.3) afforded the
title compound as a pale yellow oil.
Step 7
Amine 14
[0290] To a solution of tert-butyl
{2-chloro-5-[3-(dimethylamino)propyl]benzyl}cyclopropylcarbamate
from the previous step (1 eq.) in dichloromethane (0.2 M) was added
HCl (4 M dioxane solution, 8 eq.). The resulting mixture was
stirred at RT for 18 h. The reaction was quenched with 1 N aq. NaOH
and extracted with dichloromethane. The combined organic extracts
were washed with brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded the crude product
as a pale yellow oil. Further purification by way of column
chromatography (SiO.sub.2, CH.sub.2Cl.sub.2.fwdarw.93:7 (v/v)
CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH) afforded the title
compound as a colorless oil.
Amine 15
N-[2,3-dichloro-5-(3-methoxypropyl)benzyl]cyclopropanamine
Step 1: 5-Bromo-2,3-dichlorobenzaldehyde
[0291] To a THF solution (0.2 M) of diisopropylamine (1.2 eq.) was
added at 0.degree. C. n-butyl lithium (2.3 M hexane solution, 1.2
eq.) dropwise over 10 min. The resulting pale yellow solution was
stirred at 0.degree. C. for 30 min before 1-bromo-3,4-chlorobenzene
was added at -78.degree. C. After 1 h of stirring at -78.degree.
C., DMF (5 eq.) was added and the resulting solution was stirred at
-78.degree. C. for another 2 h. The reaction then allowed to warm
slowly to RT before it was quenched with sat. aq. NH.sub.4Cl. The
aqueous layer was separated and back extracted with ether. The
combined organic extracts were washed with brine, dried over
MgSO.sub.4, filtered and the filtrate concentrated in vacuo. The
crude product thus obtained was purified by way of column
chromatography (SiO.sub.2, Hex.fwdarw.95:5 (v/v) Hex:EtOAc) to
afford the title compound as a white solid.
Step 2: N-(5-Bromo-2,3-dichlorobenzyl)cyclopropanamine
[0292] A mixture of 5-bromo-2,3-dichlorobenzaldehyde from the
previous step (1 eq.), cyclopropylamine (1 eq.) and sodium
cyanoborohydride (1.5 eq.) were combined in MeOH (0.2 M). At
0.degree. C., acetic acid (3 eq.) was added dropwise and the
reaction mixture was slowly warmed to RT over 16 h. The reaction
mixture was then diluted with ether and quenched with 1N aq.
NaHCO.sub.3. The aqueous layer was separated and back-extracted
with ether. The combined organic extracts were then washed with
brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2,
Hex.fwdarw.80:20 (v/v) Hex:EtOAc) afforded the title compound as a
colorless oil.
Step 3: tert-Butyl
(5-bromo-2,3-dichlorobenzyl)cyclopropylcarbamate
[0293] A THF solution (0.3 M) of
N-(5-bromo-2,3-dichlorobenzyl)cyclopropanamine from the previous
step (1 eq.) was added at -78.degree. C. potassium
hexamethyldisilazide (0.5 M in toluene, 1.2 eq.). After 1 h of
stirring at -78.degree. C., di-tert-butyl dicarbonate was added and
the resulting mixture was slowly warmed to RT over 2 h. The
reaction was quenched with sat. aq. NH.sub.4Cl and then extracted
with ether. The combined organic extracts were washed with brine,
dried over MgSO.sub.4, filtered and the filtrate concentrated in
vacuo. Further purification by way of column chromatography
(SiO.sub.2, Hex.fwdarw.95:5 (v/v) Hex:Et.sub.2O) to reveal the
title compound as a colorless oil.
Step 4: tert-Butyl
(5-allyl-2,3-dichlorobenzyl)cyclopropylcarbamate
[0294] A THF solution (0.12 M) of tert-butyl
(5-bromo-2,3-dichlorobenzyl)cyclopropylcarbamate from the previous
step (1 eq.), Pd(PCy.sub.3).sub.2 (0.05 eq.) and cesium fluoride
(2.0 eq.) was added allyl tributylstannane (1.2 eq.). The resulting
brown solution was heated at reflux for 8 h and then filtered
through a pad of SiO.sub.2. The insolubles were rinsed further with
ether and the filtrate was concentrated in vacuo to afford a brown
semisolid. Purification of the crude product thus obtained by way
of column chromatography (SiO.sub.2, Hex.fwdarw.90:10 (v/v)
Hex:Et.sub.2O) afforded the title compound as a pale yellow
oil.
Step 5: tert-Butyl
cyclopropyl[2,3-dichloro-5-(3-(hydroxypropropyl)benzyl]carbamate
[0295] To a solution of tert-butyl
(5-allyl-2,3-dichlorobenzyl)cyclopropylcarbamate from the previous
step (1 eq.) in THF (0.16 M) was added dropwise at 0.degree. C.
BH.sub.3.SMe.sub.2 complex (1.2 eq.) over 20 min. The resulting
solution was stirred at 0.degree. C. for 1 h and then at RT for
another 2 h. The reaction was then quenched at 0.degree. C. with
NaOH (1 N aqueous solution, 4 eq.) and H.sub.2O.sub.2 (30% w/w
aqueous solution, 4 eq.). The biphasic mixture was slowly warmed to
RT and stirred at RT for 2 h. The aqueous layer then was separated
and back extracted with ether. The combined organic extracts were
washed with brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded the title compound
which can be purified further by way of column chromatography
(SiO.sub.2, 80:20 (v:v) Hex:EtOAc.fwdarw.60:40 (v/v)
Hex:EtOAc).
Step 6: tert-Butyl
cyclopropyl[2,3-dichloro-5-methoxypropyl)benzyl]carbamate
[0296] To a solution of tert-butyl
cyclopropyl[2,3-dichloro-5-(3-(hydroxypropropyl)benzyl]carbamate
from the previous step (1 eq.) in THF (0.2 M) was added sodium
hydride (2 eq.). The resulting suspension was stirred at RT for 30
min and then added iodomethane (8 eq.). After 12 h of heating at
reflux, the reaction mixture was cooled to RT and quenched with
sat. aq. NH.sub.4Cl. The aqueous layer was separated and extracted
with ether. The combined organic extracts were washed with brine,
dried over MgSO.sub.4 and filtered. Concentration of the filtrate
in vacuo afforded the crude product as a yellow oil. Further
purification by way of column chromatography (SiO.sub.2,
Hex.fwdarw.80:20 (v/v) Hex:EtOAc) afforded the title compound as a
pale yellow oil.
Step 7
Amine 15
[0297] To a solution of tert-butyl
cyclopropyl[2,3-dichloro-5-methoxypropyl)benzyl]carbamate from the
previous step (1 eq.) in dichloromethane (0.2 M) was added HCl (4 M
dioxane solution, 8 eq.). The resulting mixture was stirred at RT
for 18 h. The reaction was quenched with 1 N aq. NaOH and extracted
with dichloromethane. The combined organic extracts were washed
with brine, dried over MgSO.sub.4 and filtered. Concentration of
the filtrate in vacuo afforded the crude product as a pale yellow
oil. Further purification by way of column chromatography
(SiO.sub.2, CH.sub.2Cl.sub.2.fwdarw.93:7 (v/v) CH.sub.2Cl.sub.2:
2.0 M NH.sub.3 in MeOH) afforded the title compound as a colorless
oil.
Amine 16
{8-Cyclopropylamino)methyl]quinoline-6-yl}acetonitrile
Step 1: (8-Formylquinolin-6-yl)acetonitrile
[0298] To a solution of (8-bromoquinolin-6-yl)acetonitrile (1 eq.)
in anhydrous, deoxygenated DMF (0.08 M) was added freshly-dried
sodium formate (1.5 eq.) and Pd(PPh.sub.3)Cl.sub.2 (2% loading).
Through the resulting yellow suspension, was bubbled CO and then
reaction was heated to 80.degree. C. for 16 h. The now black
reaction suspension was cooled to RT, diluted with water, and
extracted with EtOAc. The combined organic extracts were washed
with brine, dried over MgSO.sub.4 and filtered. Concentration of
the filtrate in vacuo afforded the title compound.
Step 2
Amine 16
[0299] Amine 16 was prepared according to the procedure described
in Amine 3, but using instead (8-formylquinolin-6-yl)acetonitrile
from the previous step as the starting material. The title compound
was isolated as a yellow oil.
Amine 17
N-{[2-(3-Methoxypropyl)quinoline-4-yl]methyl}cyclopropanamine
Step 1: Methyl 2-hydroxyquinoline-4-carboxylate
[0300] To a solution of 2-hydroxyquinoline-4-carboxylic acid (1
eq.) in methanol (0.11 M) was added HCl (4 M dioxane solution, 1
eq.) and the resulting suspension was heated at reflux for 24 h.
The reaction was quenched with sat. aq. NaHCO.sub.3 and extracted
with EtOAc. The combined organic extracts were washed with brine,
dried over MgSO.sub.4 and filtered. Concentration of the filtrate
in vacuo afforded the title compound.
Step 2: Methyl
2-{[trifluoromethyl)sulfonyl]oxy}quinoline-4-carboxylate
[0301] To a solution of methyl 2-hydroxyquinoline-4-carboxylate
from the previous step (1 eq.) in dichloromethane (0.2 M) was added
sequentially at 0.degree. C. pyridine (1.4 eq.) and triflic
anhydride (1.1 eq.). The reaction mixture was stirred at 0.degree.
C. for 1 h and then at RT for 2 h. The reaction mixture was
quenched with water and extracted with EtOAc. The combined organic
extracts were washed with water, sat. aq. NaHCO.sub.3 and brine.
Drying over MgSO.sub.4, filtration and concentration of the
filtrate in vacuo afforded the title compound.
Step 3: Propyl
2-[(1E)-3-methoxyprop-1-en-1-yl]quinoline-4-carboxylate
[0302] Methyl
2-{[trifluoromethyl)sulfonyl]oxy}quinoline-4-carboxylate from the
previous step (1 eq.) and
2-[(1E)-3-methoxyprop-1-en-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(1 eq.) were combined in n-propanol (0.1 M). To this solution was
then added palladium acetate (5% loading), triphenylphosphine (15%
loading) and sodium carbonate (2 M aqueous solution, 4 eq.). The
resulting suspension was heated at 80.degree. C. for 2 h. The
reaction mixture was quenched with water and extracted with EtOAc.
The combined organic extracts were washed with water, sat. aq.
NaHCO.sub.3 and brine. Drying over MgSO.sub.4, filtration and
concentration of the filtrate in vacuo afforded the crude product
as a brown tar. Purification by way of column chromatography
(SiO.sub.2, 10:1 (v/v) Hex:EtOAc.fwdarw.1:1 (v/v) Hex:EtOAc)
afforded the title compound as a yellow oil.
Step 4: Propyl 2-(3-methoxypropyl]quinoline-4-carboxylate
[0303] To a solution of propyl
2-[(1E)-3-methoxyprop-1-en-1-yl]quinoline-4-carboxylate from the
previous step (1 eq.) in toluene (0.06 M) was added at 80.degree.
C. benzenesulfonyl hydrazide (3.times.1 eq.) over 3 h. The reaction
mixture was diluted with EtOAc and washed sequentially with water,
sat. aq. NaHCO.sub.3 and brine. Drying over MgSO.sub.4, filtration
and concentration of the filtrate in vacuo afforded the crude
product as a yellow oil. Purification by way of column
chromatography (SiO.sub.2, 10:1 (v/v) Hex:EtOAc.fwdarw.1:1 (v/v)
Hex:EtOAc) afforded the title compound as a yellow oil.
Step 5: [2-(3-Methoxypropyl)quinoline-4-yl]methanol
[0304] To a solution of propyl
2-(3-methoxypropyl]quinoline-4-carboxylate from the previous step
(1 eq.) in toluene (0.1 M) was added at -78.degree. C. DIBAL (1.5 M
toluene solution, 2 eq.) dropwise over 10 min. The reaction mixture
was stirred at -78.degree. C. for 30 min and then at 0.degree. C.
for 2 h. The reaction mixture was quenched with sat. aq. Rochelle's
salt and extracted with EtOAc. The combined organic extracts were
washed sequentially with water, sat. aq. NaHCO.sub.3 and brine.
Drying over MgSO.sub.4, filtration and concentration of the
filtrate in vacuo afforded the crude product as a milky oil.
Purification by way of column chromatography (SiO.sub.2, 10:1 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a pale
yellow oil.
Step 6: 2-(3-Methoxypropyl)quinoline-4-carbaldehyde
[0305] To a solution of [2-(3-methoxypropyl)quinoline-4-yl]methanol
from the previous step (1 eq.) in CH.sub.2Cl.sub.2 (0.05 M) was
added Dess-Martin periodinane (1.1 eq.) portionwise. The resulting
suspension was stirred at RT for 3 h. The reaction was quenched
with MeOH and H.sub.2O. The organic layer was separated and the
aqueous layer was back-extracted with EtOAc. The combined organic
extracts were washed sat. aq. NaHCO.sub.3 and brine, dried over
Na.sub.2SO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded the title compound which was purified further by way
of flash chromatography (SiO.sub.2, 2:1 (v/v) Hex:EtOAc).
Step 7
Amine 17
[0306] To a solution of 2-(3-methoxypropyl)quinoline-4-carbaldehyde
from the previous step (1 eq.) in THF (0.05 M) was added
cyclopropylamine (2 eq.) and magnesium sulfate (1 eq.). The
resulting mixture was stirred at RT for 3 h. The insolubles were
then filtered off and the filtrate evaporated in vacuo. The
resulting residue was taken up in methanol (0.05 M) and added
sodium borohydride (2 eq.). After 2 h of stirring at RT, the
reaction was quenched by the addition of 1 N aq. HCl. The volatiles
were removed in vacuo and the resulting residue was partitioned
between EtOAc and H.sub.2O. The organic layer was separated and the
aqueous layer was back extracted with EtOAc. The combined organic
extracts were washed with brine, dried over Na.sub.2SO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded the title
compound as a pale yellow oil.
Amine 18
3-{4-Chloro-3-[(cyclopropylamino)methyl]phenyl}propanenitrile
Step 1:
(2E)-3-[3-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-4-chlorophenyl]-
acrylonitrile
[0307] To a solution of diethyl cyanomethylphosphonate (1.1 eq.) in
THF (0.14 M) was added at 0.degree. C. potassium tert-butoxide (1 M
THF solution, 1.1 eq.). The resulting yellow solution was stirred
at 0.degree. C. for 1 h before
3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorobenzaldehyde
from step 3 of Amine 10 synthesis (1 eq.) in THF (0.14 M) was
added. The resulting mixture was stirred at RT 3 h. The reaction
was quenched by the addition of sat. aq. NH.sub.4Cl and then
extracted with EtOAc. The combined organic extracts were washed
with sat. aq. NaHCO.sub.3, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded an orange oil.
Purification of the crude product thus obtained by way of flash
chromatography (SiO.sub.2, Hex.fwdarw.2:1 (v/v) Hex:EtOAc) afforded
the title compound.
Step 2: 3-[4-Chloro-3-(hydroxymethyl)phenyl]propanenitrile
[0308] To a solution of
(2E)-3-[3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorophenyl]acrylon-
itrile from the previous step (1 eq.) in toluene (0.01 M) was added
at 80.degree. C. benzenesulfonyl hydrazide (3.times.1 eq.) over 3
h. The reaction mixture was diluted with EtOAc and washed
sequentially with water, sat. aq. NaHCO.sub.3 and brine. Drying
over MgSO.sub.4, filtration and concentration of the filtrate in
vacuo afforded a yellow oil. The residue was taken up in THF (0.1
M) and added tetrabutylammonium fluoride (1.0 M THF solution, 1.1
eq.). The resulting reaction mixture was stirred at RT for 2 h.
After quenching the reaction with sat. aq. NH.sub.4Cl, the mixture
was extracted with EtOAc. The combined organic extracts were washed
with sat. aq. NaHCO.sub.3 and brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo and purification
of the crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title
compound as a pale yellow oil.
Step 3: 3-(4-Chloro-3-formylphenyl)propanenitrile
[0309] To a solution of
3-[4-chloro-3-(hydroxymethyl)phenyl]propanenitrile from the
previous step (1 eq.) in CH.sub.2Cl.sub.2 (0.1 M) was added
Dess-Martin periodinane (1.1 eq.) portionwise. The resulting
suspension was stirred at RT for 2 h. The reaction was quenched
with MeOH and H.sub.2O. The organic layer was separated and the
aqueous layer was back-extracted with EtOAc. The combined organic
extracts were washed sat. aq. NaHCO.sub.3 and brine, dried over
Na.sub.2SO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded the title compound as a pale yellow oil.
Step 4
Amine 18
[0310] To a solution of 3-(4-chloro-3-formylphenyl)propanenitrile
from the previous step (1 eq.) in THF (0.1 M) was added
cyclopropylamine (2 eq.) and MgSO.sub.4 (1 eq.). The resulting
suspension was stirred at RT for 3 h. The insolubles were then
filtered off and the filtrate evaporated in vacuo. The resulting
residue was taken up in methanol (0.1 M) and added sodium
borohydride (2 eq.). After 2 h of stirring at RT, the reaction was
quenched by the addition of 1 N aq. HCl. The volatiles were removed
in vacuo and the resulting residue was partitioned between EtOAc
and H.sub.2O. The organic layer was separated and the aqueous layer
was back extracted with EtOAc. The combined organic extracts were
washed with brine, dried over Na.sub.2SO.sub.4 and filtered.
Concentration of the filtrate in vacuo and purification of the
crude product thus obtained by way of column chromatography
(SiO.sub.2, Hex.fwdarw.EtOAc) afforded the title compound as a pale
yellow oil.
Amine 19
N-[5-(3-Methoxypropyl)-2-methylbenzyl]cyclopropanamine
[0311] Amine 19 was prepared according to the procedure described
in Amine 14, but using instead 5-chloro2-methylbenzoic acid from
the previous step as the starting material in step 1 and
[BrPdP.sup.tBu.sub.3].sub.2 as the palladium source in step 4. The
title compound was isolated as a pale yellow oil.
Amine 20
{4-Chloro-3-[(cyclopropylamino)methyl]phenyl}acetonitrile
Step 1:
[3-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-4-chlorophenyl]methano-
l
[0312] To a solution of
3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorobenzaldehyde
from step 3 of Amine 10 synthesis (1 eq.) in methanol (0.14 M) was
added sodium borohydride (5 eq.). The resulting mixture was stirred
at RT 3 h. The reaction was quenched by the addition of sat. aq.
NH.sub.4Cl and then extracted with EtOAc. The combined organic
extracts were washed with sat. aq. NaHCO.sub.3, dried over
MgSO.sub.4 and filtered. Concentration of the filtrate in vacuo
afforded an colorless oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, Hex.fwdarw.1:1
(v/v) Hex:EtOAc) afforded the title compound.
Step 2:
[3-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-4-chlorophenyl]acetoni-
trile
[0313] To a solution of
[3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorophenyl]methanol
from the previous step (1 eq.) in dichloromethane (0.14 M) was
added sequentially at 0.degree. C. Hunig's base (1 eq.) and
methanesulfonyl chloride (1.1 eq.). The reaction mixture was warmed
to RT and stirred at RT for 3 h. The reaction was then quenched
with water and extracted with EtOAc. The combined organic extracts
were washed with brine, dried over MgSO.sub.4, filtered and the
filtrate concentrated in vacuo. The crude mesylate thus obtained
was taken up in DMF (0.14 M) and added sodium cyanide (1.5 eq.).
After 16 h of stirring at RT, the reaction mixture was partitioned
between water and ether. The organic layer was separated and washed
with sat. aq. NaHCO.sub.3 and brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo and purification
of the crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.2:1 (v/v) Hex:EtOAc) afforded the title
compound as a pale yellow oil.
Step 3: [4-Chloro-3-(hydroxymethyl)phenyl]acetonitrile
[0314] To a solution of
3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorophenyl]acetonitrile
from the previous step (1 eq.) in THF (0.15 M) and added
tetrabutylammonium fluoride (1.0 M THF solution, 1.2 eq.). The
resulting reaction mixture was stirred at RT for 2 h. After
quenching the reaction with water, the resulting mixture was
extracted with EtOAc. The combined organic extracts were washed
with sat. aq. NaHCO.sub.3 and brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo and purification
of the crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title
compound as a pale yellow oil.
Step 4: (4-Chloro-3-formylphenyl)acetonitrile
[0315] To a solution of
[4-chloro-3-(hydroxymethyl)phenyl]acetonitrile from the previous
step (1 eq.) in CH.sub.2Cl.sub.2 (0.14 M) was added Dess-Martin
periodinane (1.1 eq.) portionwise. The resulting suspension was
stirred at RT for 3 h. The reaction was quenched with MeOH and
H.sub.2O. The organic layer was separated and the aqueous layer was
back-extracted with EtOAc. The combined organic extracts were
washed sat. aq. NaHCO.sub.3 and brine, dried over Na.sub.2SO.sub.4
and filtered. Concentration of the filtrate in vacuo afforded the
title compound as a pale yellow oil.
Step 5
Amine 20
[0316] To a solution of (4-chloro-3-formylphenyl)acetonitrile from
the previous step (1 eq.) in THF (0.1 M) was added cyclopropylamine
(2 eq.) and MgSO.sub.4 (1 eq.). The resulting suspension was
stirred at RT for 18 h. The insolubles were then filtered off and
the filtrate evaporated in vacuo. The resulting residue was taken
up in methanol (0.1 M) and added sodium borohydride (2 eq.). After
2 h of stirring at RT, the reaction was quenched by the addition of
1 N aq. HCl. The volatiles were removed in vacuo and the resulting
residue was partitioned between EtOAc and H.sub.2O. The organic
layer was separated and the aqueous layer was back extracted with
EtOAc. The combined organic extracts were washed with brine, dried
over Na.sub.2SO.sub.4 and filtered. Concentration of the filtrate
in vacuo and purification of the crude product thus obtained by way
of column chromatography (SiO.sub.2, Hex.fwdarw.EtOAc) afforded the
title compound as a pale yellow oil.
Amine 21
N-[5-(2-Methoxyethyl)-2-methylbenzyl]cyclopropanamine
Step 1: tert-Butyl
cyclopropyl[5-(2-hydroxyethyl)-2-methylbenzyl]carbamate
[0317] To a dichloromethane solution (0.33 M) of tert-butyl
(5-allyl-2-methylbenzyl)cyclopropylcarbamate from step 4 of Amine
19 synthesis (1 eq) was bubbled, at -78.degree. C., ozone until a
persistent blue color was observed. At this time, the reaction
mixture was diluted with an equivalent volume of ethanol and added
sodium borohydride (2.5 eq.). The reaction was then allowed to
slowly warm to RT overnight. The reaction was quenched by the
addition of sat. aq. NH.sub.4Cl before the volatiles were removed
in vacuo. The resulting residue was extracted with ether. The
combined organic extracts were washed with brine, dried over
MgSO.sub.4 and filtered. Concentration of the filtrate in vacuo and
purification of the crude product thus obtained by way of flash
chromatography (SiO.sub.2, Hex.fwdarw.3:2 (v/v) Hex:EtOAc) afforded
the title compound as a colorless oil.
Step 2: tert-Butyl
cyclopropyl[5-(methoxyethyl)-2-methylbenzyl]carbamate
[0318] To a solution of tert-butyl
cyclopropyl[5-(2-hydroxyethyl)-2-methylbenzyl]carbamate from the
previous step (1 eq.) in THF (0.2 M) was added sodium hydride (2
eq.). The resulting suspension was stirred at RT for 30 min and
then added iodomethane (8 eq.). After 12 h of heating at reflux,
the reaction mixture was cooled to RT and quenched with sat. aq.
NH.sub.4Cl. The aqueous layer was separated and extracted with
ether. The combined organic extracts were washed with brine, dried
over MgSO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded the crude product as a colorless oil. Further
purification by way of column chromatography (SiO.sub.2,
Hex.fwdarw.7:3 (v/v) Hex:EtOAc) afforded the title compound as a
colorless oil.
Step 3
Amine 21
[0319] To a solution of tert-butyl
cyclopropyl[5-(methoxyethyl)-2-methylbenzyl]carbamate from the
previous step (1 eq.) in dichloromethane (0.2 M) was added HCl (4 M
dioxane solution, 5 eq.). The resulting mixture was stirred at RT
for 16 h. The reaction was quenched with 1 N aq. NaOH and extracted
with dichloromethane. The combined organic extracts were washed
with brine, dried over MgSO.sub.4 and filtered. Concentration of
the filtrate in vacuo afforded the crude product as a pale yellow
oil. Further purification by way of column chromatography
(SiO.sub.2, Hex.fwdarw.3:2 (v/v) Hex:EtOAc) afforded the title
compound as a pale yellow oil.
Amine 22
N-[2,5-Bis(trifluoromethyl)benzyl]cyclopropanamine
[0320] Amine 22 was prepared according to the reaction sequence
described for Amine 3, but using instead
2,5-bis(trifluoromethyl)benzaldehyde as the starting material. The
title compound was isolated as a colorless oil.
Amine 23
2-{8-[(Cyclopropylamino)methyl]quinoline-6-yl}-2-methylpropanenitrile
[0321] Amine 23 was prepared according to the procedure described
in Amine 16, but using instead
2-(8-bromoquinolin-6-yl)-2-methylpropanenitrile acetonitrile as the
starting material. The title compound was isolated as a yellow
oil.
Amine 24
N-(1-Phenylethyl)cyclopropanamine
[0322] To a solution of 1-phenylethanone (1 eq.) in dichloromethane
(0.17 M) was added cyclopropylamine (3 eq.) and magnesium sulfate
(9 eq.). The resulting mixture was stirred at reflux for 2 days.
The insolubles were then filtered off and the filtrate evaporated
in vacuo. The resulting residue was taken up in methanol (0.2 M)
and added sodium borohyride (1.5 eq.). The reaction mixture was
then stirred at RT overnight. After quenching with 1 N aq. HCl, the
volatiles were removed in vacuo. The resulting residue was
partitioned between 1 N NaOH and extracted with ether. The combined
organic extracts were washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded the title
compound as a colorless oil.
Amine 25
N-Benzylcyclopropanamine
[0323] Amine 26 was prepared according to the procedure described
in Amine 24, but using instead benzaldehyde as the starting
material. The title compound was isolated as a colorless oil.
Amine 26
N-(2-Phenylethyl)cyclopropanamine
[0324] To a solution of cyclopropanamine (1 eq.) in dichloromethane
(0.13 M) was added sequentially at 0.degree. C. pyridine (1.5 eq.)
and phenylacetyl chloride (9 eq.). The resulting mixture was slowly
warmed to RT and stirred at RT for 3 h. After quenching with 1 N
aq. HCl, the reaction mixture was extracted with EtOAc. The
combined organic extracts were washed with sat. aq. NaHCO.sub.3 and
brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. The crude amide thus obtained was taken up
in THF (0.3 M) and added BH.sub.3.SMe.sub.2 complex (3 eq.). The
reaction was heated to reflux and the volatiles were slowly
distilled off. The resulting distillation residue was carefully
quenched with 1 N aq. HCl and allowed to stir at 50.degree. C.
overnight. The reaction was cooled to 0.degree. C. and the pH of
the solution was brought to .about.12 with 1 N aq. NaOH before it
was extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. The crude product thus obtained could be
further purified by way of column chromatography (SiO.sub.2, 2:1
(v/v) Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a
colorless oil.
Amine 27
N-(2,3-dichlorobenzyl)-2,2,2-trifluoroethanamine
[0325] Amine 27 was prepared according to the reaction sequence
described for Amine 3, but using instead 2,3-dichlorobenzaldehyde
as the starting aldehyde and 2,2,2-trifluoroethylamine as the
starting amine. The title compound was isolated as a colorless
oil.
Amine 28
N-methyl-2-phenylpropan-2-amine
[0326] To a solution of 2-phenylpropan-2-amine (1 eq.) in benzene
(0.25 M) was added formaldehyde (37% w/w aqueous solution, 2 eq.).
The vessel attached a Dean-Stark apparatus and heated at 80.degree.
C. for 36 h. The reaction mixture was cooled to RT, dried with
Na.sub.2SO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded the crude imine. This was then taken up in methanol
(1.4 M) and added sodium borohydride (10 eq.). The resulting
mixture was stiffed at RT for 2 h and then quenched with 1 N aq.
HCl. The volatiles were removed in vacuo and the pH of the
resulting residue was carefully brought up to .about.12 with 1 N
aq. NaOH. The mixture was then extracted with EtOAc. The combined
organic extracts were washed with brine, dried over MgSO.sub.4,
filtered and the filtrate concentrated in vacuo. Purification of
the crude product thus obtained by way of column chromatography
(SiO.sub.2, 2:1 (v/v) Hex:EtOAc.fwdarw.EtOAc) afforded the title
compound as a colorless oil.
Amine 29
1-[2-Chloro-5-(2-methoxyethyl)phenyl]-N-(cyclopropylmethyl)methanamine
[0327] To a solution of 2-chloro-5-(2-methoxyethyl)benzaldehyde
from Amine 7, Step 6 (1 eq.) in methanol (0.8 M) was added
1-cyclopropylmethanamine (1.2 eq.) and sodium bicarbonate (1.5 eq).
The vessel was sealed and heated at 70.degree. C. for 2 h. The
insolubles were removed via filtration and to the filtrate was then
added sodium borohydride (1.5 eq.) at 0.degree. C. The reaction
mixture was allowed to warm slowly to RT overnight. The volatiles
were removed in vacuo and the resulting residue was partitioned
between 1 N aq. NaOH and ether. The aqueous layer was separated and
back extracted with ether. The combined ethereal extracts were
washed with brine, dried over Na.sub.2SO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded the title
compound.
Amine 30
1-[2-Chloro-5-(2-methoxyethyl)phenyl]-N-methylmethanamine
[0328] Amine 30 was prepared according to the reaction sequence
described for Amine 29, but using instead methylamine (2.0 M
solution in methanol) as starting material. The title compound was
isolated as a colorless oil.
Amine 31
1-[2-Chloro-5-(2-methoxyethyl)phenyl]-N-(cyclobutylmethyl)methanamine
Step 1: 1-Cyclobutylmethanamine
[0329] To a solution of cyclobutane carbonitrile (1 eq.) in ethanol
(0.5 M) was added glacial acetic acid (1.05 eq.) and platinum oxide
(5% loading). The resulting suspension was hydrogenated on a Parr
apparatus at 52 psi for 18 h. The reaction suspension was then
filtered and the filtrate concentrated in vacuo. The resulting
residue was partitioned between 1 N aq. NaOH and ether. The aqueous
layer was separated and back extracted with ether. The combined
ethereal extracts were washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded the title
compound.
Step 2
Amine 31
[0330] Amine 31 was prepared according to the procedure described
in Amine 30, but using instead 1-cyclobutylmethanamine from the
previous step as the starting material. The title compound was
isolated as a colorless oil.
Amine 32
N-2-Chloro-5-(2-methoxyethyl)benzyl]propan-2-amine
[0331] Amine 32 was prepared according to the procedure described
in Amine 30, but using instead isopropylamine as the starting
material. The title compound was isolated as a colorless oil.
Amine 33
N-[2-Chloro-5-(2-methoxyethyl)benzyl]prop-2-en-1-amine
[0332] Amine 33 was prepared according to the procedure described
in Amine 30, but using instead allylamine as the starting material.
The title compound was isolated as a colorless oil.
Amine 34
N-[2-Chloro-5-(2-methoxyethyl)benzyl]cyclobutanamine
[0333] Amine 34 was prepared according to the procedure described
in Amine 30, but using instead cyclobutylamine as the starting
material. The title compound was isolated as a colorless oil.
Amine 35
N-[2-Chloro-5-(2-methoxyethyl)phenyl]-N-ethanamine
[0334] Amine 35 was prepared according to the reaction sequence
described for Amine 29, but using instead ethylamine (2.0 M
solution in methanol) as starting material. The title compound was
isolated as a colorless oil.
Amine 36
N-[3-{[tert-Butyl(dimethyl)silyl]oxy}-5-[3-methoxypropyl)benzyl]cyclopropa-
namine
Step 1: 3-Bomo-5-hydroxybenzaldehyde
[0335] To a toluene solution (1.6 M) of n-butyl lithium (2.5 M
hexane solution, 2.1 eq.) was added at -10.degree. C. n-butyl
magnesium chloride (2.0 M THF solution, 0.6 eq.). The reaction
mixture was stirred at -10.degree. C. for 30 min before a toluene
solution (0.7 M) of 3,5-dibromophenol (1 eq.) was added dropwise at
-10.degree. C. over a period of 35 min. After stirring at
-10.degree. C. for a further 30 min, the reaction mixture was
cooled to -40.degree. C. before DMF (20 eq.) was added dropwise
over 20 min. The reaction mixture was then slowly warmed to RT and
allowed to stir at RT for 1 h. The reaction was carefully quenched
at 0.degree. C. with 10% aq. HCl and extracted with ether. The
combined organic extracts were washed with water and brine, dried
over MgSO.sub.4 and filtered. Concentration of the filtrate in
vacuo afforded a yellow solid. Recystallization of the crude
product thus obtained from ether-hexane afforded the title compound
as a beige powder.
Step 2: 3-Hydroxy-5-[(1E)-3-methoxyprop-1-en-1-yl]benzaldehyde
[0336] 3-Bomo-5-hydroxybenzaldehyde from the previous step (1 eq.)
and
2-[(1E)-3-methoxyprop-1-en-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(1 eq.) were combined in DMF (0.05 M). To this solution was then
added palladium acetate (10% loading), triphenylphosphine (20%
loading) and sodium carbonate (2 M aqueous solution, 4 eq.). The
resulting suspension was heated at 80.degree. C. for 16 h. The
reaction mixture was quenched with 10% aq. HCl and extracted with
ether. The combined organic extracts were washed with water, sat.
aq. NaHCO.sub.3 and brine. Drying over MgSO.sub.4, filtration and
concentration of the filtrate in vacuo afforded the crude product
as a brown tar. Purification by way of column chromatography
(SiO.sub.2, 4:1 (v/v) Hex:EtOAc.fwdarw.2:1 (v/v) Hex:EtOAc)
afforded the title compound as a yellow oil.
Step 3:
3-{[tert-Butyl(dimethyl)silyl]oxy}-5-[(1E)-3-methoxyprop-1-en-1-yl-
]benzaldehyde
[0337] 3-Hydroxy-5-[(1E)-3-methoxyprop-1-en-1-yl]benzaldehyde from
the previous step (1 eq.) and tert-butylchlorodimethylsilane (1
eq.) were combined in DMF (0.5 M). To this solution was then added
imidazole (1.5 eq.) and the reaction mixture was stirred at RT for
16 h. The resulting solution was quenched with water and extracted
with 1:1 (v:v) ether:hexanes. The combined organic extracts were
washed with brine, dried over MgSO.sub.4 and filtered through a
plug of SiO.sub.2. Concentration of the filtrate in vacuo afforded
the title compound as a pale yellow oil.
Step 4:
N-{3-{[tert-Butyl(dimethyl)silyl]oxy}-5-[(1E)-3-methoxyprop-1-en-1-
-yl]benzyl}cyclopropanamine
[0338] To a solution of
3-{[tert-butyl(dimethyl)silyl]oxy}-5-[(1E)-3-methoxyprop-1-en-1-yl]benzal-
dehyde from the previous step (1 eq.) in dichloromethane (0.5 M)
was added cyclopropylamine (2 eq.) and magnesium sulfate (1.5 eq.).
The resulting suspension was stirred at RT for 12 h. The insolubles
were removed via filtration. Concentration of the filtrate in vacuo
afforded the crude imine as a yellow oil. This was then taken up in
methanol (0.3 M) and then added at 0.degree. C. sodium borohydride
(1.5 eq.) portionwise over 5 min. The reaction mixture was slowly
warmed to RT over 1 h and then stirred at RT for 2 h. After
carefully quenching with sat. aq. NaHCO.sub.3, the resulting
mixture was extracted with ether. The combined organic extracts
were washed with water and brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded the title
compound as a golden, yellow oil.
Step 5
Amine 36
[0339] To a solution of
N-{3-{[tert-butyl(dimethyl)silyl]oxy}-5-[(1E)-3-methoxyprop-1-en-1-yl]ben-
zyl}cyclopropanamine from the previous step (1 eq.) in EtOAc (0.04
M) was added palladium (10% w/w over activated carbon, 10%
loading). The vessel was evacuated and back filled with hydrogen.
The reaction suspension was then stirred under a balloon atmosphere
of hydrogen for 1.5 h. The reaction was quenched with
dichloromethane and filtered through a bed of celite. The
insolubles were washed further with EtOAc and methanol.
Concentration of the filtrate in vacuo afforded the title compound
as a colorless oil.
Amine 37
Ethyl
2-{[2-chloro-3-[(cyclopropylamino)methyl]-5-(3-methoxypropyl)phenoxy-
]methyl}cyclopropane carboxylate
Step 1:
3-{[tert-Butyl(dimethyl)silyl]oxy}-5-(3-methoxypropyl)benzaldehyde
[0340] To a solution of
3-{[tert-butyl(dimethyl)silyl]oxy}-5-[(1E)-3-methoxyprop-1-en-1-yl]benzal-
dehyde from Amine 36, Step 3 (1 eq.) in EtOAc (0.1 M) was added
palladium (10% w/w over activated carbon, 10% loading). The vessel
was evacuated and back filled with hydrogen. The reaction
suspension was then stirred under a balloon atmosphere of hydrogen
for 1 h. The reaction was quenched with dichloromethane and
filtered through a bed of celite. The insolubles were washed
further with EtOAc and methanol. Concentration of the filtrate in
vacuo and purification of the crude product thus obtained by way of
column chromatography (SiO.sub.2, Hex.fwdarw.3:2 (v/v) Hex:EtOAc)
afforded the title compound as a pale yellow oil.
Step 2: 3-Hydroxy-5-(3-methoxypropyl)benzaldehyde
[0341] To a solution of
3-{[tert-butyl(dimethyl)silyl]oxy}-5-(3-methoxypropyl)benzaldehyde
from the previous step (1 eq.) in THF (0.2 M) was added
tetrabutylammonium fluoride (1.0 M THF solution, 1.1 eq.). The
resulting reaction mixture was then stirred at RT for 30 min. The
reaction was quenched sat. aq. NH.sub.4Cl and then extracted with
ether. The combined organic extracts were washed with water and
brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Further purification of the crude product
thus obtained by way of column chromatography (SiO.sub.2,
Hex.fwdarw.3:2 (v/v) Hex:EtOAc) afforded the title compound as a
pale yellow oil.
Step 3: 2-Chloro-3-hydroxy-5-(3-methoxypropyl)benzaldehyde
[0342] To a solution of 3-hydroxy-5-(3-methoxypropyl)benzaldehyde
from the previous step (1 eq.) in dichloromethane (0.2 M) was added
sulfuryl chloride (1 eq.). The resulting reaction mixture was then
stirred at RT for 18 h. The volatiles were removed in vacuo and
purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, Hex.fwdarw.3:2 (v/v) Hex:EtOAc) afforded
the title compound as a yellow oil.
Step 4: Ethyl
2-{[2-chloro-3-formyl-5-(3-methoxypropyl)phenoxy]methyl}cyclopropanecarbo-
xylate
[0343] To a solution of ethyl
2-(hydroxymethyl)cyclopropanecarboxylate from Experiment 86, Step 1
(1.2 eq.) in dichloromethane (0.15 M) was added at -78.degree. C.
Hunig's base (3 eq.) and methanesulfonyl chloride (1.5 eq.). The
resulting solution was stirred at -78.degree. C. for 15 min and
then warmed to RT over 3 h. The reaction was quenched with sat. aq.
NaHCO.sub.3 and then extracted with ether.
[0344] The combined organic extracts were washed with water and
brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo to afford the crude mesylate as a pale yellow
oil. This was then taken up in DMF (0.014 M) and added cesium
carbonate (1.2 eq.) and
2-chloro-3-hydroxy-5-(3-methoxypropyl)benzaldehyde from the
previous step (1 eq.). The resulting suspension was stirred at
50.degree. C. for 3 h. The reaction was quenched with sat. aq.
NH.sub.4Cl and then extracted with ether. The combined organic
extracts were washed with water and brine, dried over MgSO.sub.4
and filtered. Concentration of the filtrate in vacuo and
purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, Hex.fwdarw.7:3 (v/v) Hex:EtOAc) afforded
the title compound.
Step 5
Amine 37
[0345] Amine 37 was prepared according to the procedure described
in Amine 3, but using instead ethyl
2-{[2-chloro-3-formyl-5-(3-methoxypropyl)phenoxy]methyl}cyclopropanecarbo-
xylate from the previous step as the starting material. The title
compound was isolated as a white foam.
Amine 38
N-[3,5-Bis(2-methoxyethoxy)benzyl]cyclopropanamine
Step 1: 3,5-Bis(2-methoxyethoxy)benzaldehyde
[0346] To a solution of 3,5-dihydroxybenzaldehyde (1 eq.) in DMF
(0.5 M) was added 2-bromoethyl methyl ether (3.5 eq.) and cesium
carbonate (5 eq.). The resulting suspension was heated at
80.degree. C. for 16 h. The reaction was quenched with sat. aq.
NH.sub.4Cl and then extracted with ether. The combined organic
extracts were washed with water and brine, dried over
Na.sub.2SO.sub.4, filtered and the filtrate concentrated in vacuo.
Purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, Hex.fwdarw.3:1 (v/v) Hex:EtOAc) afforded
the title compound as a yellow oil.
Step 2
Amine 38
[0347] To a solution of 3,5-bis(2-methoxyethoxy)benzaldehyde from
the previous step (1 eq.) in dichloromethane (0.3 M) was added
cyclopropylamine (2 eq.) and magnesium sulfate (1.5 eq.). The
resulting suspension was stirred at RT for 12 h. The insolubles
were removed via filtration. Concentration of the filtrate in vacuo
afforded the crude imine as a yellow oil. This was then taken up in
methanol (0.8 M) and then added at 0.degree. C. sodium borohydride
(1.5 eq.) portionwise over 5 min. The reaction mixture was slowly
warmed to RT over 1 h and then stirred at RT for 1.5 h. The
reaction was quenched with sat. aq. NaHCO.sub.3 and then extracted
with EtOAc. The combined organic extracts were washed with water
and brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of column chromatography (SiO.sub.2, 95:5 (v/v)
CH.sub.2Cl.sub.2:EtOH.fwdarw.90:10 (v/v) CH.sub.2Cl.sub.2:EtOH)
afforded the title compound as a colorless oil.
Amine 39
N-[3,5-Bis(4,4,4-trifluorobutoxy)benzyl]cyclopropanamine
[0348] Amine 39 was prepared according to the reaction sequence
described for Amine 38, but using instead 4,4,4-trifluorobutan-1-ol
as starting material. The title compound was isolated as a
colorless oil.
Amine 40
[5-Chloro-2-(3-methoxy-propyl)-pyridin-4-ylmethyl]-cyclopropyl-amine
Step 1: 2-Bromo-5-chloro-pyridine-4-carbaldehyde
[0349] To a stirred sol. of diisopropylamine (20.9 mL, 148 mmol) in
dry THF (350 mL) at -5.degree. C. was added dropwise BuLi (1.6M in
hexane, 89.5 mL, 143 mmol), and the resulting sol. was stirred for
30 min at -5.degree. C. The sol. was allowed to cool to -70.degree.
C., and a sol. of 2-bromo-5-chloropyridine (25.0 g, 130 mmol) in
THF (100 mL) was added dropwise at -70.degree. C. over 15 min, such
that the internal temperature did not exceed -65.degree. C. The
mixture was stirred at -70.degree. C. for 30 min. DMF (10.52 mL,
136 mmol) was added dropwise over 20 min such that the internal
temperature did not exceed -70.degree. C. The orange mixture was
stirred at -70.degree. C. for 40 min. The mixture was allowed to
warm up to rt, and was poured onto a mixture of water (200 mL) and
aq. 1M NaOH (50 mL). The mixture was extracted with EtOAc
(2.times.), and the combined org. extracts were washed back with
aq. 1M NaOH (2.times.). The org. extracts were dried over
MgSO.sub.4, filtered, and the solvents were removed under reduced
pressure. Purification of the crude by FC (EtOAc/heptane
1:9.fwdarw.1:8.fwdarw.1:6.fwdarw.1:4.fwdarw.1:2.fwdarw.1:1) yielded
the title compound (21.55 g, 72%). LC-MS: t.sub.R=0.74 min; ES+:
295.01.
Step 2: 2-Bromo-5-chloro-4-dimethoxymethyl-pyridine
[0350] To a sol. of 2-bromo-5-chloro-pyridine-4-carbaldehyde (43.9
g, 199 mmol) in MeOH (800 mL) were successively added at rt
trimethyl orthoformate (65.3 mL, 597 mmol) and p-toluenesulfonic
acid monohydrate (1.90 g, 10.0 mmol). This reaction mixture was
then heated to reflux for 3 h. The mixture was allowed to cool to
rt and was concentrated under reduced pressure. The residue was
dissolved in CH.sub.2Cl.sub.2 and this mixture was washed with aq.
10% K.sub.2CO.sub.3. The org. layer was dried over MgSO.sub.4,
filtered, and the solvents were removed under reduced pressure.
Drying under high vacuum yielded the title compound (51.7 g, 97%).
LC-MS: t.sub.R=0.92 min; ES+: 309.06.
Step 3:
5-Chloro-4-dimethoxymethyl-2-(3-methoxy-propyl)-pyridine
[0351] To a suspension of Mg (911 mg, 37.5 mmol) and of iodine (one
crystal) in dry THF (30 mL) was added dropwise 5% of the total
amount of 1-bromo-3-methoxypropane (4.59 g, 30.0 mmol). The mixture
was heated to reflux with the help of a heat gun until the Grignard
formation had started. The rest of the 1-bromo-3-methoxypropane was
added slowly, while an exothermic reaction proceeded. After the end
of the addition, the reaction mixture was stirred under reflux for
20 min, and was allowed to cool to rt. This Grignard sol. (1M in
THF, 23.5 mL, 23.5 mmol) was added dropwise to a mixture of
2-bromo-5-chloro-4-dimethoxymethyl-pyridine (2.50 g, 9.38 mmol) and
Ni(dppp)Cl.sub.2 (495 mg, 0.938 mmol) in THF (50 mL) at 0.degree.
C. The reaction mixture was stirred at rt for 30 min, and was then
heated to reflux for 2 h. The mixture was allowed to cool to rt,
and was dissolved with EtOAc. This mixture was washed with aq. sat.
NaHCO.sub.3. The org. layer was dried over MgSO.sub.4, filtered,
and the solvents were removed under reduced pressure. Purification
of the residue by FC (heptane.fwdarw.EtOAc/heptane 1:1) yielded the
title compound (1.51 g, 62%). LC-MS: t.sub.R=0.80 min; ES+:
260.15.
Step 4: 5-Chloro-2-(3-methoxy-propyl)-pyridine-4-carbaldehyde
[0352] 5-Chloro-4-dimethoxymethyl-2-(3-methoxy-propyl)-pyridine
(25.5 g, 98.2 mmol) was dissolved in aq. 1M HCl (500 mL), and the
mixture was heated to 80.degree. C. for 2 h. The mixture was
allowed to cool to rt, and EtOAc was added. The mixture was cooled
to 0.degree. C., and was basified with an aq. 2.5M NaOH until a
pH=10 was reached. The layers were separated, and the org. layer
was dried over MgSO.sub.4, filtered, and concentrated under reduced
pressure. Drying the residue under high vacuum yielded the crude
title compound (98.1 mmol, 99%) that was used further without
purification. LC-MS: t.sub.R=0.62 min; ES+: 246.12.
Step 5:
[5-Chloro-2-(3-methoxy-propyl)-pyridin-4-ylmethyl]-cyclopropyl-ami-
ne
[0353] A mixture of
5-chloro-2-(3-methoxy-propyl)-pyridine-4-carbaldehyde (21.0 g, 98.2
mmol) and cyclopropylamine (13.8 mL, 196 mmol) in MeOH (450 mL) was
stirred at rt overnight. NaBH.sub.4 (4.83 g, 128 mmol) was added at
0.degree. C., and the mixture was stirred at rt overnight. Ice was
added, and the mixture was concentrated under reduced pressure. The
crude product was dissolved in EtOAc, and this mixture was washed
with aq. 1M NaOH. The aq. layer was extracted back with EtOAc. The
combined org. extracts were dried over MgSO.sub.4, filtered, and
the solvents were removed under reduced pressure. Purification of
the crude by FC (EtOAc/heptane
1:5.fwdarw.1:4.fwdarw.1:3.fwdarw.1:1.fwdarw.3:1.fwdarw.EtOAc)
yielded the title compound (11.8 g) and
[5-chloro-2-(3-methoxy-propyl)-pyridin-4-ylmethylene]-cyclopropyl-amine
(10.7 g). This unreacted imine was dissolved in MeOH (20 mL), and
this sol. was cooled to 0.degree. C. NaBH.sub.4 (3.20 g, 84.6 mmol)
was added, and the mixture was stirred at rt overnight. NaBH.sub.4
(3.20 g, 84.6 mmol) was added again, and the mixture was stirred
for 3 days. Ice was added to the reaction mixture, and the mixture
was concentrated under reduced pressure. The crude product was
dissolved in EtOAc and the resulting mixture was washed with aq. 1M
NaOH. The aq. phase was extracted back with EtOAc. The combined
org. extracts were dried over MgSO.sub.4, filtered, and the
solvents were removed under reduced pressure. Purification of the
crude by FC (EtOAc/heptane 1:3.fwdarw.1:2.fwdarw.1:1.fwdarw.EtOAc)
yielded the title compound (9.4 g). The fractions of the title
compound were mixed together (21.2 g, 85%). LC-MS: t.sub.R=0.55
min; ES+: 296.16.
Amine 41
N-{[2-M
ethoxy-6-(3-methoxypropyl)pyridin-4-yl]methyl}cyclopropanamine
Step 1: 2,6-Dichloro-N-cyclopropylisonicotinamide
[0354] To a solution of 2,6-dichloroisonicotinic acid (1 eq.) in
DMF (0.05 M) was added sequentially cyclopropylamine (1.05 eq.),
Hunig's base (3 eq.) and
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.2 eq.). The resulting solution was stirred
at RT for 4 h. The reaction was quenched with sat. aq. NH.sub.4Cl
and extracted with EtOAc. The combined organic extracts were washed
with brine, dried over Na.sub.2SO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 10:1 (v/v)
CH.sub.2Cl.sub.2:EtOAc) afforded the title compound as a white
solid.
Step 2: 2-Chloro-N-cyclopropyl-6-methoxyisonicotinamide
[0355] To a solution of 2,6-dichloro-N-cyclopropylisonicotinamide
from the previous step (1 eq.) in methanol (0.2 M) was added sodium
methoxide (6 eq.). The reaction vessel was sealed and the resulting
solution was heated in the microwave at 105.degree. C. for 30 min.
The volatiles were removed in vacuo and the resulting residue was
partitioned between sat. aq. NH.sub.4Cl and EtOAc. The organic
layer was separated and washed further with brine. Drying over
Na.sub.2SO.sub.4, filtration and concentration of the filtrate in
vacuo afforded the title compound as a white solid.
Step 3:
N-Cyclopropyl-2-methoxy-6-[(1E)-3-methoxyprop-1-en-1-yl]isonicotin-
amide
[0356] To a solution of
2-chloro-N-cyclopropyl-6-methoxyisonicotinamide from the previous
step (1 eq.) in DMF (0.3 M) was added
(2-[(1E)-3-methoxyprop-1-en-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(1 eq.), palladium bromide (5% loading), triphenylphosphine (10%
loading) and sodium carbonate (2 M aqueous solution, 3 eq.). The
resulting suspension was heated at 100.degree. C. for 7 h. The
reaction mixture was quenched with water and extracted with ether.
The combined organic extracts were washed with sat. aq. NaHCO.sub.3
and brine. Drying over Na.sub.2SO.sub.4, filtration and
concentration of the filtrate in vacuo afforded the crude product
as a brown tar. Purification by way of column chromatography
(SiO.sub.2, 1:1 (v/v) Hex:EtOAc) followed by recrystallization from
Hex:ether afforded the title compound as a white solid.
Step 4:
N-Cyclopropyl-2-methoxy-6-(3-methoxypropyl)isonicotinamide
[0357] To a solution of
N-cyclopropyl-2-methoxy-6-[(1E)-3-methoxyprop-1-en-1-yl]isonicotinamide
from the previous step (1 eq.) in EtOAc (0.2 M) was added palladium
(10% w/w over activated carbon, 15% loading). The reaction vessel
was evacuated and back-filled with hydrogen. The reaction
suspension was then stirred under a balloon atmosphere of hydrogen
for 4 h. The reaction was quenched with CH.sub.2Cl.sub.2, filtered
through celite and the insolubles washed further with EtOAc.
Concentration of the filtrate in vacuo afforded the title compound
as a white solid.
Step 5
Amine 41
[0358] To a solution of
N-cyclopropyl-2-methoxy-6-(3-methoxypropyl)isonicotinamide from the
previous step (1 eq.) in THF (0.2 M) was added lithium aluminum
hydride (1.0 M THF solution, 5 eq.). The resulting solution was
then heated at 70.degree. C. for 1 h. The reaction was quenched
carefully with sat. aq. NaHCO.sub.3. The resulting gel was then
diluted with EtOAc and sat. aq. Rochelle's salt and the biphasic
mixture was stirred at RT for 3 h. The organic layer was separated,
washed with brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo and purification of the
crude product thus obtained by way of column chromatography
(SiO.sub.2, 90:9:1 (v/v/v) CH.sub.2Cl.sub.2:EtOH:conc. NH.sub.4OH)
afforded the title compound as a colorless oil.
Amine 42
N-{[2-{[tert-butyl(dimethyl)silyl]oxy}-6-(3-methoxypropyl)pyridin-4-yl]met-
hyl}cyclopropanamine
Step 1:
4-[(Cyclopropylamin)methyl]-6-(3-methoxypropyl)pyridin-2-ol
[0359] To a solution of
N-{[2-methoxy-6-(3-methoxypropyl)pyridin-4-yl]methyl}cyclopropanamine
(1 eq.) in DMF (0.13 M) was added at 0.degree. C. sodium hydride
(60% w/w dispersion in mineral oil, 2.5 eq.) and ethanethiol (2.5
eq.). The resulting mixture was stirred at 150.degree. C. for 1.5
h. The reaction was diluted with water and washed with EtOAc. The
aqueous layer was then separated, saturated with NH.sub.4Cl and
extracted with EtOAc. Concentration of the combined organic
extracts in vacuo afforded the title compound as a white solid.
Step 2
Amine 42
[0360] To a solution of
4-[(cyclopropylamin)methyl]-6-(3-methoxypropyl)pyridin-2-ol from
the previous step (1 eq.) in DMF (0.1 M) was added and
tert-butylchlorodimethylsilane (1.1 eq.) and imidazole (1.1 eq.).
The resulting reaction mixture was stirred at RT for 18 h. The
reaction was quenched with water and extracted with ether. The
combined organic extracts were washed with brine, dried over
MgSO.sub.4 and filtered. Concentration of the filtrate in vacuo and
purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, 80:15:5 (v/v/v) Hex:EtOAc:triethylamine)
afforded the title compound as a colorless oil.
Amine 43
N-{[2,6-bis(3-methoxypropyl)pyridin-4-yl]methyl}cyclopropanamine
Step 1:
N-Cyclopropyl-2,6-bis[(1E)-3-methoxyprop-1-en-1-yl]isonicotinamide
[0361] To a solution of 2,6-dichloro-N-cyclopropylisonicotinamide
from Amine 41, Step 1 (1 eq.) in DMF (0.08 M) was added
(2-[(1E)-3-methoxyprop-1-en-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(2.7 eq.), palladium bromide (5% loading), triphenylphosphine (10%
loading) and sodium carbonate (2 M aqueous solution, 5 eq.). The
resulting suspension was heated at 100.degree. C. for 8 h. The
reaction mixture was quenched with water and extracted with ether.
The combined organic extracts were washed with sat. aq. NaHCO.sub.3
and brine. Drying over Na.sub.2SO.sub.4, filtration and
concentration of the filtrate in vacuo afforded the crude product
as a red oil. Purification by way of column chromatography
(SiO.sub.2, 1:1 (v/v) Hex:EtOAc) afforded the title compound as a
yellow oil.
Step 2: N-Cyclopropyl-2,6-bis(3-methoxypropyl)isonicotinamide
[0362] To a solution of
N-cyclopropyl-2,6-bis[(1E)-3-methoxyprop-1-en-1-yl]isonicotinamide
from the previous step (1 eq.) in EtOAc (0.2 M) was added palladium
(10% w/w over activated carbon, 40% loading). The reaction vessel
was evacuated and back-filled with hydrogen. The reaction
suspension was then stirred under a balloon atmosphere of hydrogen
for 24 h. The reaction was quenched with CH.sub.2Cl.sub.2, filtered
through celite and the insolubles washed further with EtOAc.
Concentration of the filtrate in vacuo and purification of the
crude product thus obtained by way of column chromatography
(SiO.sub.2, 1:1 (v/v) Hex:EtOAc.fwdarw.1:4 (v/v) Hex:EtOAc)
afforded the title compound as a colorless oil.
Step 3
Amine 43
[0363] To a solution of
N-cyclopropyl-2,6-bis(3-methoxypropyl)isonicotinamide from the
previous step (1 eq.) in THF (0.1 M) was added lithium aluminum
hydride (1.0 M THF solution, 6 eq.). The resulting solution was
then heated at 70.degree. C. for 2 h. The reaction was quenched
carefully with sat. aq. NaHCO.sub.3. The resulting gel was then
diluted with EtOAc and sat. aq. Rochelle's salt and the biphasic
mixture was stirred at RT for 3 h. The organic layer was separated,
washed with brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo and purification of the
crude product thus obtained by way of column chromatography
(SiO.sub.2, 95:5:1 (v/v/v) CH.sub.2Cl.sub.2:EtOH:conc.
NH.sub.4OH.fwdarw.90:10:1 (v/v/v) CH.sub.2Cl.sub.2:EtOH:conc.
NH.sub.4OH) afforded the title compound as a pale yellow oil.
Amine 44
N-({2-(3-methoxypropyl)-6-[(3-(methylthio)propoxy]pyridin-4-yl}methyl)cycl-
opropanamine
[0364] Amine 44 was prepared according to the reaction sequence
described for Amine 41, but using instead the sodium salt of
3-(methylthio)propan-1-ol as starting material and
N-methyl-2-pyrrolidinone as solvent in Step 2. The title compound
was isolated as a yellow oil.
Amine 45
N-{[2-(3-methoxypropyl)-6-(2-(morpholin-4-ylethoxy)pyridin-4-yl]methyl}cyc-
lopropanamine
[0365] Amine 45 was prepared according to the reaction sequence
described for Amine 41, but using instead the sodium salt of
2-morpholine-4-ylethanol as starting material and
N-methyl-2-pyrrolidinone as solvent in Step 2. The title compound
was isolated as a colorless oil.
Amine 46
N-(Pyridin-4-ylmethyl)cyclopropanamine
[0366] Amine 46 was prepared according to the reaction sequence
described for Amine 3, but using instead isonicotinaldehyde as the
starting material. The title compound was isolated as a yellow
oil.
Amine 47
N-(Pyridin-3-ylmethyl)cyclopropanamine
[0367] Amine 47 was prepared according to the reaction sequence
described for Amine 3, but using instead nicotinaldehyde as the
starting material. The title compound was isolated as a yellow
oil.
Amine 48
N-(Pyridin-2-ylmethyl)cyclopropanamine
[0368] Amine 47 was prepared according to the reaction sequence
described for Amine 3, but using instead pyridine-2-carbaldehyde as
the starting material. The title compound was isolated as a yellow
oil.
Amine 49
Ethyl (2-bromo-3[(cyclopropylamino)methyl]phenoxy)acetate
Step 1: Ethyl (2-bromo-3-formylphenoxy)acetate
[0369] To a solution of 2-bromo-3-hydroxybenzaldehyde (1 eq.) in
DMF (0.4 M) was added cesium carbonate (1.2 eq.) and ethyl
bromoacetate (1 eq.). The resulting suspension was stirred at RT
for 16 h. The reaction mixture was quenched with water and
extracted with EtOAc. The combined organic extracts were washed
with water and brine. Drying over MgSO.sub.4, filtration and
concentration of the filtrate in vacuo afforded the crude product
as a red oil. Purification by way of column chromatography
(SiO.sub.2, 5:1 (v/v) Hex:EtOAc.fwdarw.1:1 (v/v) Hex:EtOAc)
afforded the title compound.
Step 2
Amine 49
[0370] Amine 47 was prepared according to the reaction procedure
described in Amine 3, but using instead ethyl
(2-bromo-3-formylphenoxy)acetate from the previous step as the
starting material.
[0371] The title compound was isolated as a pale yellow oil.
Amine 50
Ethyl 3-{2-bromo-3-[(cyclopropylamino)methyl]phenoxy}propanoate
Step 1: 3-(2-Bromo-3-formylphenoxy)propanoic acid
[0372] To a solution of 2-bromo-3-hydroxybenzaldehyde (1 eq.) in
THF (1.2 M) was added sequentially potassium tert-butoxide (1.0 M
THF solution, 0.8 eq.) and oxetan-2one at RT. The resulting yellow
suspension was stirred at RT for 16 h. The reaction mixture was
quenched with 10% aq. HCl and extracted with EtOAc. The combined
organic extracts were washed with water and brine. Drying over
MgSO.sub.4, filtration and concentration of the filtrate in vacuo
afforded the title compound as a white solid.
Step 2: Ethyl 3-(2-Bromo-3-formylphenoxy)propanoate
[0373] To a solution of 3-(2-bromo-3-formylphenoxy)propanoic acid
from the previous step (1 eq.) in EtOH (0.13 M) was added conc.
sulfuric acid (0.8 eq.). The reaction was heated at reflux for 30
min. The reaction mixture was quenched with water and extracted
with EtOAc. The combined organic extracts were washed with water
and sat. aq. NaHCO.sub.3. Drying over Na.sub.2SO.sub.4, filtration
and concentration of the filtrate in vacuo afforded the title
compound as a yellow oil.
Step 3
Amine 50
[0374] Amine 50 was prepared according to the reaction procedure
described in Amine 3, but using instead ethyl
3-(2-bromo-3-formylphenoxy)propanoate from the previous step as the
starting material. The title compound was isolated as a pale yellow
oil.
Amine 51
Ethyl 5-{2-bromo-3-[(cyclopropylamino)methyl]phenoxy)pentanoate
[0375] Amine 51 was prepared according to the reaction sequence
described for Amine 49, but using instead ethyl
5-{2-bromo-3-[(cyclopropylamino)methyl]phenoxy}pentanoate as the
starting material. The title compound was isolated as a pale yellow
oil.
[0376] The aldehyde building blocks in Table 2 were synthesized as
follows.
TABLE-US-00002 TABLE 2 Compound Structure Aldehyde 1 ##STR00080##
Aldehyde 2 ##STR00081## Aldehyde 3 ##STR00082## Aldehyde 4
##STR00083## Aldehyde 5 ##STR00084##
Aldehyde 1
4-[2-(2,6-Dichloro-4-methylphenoxy)ethoxy]benzaldehyde
Step 1: 2-(2,6-Dichloro-4-methylphenoxy)ethanol
[0377] 2,6-Dichloro-4-methylphenol (1 eq.), ethylene carbonate (1
eq.) and imidazole (0.5% loading) were combined and heated at
150.degree. C. for 4 h to afford the title compound as a brown
oil.
Step 2: Aldehyde 1
[0378] 2-(2,6-Dichloro-4-methylphenoxy)ethanol from the previous
step (1 eq.) and 4-hydroxybenzaldehyde (1 eq.) were taken up in
freshly deoxygenated 3:1 (v/v) toluene:THF (0.3 M). To this
solution was then added 1,1'-(azodicarbonyl)-dipiperidine (1.2 eq.)
and finally tributylphosphine (1.2 eq.). The resulting orange
solution was heated at 80.degree. C. for 4 h. The reaction mixture
was cooled to RT, diluted with ether, and washed with 1 N aq. NaOH.
The aqueous wash was back extracted with ether and the combined
organic extracts were dried over MgSO.sub.4. Filtration and
concentration of the filtrate in vacuo afforded a yellow
semi-solid. Purification of the crude product thus obtained by way
of flash chromatography (SiO.sub.2, Hex.fwdarw.4:1 (v/v) Hex:EtOAc)
afforded the title compound as white needles.
Aldehyde 2
4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]benzaldehyde
Step 1: 3-(4-Bromophenyl)propan-1-ol
[0379] To a THF solution (0.5 M) of methyl
(2E)-3-(4-bromophenyl)acrylate (1 eq.) was added, at 0.degree. C.,
lithium aluminum hydride (1.0 M THF solution, 1 eq.) dropwise over
a period of for 3 h. The reaction mixture was then warmed slowly to
RT over 1 h. At 0.degree. C., the reaction was carefully quenched
with freshly-deoxygenated H.sub.2O. The organic layer was separated
and washed with cold 10% aq. HCl. The aqueous washes were combined
and back-extracted with ether. The organic extracts were then
washed further with sat. aq. NaHCO.sub.3 and brine, dried over
MgSO.sub.4, filtered and the filtrate concentrated in vacuo to
reveal a yellow oil. Purification by way of full vacuum
distillation afforded the title compound as a colorless oil.
Step 2:
2-[3-(4-Bromophenyl)propoxy]-3-chloro-1,4-difluorobenzene
[0380] 3-(4-Bromophenyl)propan-1-ol from the previous step (1 eq.)
and 2-chloro-3,6-difluorophenol (1 eq.) were taken up in freshly
deoxygenated toluene (0.3 M). To this solution was then added
1,1'-(azodicarbonyl)-dipiperidine (1.2 eq.) and finally
tributylphosphine (1.2 eq.). The resulting yellow solution was
heated at 80.degree. C. for 2 h. The reaction mixture was cooled to
RT, diluted with ether, and washed with 1 N aq. NaOH. The aqueous
wash was back extracted with ether and the combined organic
extracts were dried over MgSO.sub.4. Filtration and concentration
of the filtrate in vacuo afforded a yellow semi-solid. Purification
of the crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.15:1 (v/v) Hex:EtOAc) afforded the title
compound as a colorless oil.
Step 3: Aldehyde 2
[0381] To a solution of
2-[3-(4-bromophenyl)propoxy]-3-chloro-1,4-difluorobenzene from the
previous step (1 eq.) in anhydrous, deoxygenated DMF (0.5 M) was
added freshly dried sodium formate (1.5 eq.) and
Pd(PPh.sub.3)Cl.sub.2 (2% loading). The resulting yellow suspension
was bubbled CO and then heated to 95.degree. C. for 6 h. The now
black reaction suspension was cooled to RT, diluted with water, and
extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4 and filtered. Concentration of
the filtrate in vacuo afforded a yellow oil. Purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.4:1 (v/v) Hex:EtOAc) afforded the title
compound as a colorless oil.
Aldehyde 3
4-(3-{[tert-Butyl(dimethyl)silyl]oxy}propyl)benzaldehyde
Step 1: [3-(4-Bromophenyl)propoxy](tert-butyl)dimethylsilane
[0382] To a solution of 3-(4-bromophenyl)propan-1-ol (1 eq.) in DMF
(0.25 M) was added imidazole (1.2 eq.) and tert-butyldimethylsilyl
chloride (1.1 eq.). The resulting solution was stirred at RT for 13
h. The reaction mixture was quenched with sat. aq. NH.sub.4Cl and
extracted with hexanes. The combined organic extracts were washed
further with water and brine. Concentration of the organic extracts
in vacuo afforded the title compound as a colorless oil.
Step 2: Aldehyde 3
[0383] To a solution of
[3-(4-bromophenyl)propoxy](tert-butyl)dimethylsilane from the
previous step (1 eq.) in anhydrous, deoxygenated DMF (1.2 M) was
added freshly dried sodium formate (1.5 eq.) and
Pd(PPh.sub.3)Cl.sub.2 (2% loading). The resulting yellow suspension
was bubbled CO and then heated to 90.degree. C. for 8 h. The now
black reaction suspension was cooled to RT, diluted with water, and
extracted with hexanes. The combined organic extracts were washed
with brine, dried over MgSO.sub.4 and filtered. Concentration of
the filtrate in vacuo afforded a yellow oil. Purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.4:1 (v/v) Hex:EtOAc) afforded the title
compound as a colorless oil.
Aldehyde 4
4-[2-(2,6-dichloro-4-methylphenoxy)ethyl]benzaldehyde
Step 1: 2-[2-(4-Bromophenyl)ethoxy]-1,3-dichloro-5-methylbenzene
2-(4-Bromophenyl)ethanol (1 eq.) and 2,6-dichloro-4-methylphenol
(1.5 eq.) were taken up in freshly deoxygenated toluene (0.1 M). To
this solution was then added 1,1'-(azodicarbonyl)-dipiperidine (1.2
eq.) and finally tributylphosphine (1.2 eq.). The resulting yellow
solution was heated at 80.degree. C. for 2 h. The reaction mixture
was cooled to RT, diluted with ether, and washed with 1 N aq. NaOH.
The aqueous wash was back extracted with ether and the combined
organic extracts were dried over MgSO.sub.4. Filtration and
concentration of the filtrate in vacuo afforded a yellow
semi-solid. Purification of the crude product thus obtained by way
of flash chromatography (SiO.sub.2, Hex.fwdarw.10:1 (v/v)
Hex:EtOAc) afforded the title compound as a colorless oil.
Step 2: Aldehyde 4
[0384] To a solution of
2-[2-(4-bromophenyl)ethoxy]-1,3-dichloro-5-methylbenzene from the
previous step (1 eq.) in THF (0.08 M) was added, at -78.degree. C.,
n-butyl lithium (2.5 M hexane solution, 1.1 eq) dropwise over 15
min. The reaction mixture was stirred at -78.degree. C. for a
further 30 min before DMF (2 eq.) was slowly added. The resulting
solution was allowed to warm to RT over 3 h and then quenched with
H.sub.2O. The organic layer was separated and the aqueous layer was
back extracted with ether. The combined organic extracts were
washed with sat. aq. NaHCO.sub.3 and brine, dried over MgSO.sub.4
and filtered. Concentration of the filtrate in vacuo afforded the
title compound as a yellow oil.
Aldehyde 5
4-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethoxy)benzaldehyde
Step 1: 2-(4-Bromophenoxy)ethanol
[0385] 4-Bromophenol (1 eq.), ethylene carbonate (1 eq.) and
imidazole (0.5% loading) were combined and heated at 150.degree. C.
for 2 h to afford the title compound as a brown oil.
Step 2: 2-[(4-Bromophenoxy)ethoxy](tert-butyl)dimethylsilane
[0386] To a solution of 2-[(4-bromophenoxy)ethanol (1 eq.) in DMF
(0.5 M) was added imidazole (1.2 eq.) and tert-butyldimethylsilyl
chloride (1.1 eq.). The resulting solution was stirred at RT for 13
h. The reaction mixture was quenched with sat. aq. NH.sub.4Cl and
extracted with hexanes. The combined organic extracts were washed
further with water and brine. Concentration of the organic extracts
in vacuo afforded the title compound as a yellow oil.
Step 3: Aldehyde 5
[0387] To a solution of
2-(4-bromophenoxy)ethoxy](tert-butyl)dimethylsilane from the
previous step (1 eq.) in THF (0.2 M) was added, at -78.degree. C.,
n-butyl lithium (2.5 M hexane solution, 1.1 eq) dropwise over 15
min. The reaction mixture was stirred at -78.degree. C. for a
further 30 min before DMF (2 eq.) was slowly added. The resulting
solution was allowed to warm to RT over 3 h and then quenched with
H.sub.2O. The organic layer was separated and the aqueous layer was
back-extracted with ether. The combined organic extracts were
washed with sat. aq. NaHCO.sub.3 and brine, dried over MgSO.sub.4
and filtered. Concentration of the filtrate in vacuo afforded the
title compound as a yellow oil.
[0388] Compounds of the present invention were prepared according
to the following methods.
Example 1
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-(2,3-dimethylbenzyl)propanamide
##STR00085##
[0389] Step 1:
2-Cyano-N-cyclopropyl-N-(2,3-dimethylbenzyl)acetamide
[0390] To a DMF solution (0.6 M) of cyanoacetic acid (1 eq.),
Hunig's base (3 eq.) and Amine 1 (1 eq.) was added portionwise
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylur onium
hexafluorophosphate (1.2 eq.). The resulting reaction solution was
stirred at RT for 16 h. The now reddish solution was diluted with
ether and washed with H.sub.2O and 10% aq. HCl. The aqueous washes
were back extracted with ether. The combined organic extracts were
washed with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo to afford a yellow semi-solid. Purification
of the crude product thus obtained by way of flash chromatography
(SiO.sub.2, 10:1.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title
compound as off-white crystalline plates.
Step 2:
(2E)-2-Cyano-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)e-
thoxy}phenyl]-N-(2,3-dimethylbenzyl)acrylamide
[0391] 2-Cyano-N-cyclopropyl-N-(2,3-dimethylbenzyl)acetamide from
the previous step (1 eq.) and Aldehyde 1 (1 eq.) were combined in
benzene (0.04 M). To this solution was then added a few drops of
piperidine and a Dean-Stark apparatus was attached to the reaction
vessel. The resulting pale yellow solution was heated at reflux for
48 h. The volatiles were removed in vacuo and the crude product
thus obtained was purified by way of column chromatography
(SiO.sub.2, 10:1.fwdarw.1:1 (v/v) Hex:EtOAc). The title compound
was isolated as a white foam.
Step 3: tert-Butyl
(3-[cyclopropyl(2,3-dimethylbenzyl)amino]-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
[0392]
(2E)-2-Cyano-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)et-
hoxy]phenyl}-N-(2,3-dimethylbenzyl)acrylamide from the previous
step (1 eq.) and cobalt(II) chloride hexahydrate (2 eq.) were
combined in a 8:1 (v/v) MeOH:THF solution (0.02 M). To this mixture
was then added sodium borohydride (10 eq.) slowly and portionwise.
The resulting black suspension was stirred at RT for 8 h. The
reaction mixture was then diluted with 95:5 (v/v)
CH.sub.2Cl.sub.2:MeOH and quenched with 1 N aq. NaOH. The resulting
emulsion was then filtered through a bed of celite and the
insolubles were rinsed with 95:5 (v/v) CH.sub.2Cl.sub.2:MeOH. The
organic layer was separated and washed further with 1 N aq. NaOH,
H.sub.2O and brine. Drying over MgSO.sub.4, filtration and
concentration of the filtrate in vacuo afforded the crude amine as
a golden oil. This residue was then taken up in CH.sub.2Cl.sub.2
(0.06 M) and added di-tert-butyl dicarbonate (1 eq.). Finally,
sodium hydroxide (1.0 N aqueous solution, 3 eq.) was added and the
resulting biphasic mixture was vigorously stirred for 4 h.
Following careful acidification with 10% aq. HCl to a pH of
.about.2, the aqueous layer was separated and back extracted with
ether. The combined organic extracts were then washed H.sub.2O and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded a yellow oil. Purification of the crude
product thus obtained by way of column chromatography (SiO.sub.2,
Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title compound as a
white froth.
Step 4:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-(2,3-dimethylbenzyl)propanamide
[0393] To a CH.sub.2Cl.sub.2 solution (0.05 M) of
tert-butyl(3-[cyclopropyl(2,3-dimethylbenzyl)amino]-2-{4-[2-(2,6-dichloro-
-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from the
previous step (1 eq.) was added HCl (4.0 M dioxane solution, 30
eq.). The resulting solution was stirred at RT for 3 h. Following
the removal of the volatiles in vacuo, the resulting residue was
directly loaded onto a SiO.sub.2 column packed with 97:3 (v/v)
CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH. Elution with the same
solvent system furnished the title compound as a white froth. MS
(ESI+): 555.0.
Example 2
3-Amino-N-cyclopropyl-1-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-met-
hylphenoxy)ethoxy]benzyl}propanamide
##STR00086##
[0395] Prepared according to the procedure described in Example 1
but using instead Amine 2 as starting material. The title compound
was obtained as a white froth. MS (ESI+): 595.0.
Example 3
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-(1,2,3,4-tetrahydroquinolin-8-ylmethyl)propanamide
##STR00087##
[0397] Prepared according to the procedure described in Example 1
but using instead Amine 4 as starting material. The title compound
was obtained as a white froth. MS (ESI+): 582.2.
Example 4
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)benzyl]propanamide
##STR00088##
[0399] Prepared according to the procedure described in Example 1
but using instead Amine 5 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 599.5.
Example 5
3-Amino-2-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl}-N-cyclopropyl-
-N-[3-(3-methoxypropyl)benzyl]propanamide
##STR00089##
[0401] Prepared according to the procedure described in Example 1
but using instead Amine 5 and Aldehyde 2 as starting materials. The
title compound was obtained as a colorless oil. MS (ESI+):
584.9.
Example 6
3-Amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00090##
[0403] Prepared according to the procedure described in Example 1
but using instead Amine 6 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 633.0.
Example 7
3-Amino-2-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl}-N-[2-chloro-5-
-(3-methoxypropyl)benzyl]-N-cyclopropylpropanamide
##STR00091##
[0405] Prepared according to the procedure described in Example 1
but using instead Amine 6 and Aldehyde 2 as starting materials. The
title compound was obtained as a colorless oil. MS (ESI+):
618.9.
Example 8
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{3-[2-(methylsulfonyl)ethyl]benzyl}propanamide
##STR00092##
[0407] Prepared according to the procedure described in Example 1
but using instead Amine 8 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 633.1.
Example 9
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-(quinolin-4-ylmethyl)propanamide
##STR00093##
[0408] Step 1: Methyl
(2E)-2-cyano-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}acrylate
[0409] Methyl cyanoacetate (1 eq.) and Aldehyde 1 (1 eq.) were
combined in toluene (0.16 M). To this solution was then added a few
drops of piperidine and a Dean-Stark apparatus was attached to the
reaction vessel. The resulting pale yellow solution was heated at
reflux for 3 h. The volatiles were removed in vacuo to afford the
title compound was isolated as an off-white powder.
Step 2: Methyl
3-[(tert-butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)etho-
xy]benzyl}propanoate
[0410] Methyl
(2E)-2-cyano-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}acrylate
from the previous step (1 eq.) and cobalt(II) chloride hexahydrate
(2 eq.) were combined in a 5:3 (v/v) THF:MeOH solution (0.016 M).
To this mixture was then added sodium borohydride (10 eq.) slowly
and portionwise. The resulting black suspension was stirred at RT
for 2 h. The reaction mixture was then carefully quenched with 10%
aq. HCl and extracted with ether. The combined organic extracts
were washed further with H.sub.2O and brine. Drying over
MgSO.sub.4, filtration and concentration of the filtrate in vacuo
afforded the crude amine as a golden oil. This residue was combined
with di-tert-butyl dicarbonate (1 eq.), Hunig's base (1.5 eq.) and
a few crystals of 4-(dimethylamino)pyridine in CH.sub.2Cl.sub.2
(0.06 M). The resulting yellow solution was stirred at RT for 8 h.
The volatiles were then removed in vacuo to afford an orange
residue which was partitioned between ether and 10% aq. HCl. The
organic layer was separated and the aqueous layer was back
extracted with ether. The combined organic extracts were then
washed H.sub.2O and brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded a yellow oil.
Purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded
the title compound as a pale yellow oil.
Step 3:
3-[tert-Butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenox-
y)ethoxy]benzyl}propanoic acid
[0411] Methyl
3-[(tert-butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)etho-
xy]benzyl}propanoate from the previous step (1 eq.) was dissolved
in a 2:1 (v/v) THF:MeOH solution (0.056 M). To this was then added
sodium hydroxide (1.0 M aqueous solution, 3 eq.) and the resulting
solution was stirred at RT for 18 h. The volatiles were then
removed in vacuo. Following careful acidification of the resulting
mixture to pH .about.1 with 10% aq. HCl, the solution was extracted
with ether and EtOAc. The combined organic extracts were washed
further with H.sub.2O and brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded a yellow
oil. Purification of the crude product thus obtained by way of
column chromatography (SiO.sub.2, 66:33:1 (v/v/v) Hex:EtOAc:AcOH)
afforded the title compound as a white froth.
Step 4: tert-Butyl
(3-[cyclopropyl(quinolin-4-ylmethyl)amino]-2-{4-[2-(2,6-dichloro-4-methyl-
phenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
[0412]
3-[tert-Butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}propanoic acid from the previous step (1 eq.) was
combined with Hunig's base (3 eq.) and Amine 3 (1 eq.) in anhydrous
DMF (0.6 M). To this was then added portionwise
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.2 eq.). The resulting yellow solution was
stirred at RT for 18 h. The now reddish solution was diluted with
ether and washed with H.sub.2O. The aqueous washes were back
extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo to afford a yellow semi-solid. Purification
of the crude product thus obtained by way of flash chromatography
(SiO.sub.2, 10:1 (v/v) Hex:EtOAc.fwdarw.EtOAc) afforded the title
compound as a white froth.
Step 5:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-(quinolin-4-ylmethyl)propanamide
[0413] To a CH.sub.2Cl.sub.2 solution (0.05 M) of tert-butyl
(3-[cyclopropyl(quinolin-4-ylmethyl)amino]-2-{4-[2-(2,6-dichloro-4-methyl-
phenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from the previous step
(1 eq.) was added HCl (4.0 M dioxane solution, 30 eq.). The
resulting solution was stirred at RT for 3 h. Following the removal
of the volatiles in vacuo, the resulting residue was directly
loaded onto a SiO.sub.2 column packed with 95:5 (v/v)
CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH. Elution with the same
solvent system furnished the title compound as a white froth. MS
(ESI+): 578.0.
Example 10
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-(quinolin-8-ylmethyl)propanamide
##STR00094##
[0415] Prepared according to the procedure described in Example 9
but using instead Amine 4 as starting material. The title compound
was obtained as a white froth. MS (ESI+): 578.1.
Example 11
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-d-
ichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00095##
[0417] Prepared according to the procedure described in Example 9
but using instead Amine 6 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 619.3.
Example 12
N-(3-{[Acetyl(methyl)amino]methyl}benzyl)-3-amino-N-cyclopropyl-2-{4-[2-(2-
,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00096##
[0419] Prepared according to the procedure described in Example 9
but using instead Amine 9 as starting material. The title compound
was obtained as a white froth. MS (ESI+): 612.2.
Example 13
N-(5-{[Acetyl(methyl)amino]methyl}-2-chlorobenzyl)-3-amino-N-cyclopropyl-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00097##
[0421] Prepared according to the procedure described in Example 9
but using instead Amine 10 as starting material. The title compound
was obtained as a white froth. MS (ESI+): 646.1.
Example 14
3-Amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[3-(2,6-dichloro-4-methy-
lphenoxy)propyl]benzyl}propanamide
##STR00098##
[0422] Step 1:
[4-(3-{[tert-Butyl(dimethyl)silyl]oxy}propyl)phenyl]methanol
[0423] At 0.degree. C., sodium borohydride (1.5 eq.) was added
portionwise to a MeOH solution (0.2 M) of Aldehyde 3 (1 eq.). The
resulting mixture was stirred at 0.degree. C. for 15 min and then
at RT for 30 min. Following the removal of the volatiles in vacuo,
the resulting residue was partitioned between ether and 1 N aq.
NaOH. The aqueous layer was separated and back extracted with
ether. The combined organic extracts were washed with H.sub.2O and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded the title compound as a colorless
oil.
Step 2:
tert-Butyl{3-[4-(iodomethyl)phenyl]propoxy}dimethylsilane
[0424] At 0.degree. C., iodine (1.2 eq.) and imidazole (1.2 eq.)
were added to a CH.sub.2Cl.sub.2 solution (0.12 M) of
triphenylphosphine (1.2 eq.). The resulting yellow-orange
suspension was stirred at 0.degree. C. for 10 min and then at RT
for 30 min. Finally,
4-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)phenyl]methanol from
the previous step (1 eq.) was added. After another 5 h of stirring
at RT, the volatiles were removed in vacuo. The resulting brown
residue was partitioned between ether and H.sub.2O. The aqueous
layer was separated and back-extracted with ether. The combined
organic extracts were washed with 1 M aq. Na.sub.2S.sub.2O.sub.3
and brine, dried over MgSO.sub.4 and filtered. The filtrate was
added hexanes and passed through a plug of SiO.sub.2. Removal of
the volatiles in vacuo afforded the title compound as a pale pink
oil.
Step 3:
3-[4-(3-{[tert-Butyl(dimethyl)silyl]oxy}propyl)phenyl]-2-cyano-N-c-
yclopropyl-N-(2,3-dichlorobenzyl)propanamide
[0425] 2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)acetamide (1
eq.), prepared from Amine 2 and cyanoacetic acid as detailed in
Step 1 of Example 1, was dissolved in THF (0.1 M). At -78.degree.
C., potassium bis(trimethylsilyl)amide (15% w/w toluene solution, 1
eq.) was then added and the resulting yellow suspension was stirred
at -78.degree. C. for 15 min and at -40.degree. C. for 15 min.
tert-Butyl{3-[4-(iodomethyl)phenyl]propoxy}dimethylsilane from the
previous step (1 eq.) was then added, at -78.degree. C., as a 0.33
M THF solution over a period of 10 min. The resulting pale yellow
mixture was allowed to warm slowly to RT over 5 h. The reaction was
quenched with sat. aq. NH.sub.4Cl and extracted with ether. The
combined organic extracts were washed with H.sub.2O and brine,
dried over MgSO.sub.4 and filtered. Concentration of the filtrate
in vacuo afforded a viscous yellow oil. Purification of the crude
product thus obtained by way of column chromatography (SiO.sub.2,
10:1 (v/v) Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a
colorless oil.
Step 4:
2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-[4-(3-hydroxypropyl-
)phenyl]propanamide
[0426] To a solution of
3-[4-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)phenyl]-2-cyano-N-cyclopro-
pyl-N-(2,3-dichlorobenzyl)propanamide from the previous step (1
eq.) in THF (0.1 M) was added tetrabutylammonium fluoride (1.0 M
THF solution, 1.5 eq.). The resulting reaction mixture was stirred
at RT for 3 h. After quenching the reaction with 10% aq. HCl, the
mixture was extracted with ether. The combined organic extracts
were washed with sat. aq. NaHCO.sub.3 and brine, dried over
MgSO.sub.4 and filtered. Concentration of the filtrate in vacuo
afforded a pale yellow oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 10:1 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a colorless
oil.
Step 5:
2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-{4-[(3-(2,6-dichlor-
o-4-methylphenoxy)propyl]phenyl}propanamide
[0427]
2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-[4-(3-hydroxypropyl)-
phenyl]propanamide from the previous step (1 eq.) and
2,6-dichloro-4-methylphenol (2 eq.) were taken up in
freshly-deoxygenated toluene (0.1 M). To this solution was then
added 1,1'-(azodicarbonyl)-dipiperidine (2 eq.) and finally
tributylphosphine (2 eq.). The resulting yellow solution was heated
at 80.degree. C. for 2 h. The reaction mixture was cooled to RT,
diluted with ether, and washed with 1 N aq. NaOH. The aqueous wash
was back extracted with ether and the combined organic extracts
were dried over MgSO.sub.4. Filtration and concentration of the
filtrate in vacuo afforded a yellow semi-solid. Purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, 10:1 (v/v) Hex:EtOAc.fwdarw.EtOAc) afforded the title
compound as a colorless oil.
Step 6:
3-Amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[3-(2,6-dichloro-
-4-methylphenoxy)propyl]benzyl}propanamide
[0428]
2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-{4-[(3-(2,6-dichloro-
-4-methylphenoxy) propyl]phenyl}propanamide from the previous step
(1 eq.) and palladium (10% w/w over carbon, 50% loading) were
suspended in freshly deoxygenated MeOH (0.03 M). Then, HCl (4.0 M
dioxane solution, 20 eq) was added and the resulting suspension was
stirred under a static atmosphere of H.sub.2 for 16 h. The reaction
mixture was basified with ammonia (2.0 M MeOH solution), diluted
with CH.sub.2Cl.sub.2 and filtered through a bed of celite. The
insolubles were washed further with EtOAc. The combined filtrates
were concentrated in vacuo and the crude product thus obtained was
purified by way of flash chromatography (SiO.sub.2,
97:3.fwdarw.95:5 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH) to
furnish the title compound as a colorless oil. MS (ESI+):
593.0.
Example 15
3-Amino-2-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl}-N-cyclopropyl-
-N-(2,3-dichlorobenzyl)propanamide
##STR00099##
[0430] Prepared according to the procedure described in Example 14
but using 2-chloro-3,6-difluorphenol instead of
2,6-dichloro-4-methylphenol in Step 5. The title compound was
obtained as a colorless oil. MS (ESI+): 580.9.
Example 16
3-Amino-2-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl}-N-cyclopropyl-
-N-(2,3-dichlorobenzyl)-2-methylpropanamide
##STR00100##
[0431] Step 1:
3-[4-(3-{[tert-Butyl(dimethyl)silyl]oxy}propyl)phenyl]-2-cyano-N-cyclopro-
pyl-N-(2,3-dichlorobenzyl)-2-methylpropanamide
[0432] To a solution of
3-[4-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)phenyl]-2-cyano-N-cyclopro-
pyl-N-(2,3-dichlorobenzyl)propanamide (prepared as detailed in
Example 14, 1 eq.) in THF (0.1 M) was added, at -78.degree. C.,
potassium bis(trimethylsilyl)amide (15% w/w toluene solution, 1
eq.). The resulting yellow suspension was stirred at -78.degree. C.
for 15 min and at -40.degree. C. for 15 min. Iodomethane (1 eq.)
was then added and the reaction mixture was slowly warmed to RT
over 14 h. The reaction was quenched with sat. aq. NH.sub.4Cl and
extracted with ether. The combined organic extracts were washed
with H.sub.2O and brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded a pale yellow oil.
Purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, 10:1.fwdarw.1:1 (v/v) Hex:EtOAc)
afforded the title compound as a colorless oil.
Step 2:
2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-[4-(3-hydroxypropyl-
)phenyl]-2-methylpropanamide
[0433] To a solution of
3-[4-(3-[tert-butyl(dimethyl)silyl]oxy.gamma.propyl)phenyl]-2-cyano-N-cyc-
lopropyl-N-(2,3-dichlorobenzyl)-2-methylpropanamide from the
previous step (1 eq.) in THF (0.2 M) was added tetrabutylammonium
fluoride (1.0 M THF solution, 8 eq.). The resulting reaction
mixture was stirred at RT for 4 h. After quenching the reaction
with 10% aq. HCl, the mixture was extracted with ether. The
combined organic extracts were washed with sat. aq. NaHCO.sub.3 and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded a pale yellow oil. Purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, 10:1 (v/v) Hex:EtOAc.fwdarw.EtOAc) afforded the title
compound as a colorless oil.
Step 3:
3-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-2-cyano-N-cyc-
lopropyl-N-(2,3-dichlorobenzyl)-2-methylpropanamide
[0434]
2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-[4-(3-hydroxypropyl)-
phenyl]-2-methylpropanamide from the previous step (1 eq.) and
2-chloro-3,6-difluorphenol (4 eq.) were taken up in freshly
deoxygenated toluene (0.05 M). To this solution was then added
1,1'-(azodicarbonyl)-dipiperidine (4 eq.) and finally
tributylphosphine (4 eq.). The resulting yellow solution was heated
at 80.degree. C. for 3 h. The reaction mixture was cooled to RT,
diluted with ether, and washed with 1 N aq. NaOH. The aqueous wash
was back extracted with ether and the combined organic extracts
were dried over MgSO.sub.4. Filtration and concentration of the
filtrate in vacuo afforded a yellow semi-solid. Purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.3:2 (v/v) Hex:EtOAc) afforded the title
compound as a colorless oil.
Step 4:
3-Amino-2-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl}-N-cyc-
lopropyl-N-(2,3-dichlorobenzyl)-2-methylpropanamide
[0435]
3-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-2-cyano-N-cycl-
opropyl-N-(2,3-dichlorobenzyl)-2-methylpropanamide from the
previous step (1 eq.) and cobalt(II) chloride hexahydrate (2 eq.)
were combined in MeOH (0.1 M). To this mixture was then added
sodium borohydride (10 eq.) slowly and portionwise. The resulting
black suspension was stirred at RT for 1 h. The volatiles were then
removed in vacuo. The resulting black tar was partitioned between
EtOAc and 1 N aq. NaOH. The aqueous layer was separated and
back-extracted with EtOAc. The combined organic extracts were
washed further with H.sub.2O and brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo revealed a brown
oil. Purification of the crude product thus obtained by way of
column chromatography (SiO.sub.2, CH.sub.2Cl.sub.2.fwdarw.95:5
(v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH) afforded the title
compound as a colorless oil. MS (ESI+): 595.0.
Example 17
Ethyl
2-{[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-[2-(2,6-dichlo-
ro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]methyl}cyclopropanecar-
boxylate
##STR00101##
[0437] A mixture of
3-amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}propanamide (Example 2, 1 eq.), trans-ethyl
2-formyl-1-cyclopropanecarboxylate (1 eq.) and sodium
cyanoborohydride (1.5 eq.) were combined in MeOH (0.02 M). At
0.degree. C., acetic acid (3 eq.) was added dropwise and the
reaction mixture was slowly warmed to RT over 2 h. The reaction
mixture was then diluted with ether and quenched with 1 N aq. NaOH.
The aqueous layer was separated and back extracted with ether. The
combined organic extracts were then washed with water and brine,
dried over MgSO.sub.4 and filtered. Concentration of the filtrate
in vacuo afforded a purple residue. Purification of the crude
product thus obtained by way of flash chromatography (SiO.sub.2,
96:4 (v/v) CH.sub.2Cl.sub.2:MeOH) afforded the title compound as a
colorless oil. MS (ESI+): 721.1.
Example 18
3-(Benzylamino)-2-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl}-N-cyc-
lopropyl-N-(2,3-dichlorobenzyl)propanamide
##STR00102##
[0439] Prepared according to the procedure described in Example 17
but using instead
3-amino-2-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl}-N-cyclopropy-
l-N-(2,3-dichlorobenzyl)propanamide (Example 15) and benzaldehyde.
The title compound was obtained as a colorless oil. MS (ESI+):
670.8.
Example 19
Methyl
5-[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-(2,6-dichloro--
4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]pentanoate
##STR00103##
[0441] In a vessel equipped with a Dean-Stark apparatus, a benzene
solution (0.01 M) of
3-amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}propanamide (Example 2, 1 eq.) and methyl
5-oxopentanoate was heated at reflux for 8 h. The now yellow
solution was cooled to RT and then concentrated in vacuo. The
resulting residue was taken up in a 7:2 (v/v) MeOH:THF solution
(0.01 M) and then added sodium borohydride (10 eq.) portionwise.
After stirring at RT for 24 h, the mixture was diluted with ether
and quenched with 1 N aq. NaOH. The aqueous phase was separated and
back extracted with ether. The combined organic extracts were then
washed with water and brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded a yellow oil.
Purification of the crude product thus obtained by way of flash
chromatography (SiO.sub.2, 97:3 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH) afforded the title compound as a colorless oil.
MS (ESI+): 709.0.
Example 20
Methyl
6-[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-(2,6-dichloro--
4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]hexanoate
##STR00104##
[0443] Prepared according to the procedure described in Example 19
but using instead methyl 6-oxohexanoate. The title compound was
obtained as a colorless oil. MS (ESI+): 723.2.
Example 21
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}-3-[(2,2,2-trifluoroethyl)amino]propanamide
##STR00105##
[0445] Prepared according to the procedure described in Example 19
but using instead 2,2,2-trifluoro-1-methoxyethanol. The title
compound was obtained as a colorless oil. MS (ESI+): 677.0.
Example 22
2-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]benzyl}-N-cyclopropyl-N-(2,3--
dichlorobenzyl)-3-(methylamino)propanamide
##STR00106##
[0447] Prepared according to the procedure described in Example 19
but using instead
3-amino-2-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]benzyl}-N-cyclopropy-
l-N-(2,3-dichlorobenzyl)propanamide (Example 15) and
paraformaldehyde. The title compound was obtained as a colorless
oil. MS (ESI+): 595.3.
Example 23
6-[(3-[Cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-(2,6-dichloro-4-methy-
lphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]hexanoic acid
##STR00107##
[0449] Methyl
6-[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]hexanoate (Example 20, 1
eq.) was dissolved in a 2:1 (v/v) THF:MeOH solution (0.01 M). To
this was then added sodium hydroxide (1.0 M aqueous solution, 3
eq.) and the resulting solution was stirred at RT for 18 h. The
volatiles were then removed in vacuo. Following careful
acidification of the resulting residue to a pH of .about.4 with 10%
aq. HCl, the mixture was saturated with sodium chloride and
extracted with EtOAc. The combined organic extracts were
concentrated in vacuo. The resulting solid residue was then
azeotroped with toluene to give the title compound as a white
solid. MS (ESI+): 709.1.
Example 24
2-{[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{-4-[2-[2-(2,6-dichloro-4--
methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]methyl}cyclopropanecarboxyl-
ic acid
##STR00108##
[0451] To an ethanol solution (0.04 M) of ethyl
2-{[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{-4-[2-[2-(2,6-dichloro-4-
-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]methyl}cyclopropanecarboxy-
late (Example 17, 1 eq.) was added sodium hydroxide (1.0 M aqueous
solution, 4 eq.). The resulting solution was then heated at
80.degree. C. for 18 h. The volatiles were then removed in vacuo.
Following careful acidification of the resulting residue to a pH of
.about.4 with 10% aq. HCl, the mixture was saturated with sodium
chloride and extracted with EtOAc. The combined organic extracts
were dried over activated Na.sub.2SO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded the title compound
as a white solid. MS (ESI+): 693.1.
Example 25
3-Amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methy-
lphenoxy)ethyl]benzyl}propanamide
##STR00109##
[0452] Step 1:
{4-[2-(2,6-Dichloro-4-methylphenoxy)ethyl]phenyl}methanol
[0453] At 0.degree. C., sodium borohydride (1.5 eq.) was added
portionwise to a MeOH solution (0.2 M) of Aldehyde 4 (1 eq.). The
resulting mixture was stirred at 0.degree. C. for 15 min and then
at RT for 30 min. Following the removal of the volatiles in vacuo,
the resulting residue was partitioned between ether and 1 N aq.
NaOH. The aqueous layer was separated and back extracted with
ether. The combined organic extracts were washed with H.sub.2O and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded the title compound as a colorless
oil.
Step 2:
2-{2-[4-(Bromomethyl)phenyl]ethoxy}-1,3-dichloro-5-methylbenzene
[0454] To a solution of triphenylphosphine dibromide (1.2 eq.) and
Hunig's base (2 eq.) in dichloromethane (0.09 M) was added,
dropwise over 5 min,
{4-[2-(2,6-dichloro-4-methylphenoxy)ethyl]phenyl}methanol prepared
in the previous step (1 eq.). The resulting mixture was stirred at
RT for 2 h and then concentrated in vacuo. The residue was
suspended in a 10:1 (v/v) Hex:ether solution and filtered through a
pad of SiO.sub.2. The filtrate was concentrated in vacuo to afford
the title compound as a white solid.
Step 3:
2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-{-4-[2,6-dichloro-4-
-methylphenoxy)ethyl]phenyl}propanamide
[0455] 2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)acetamide (1
eq.), prepared from Amine 2 and cyanoacetic acid as detailed in
Step 1 of Example 1, was dissolved in THF (0.1 M). At -78.degree.
C., potassium bis(trimethylsilyl)amide (15% w/w toluene solution,
1.2 eq.) was then added and the resulting yellow suspension was
stirred at -78.degree. C. for 15 min and at -40.degree. C. for 15
min.
2-{2-[4-(bromomethyl)phenyl]ethoxy}-1,3-dichloro-5-methylbenzene
from the previous step (1 eq.) was then added, at -78.degree. C.,
as a 0.6 M THF solution over a period of 10 min. Finally,
tetrabutylammonium iodide (10% loading) was added. The resulting
pale yellow mixture was allowed to warm slowly to RT over 15 h. The
reaction was quenched with sat. aq. NH.sub.4Cl and extracted with
ether. The combined organic extracts were washed with H.sub.2O and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded a viscous yellow oil. Purification of
the crude product thus obtained by way of column chromatography
(SiO.sub.2, Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title
compound as a colorless oil.
Step 4: tert-Butyl
(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethyl]benzyl}-3-oxopropyl)carbamate
[0456]
2-Cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-{-4-[2,6-dichloro-4--
methylphenoxy)ethyl]phenyl}propanamide from the previous step (1
eq.) and cobalt(II) chloride hexahydrate (2 eq.) were combined in
MeOH (0.07 M). To this mixture was then added sodium borohydride
(10 eq.) slowly and portionwise. The resulting black suspension was
stirred at RT for 2 h. The reaction mixture was then diluted with
EtOAc and quenched with 1 N aq. NaOH. The resulting emulsion was
then filtered through a bed of celite and the insolubles were
rinsed with EtOAc and CH.sub.2Cl.sub.2. The organic layer was
separated and washed further with 1 N aq. NaOH, H.sub.2O and brine.
Drying over MgSO.sub.4, filtration and concentration of the
filtrate in vacuo afforded the crude amine as a golden oil. This
residue was then taken up in CH.sub.2Cl.sub.2 (0.06 M). To this
solution was added Hunig's base (4.7 eq.) and di-tert-butyl
dicarbonate (2 eq.). The resulting reaction mixture was stirred at
RT for 16 h. Following careful acidification with 10% aq. HCl to a
pH of .about.2, the aqueous layer was separated and back extracted
with EtOAc. The combined organic extracts were then washed H.sub.2O
and brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded a yellow oil. Purification of the crude
product thus obtained by way of column chromatography (SiO.sub.2,
Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title compound as a
white froth.
Step 5:
3-Amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-
-4-methylphenoxy)ethyl]benzyl}propanamide
[0457] To a CH.sub.2Cl.sub.2 solution (0.06 M) of tert-butyl
(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethyl]benzyl}-3-oxopropyl)carbamate (1 eq.) from the
previous step was added HCl (4.0 M dioxane solution, 14 eq.). The
resulting solution was stirred at RT for 3 h. Following the removal
of the volatiles in vacuo, the resulting residue was directly
loaded onto a SiO.sub.2 column packed with 97:3 (v/v)
CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH. Elution with the same
solvent system furnished the title compound as a white froth. MS
(ESI+): 578.9.
Example 26
4-Amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methy-
lphenoxy)ethoxy]benzyl}butanamide
##STR00110##
[0458] Step 1:
[4-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethoxy)phenyl]methanol
[0459] At 0.degree. C., sodium borohydride (1.5 eq.) was added
portionwise to a MeOH solution (0.5 M) of Aldehyde 5 (1 eq.). The
resulting mixture was stirred at 0.degree. C. for 30 min and then
at RT for 30 min. Following the removal of the volatiles in vacuo,
the resulting residue was partitioned between ether and 1 N aq.
NaOH. The aqueous layer was separated and back extracted with
ether. The combined organic extracts were washed with H.sub.2O and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded the title compound as a colorless
oil.
Step 2: tert-Butyl
{2-[4-(iodomethyl)phenoxy]ethoxy}dimethylsilane
[0460] At 0.degree. C., iodine (1.2 eq.) and imidazole (1.2 eq.)
were added to a CH.sub.2Cl.sub.2 solution (0.05 M) of
triphenylphosphine (1.2 eq.). The resulting yellow-orange
suspension was stirred at 0.degree. C. for 10 min and then at RT
for 15 min. Finally,
[4-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)phenyl]methanol from
the previous step (1 eq.) was added over 30 min as a 0.2 M
CH.sub.2Cl.sub.2 solution. After another 10 h of stirring at RT,
the volatiles were removed in vacuo. The resulting brown residue
was suspended in ether and rapidly passed through a plug of
SiO.sub.2. Removal of the volatiles in vacuo afforded the title
compound as a pink oil.
Step 3: Ethyl
2-[4-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)benzyl]pent-4-enoate
[0461] To a solution of diisopropylamine (1.1 eq.) in THF (0.12 M)
was added, at -78.degree. C., n-butyllithium (1.6 M hexane
solution, 1.1 eq.) over a period of 5 min. The resulting mixture
was stirred at -78.degree. C. for 15 min and then warmed at RT for
10 min. With the reaction mixture re-cooled to -78.degree. C.,
ethyl pent-4-enoate (1.1 eq.) was added dropwise as a 1.6 M THF
solution. The resulting solution was stirred for 30 min at
-78.degree. C. Finally,
tert-butyl{2-[4-(iodomethyl)phenoxy]ethoxy}dimethylsilane (1 eq.)
was added dropwise as a 1.5 M THF solution. The reaction mixture
was allowed to warm slowly to RT over 12 h. After the reaction was
carefully quenched with the addition of a sat. aq. NH.sub.4Cl
solution, the reaction mixture was extracted with ether. The
combined organic extracts were washed with brine, dried over
MgSO.sub.4, filtered and the filtrate concentrated in vacuo.
Purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, 10:1 (v/v) Hex:ether) afforded the title
compound as a colorless oil.
Step 4: Ethyl 2-[4-(2-hydroxyethoxy)benzyl]pent-4-enoate
[0462] To a solution of ethyl
2-[4-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)benzyl]pent-4-enoate
from the previous step (1 eq.) in THF (0.2 M) was added
tetrabutylammonium fluoride (1.0 M THF solution, 2 eq.). The
resulting reaction mixture was stirred at RT for 2 h. After
quenching the reaction with sat. aq. NH.sub.4Cl, the mixture was
extracted with ether. The combined organic extracts were washed
with water and brine, dried over MgSO.sub.4, filtered and the
filtrate concentrated in vacuo. Purification of the crude product
thus obtained by way of flash chromatography (SiO.sub.2, 10:1 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a colorless
oil.
Step 5: Ethyl
2-(4-{2-[(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}pent-4-enoate
[0463] Ethyl 2-[4-(2-hydroxyethoxy)benzyl]pent-4-enoate from the
previous step (1 eq.) and 2,6-dichloro-4-methylphenol (2 eq.) were
taken up in freshly deoxygenated toluene (0.1 M). To this solution
was then added 1,1'-(azodicarbonyl)-dipiperidine (3 eq.) and
finally tributylphosphine (3 eq.). The resulting yellow solution
was heated at 80.degree. C. for 2 h. The reaction mixture was
cooled to RT, quenched with 1 N aq. NaOH and extracted with ether.
The combined organic extracts were dried over MgSO.sub.4, filtered
and the filtrate concentrated in vacuo. Purification of the crude
product thus obtained by way of flash chromatography (SiO.sub.2,
Hex.fwdarw.7:3 (v/v) Hex:EtOAc) afforded the title compound as a
colorless oil.
Step 6:
2-{4-[2-(2,6-Dichloro-4-methylphenoxy)ethoxy]benzyl}pent-4-enoic
acid
[0464] Ethyl
2-(4-{2-[(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}pent-4-enoate
from the previous step (1 eq.) was dissolved in a 2:1 (v/v)
THF:MeOH solution (0.06 M). To this was then added lithium
hydroxide (1.0 M aqueous solution, 3.4 eq.) and the resulting
solution was stirred at 50.degree. C. for 12 h. The volatiles were
then removed in vacuo. Following careful acidification of the
resulting residue with 10% aq. HCl, the mixture was extracted with
EtOAc. The combined organic extracts were washed with H.sub.2O and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded the title compound as a viscous oil.
Step 7:
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methy-
lphenoxy)ethoxy]benzyl}pent-4-enamide
[0465]
2-{4-[2-(2,6-Dichloro-4-methylphenoxy)ethoxy]benzyl}pent-4-enoic
acid from the previous step (1 eq.) was combined with Hunig's base
(3 eq.) and Amine 2 (1.1 eq.) in anhydrous DMF (0.2 M). To this was
then added portionwise
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.2 eq.). The resulting yellow solution was
stirred at RT for 12 h. The reaction was quenched with 1 N aq. HCl
and extracted with ether and EtOAc. The combined organic extracts
were washed with H.sub.2O and brine, dried over MgSO.sub.4,
filtered and the filtrate concentrated in vacuo. Purification of
the crude product thus obtained by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title
compound as a viscous oil.
Step 8:
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methy-
lphenoxy)ethoxy]benzyl}-4-hydroxybutanamide
[0466] At -78.degree. C., a 1:1 (v/v) THF:MeOH solution (0.02 M) of
N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenox-
y)ethoxy]benzyl}pent-4-enamide from the previous step (1 eq.) was
bubbled ozone for 20 min. The resulting solution was purged of
excess ozone by bubbling with nitrogen. Sodium borohydride (4 eq.)
was then added and the reaction mixture was warm to RT over 16 h.
The resulting mixture was concentrated in vacuo, diluted with 1 N
aq. NaOH and extracted with EtOAc. The combined organic extracts
were washed with brine, dried over MgSO.sub.4, filtered and the
filtrate concentrated in vacuo. Purification of the crude product
thus obtained by way of column chromatography (SiO.sub.2, 10:1
(v/v) Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a
viscous oil.
Step 9:
4-Azido-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-
-4-methylphenoxy)ethoxy]benzyl}butanamide
[0467]
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methyl-
phenoxy)ethoxy]benzyl}-4-hydroxybutanamide from the previous step
(1 eq.) and Hunig's base (3.5 eq.) were combined in
CH.sub.2Cl.sub.2 (0.024 M). At -78.degree. C., methanesulfonyl
chloride (1.5 eq) was added and the reaction mixture was stirred at
-78.degree. C. for 10 min and at 0.degree. C. for 10 min. The
resulting mixture was quenched with sat. aq. NaHCO.sub.3 and
extracted with CH.sub.2Cl.sub.2. The combined organic extracts were
dried over MgSO.sub.4, filtered and the filtrate concentrated in
vacuo. The resulting residue was taken up in DMF (0.06 M) and added
sodium azide (5 eq). This mixture was then allowed to stir at RT
for 24 h. The resulting mixture was poured into water and extracted
with ether. The combined organic extracts were washed with water
and brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of column chromatography (SiO.sub.2, Hex.fwdarw.1:1
(v/v) Hex:EtOAc) afforded the title compound as a viscous oil.
Step 10:
4-Amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichlor-
o-4-methylphenoxy)ethoxy]benzylbutanamide
[0468] To a THF solution (0.036 M) of
4-azido-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{-4-[2-(2,6-dichloro-4-met-
hylphenoxy)ethoxy]benzyl}butanamide from the previous step (1 eq.)
was added triphenylphosphine (1.1 eq) and H.sub.2O (1.6 eq.). The
resulting solution was stirred at RT for 24 h. The volatiles were
then removed in vacuo. Purification of the crude product thus
obtained by way of column chromatography (SiO.sub.2, 97:3 (v/v)
CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH) afforded the title
compound as a colorless oil. MS (ESI+): 608.7.
Example 27
4-Amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[3-(2,6-dichloro-4-methy-
lphenoxy)propyl]benzyl}butanamide
##STR00111##
[0470] Prepared according to the procedure described in Example 26
but using instead Aldehyde 3. The title compound was obtained as a
colorless oil. MS (ESI+): 607.0.
Example 28
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-O-[2-(2,6-dichloro-4-methylphenoxy)et-
hyl]tyrosinamide
##STR00112##
[0471] Step 1: Methyl
N-(tert-butoxycarbonyl)-O-[2-(2,6-dichloro-4-methylphenoxy)ethyl]tyrosina-
te
[0472] Methyl N-(tert-butoxycarbonyl)tyrosinate (1 eq.) and
2-(2,4-dichloro-4-methylphenoxy)ethanol (1 eq.) were taken up in
freshly-deoxygenated toluene (0.18 M). To this solution was then
added 1,1'-(azodicarbonyl)-dipiperidine (1.1 eq.) and finally
tributylphosphine (3 eq.). The resulting yellow solution was heated
at 80.degree. C. for 3 h. The reaction mixture was cooled to RT,
diluted with H.sub.2O and extracted with EtOAc. The combined
organic extracts were washed with sat. aq. NaHCO.sub.3 and brine,
dried over MgSO.sub.4 and filtered. Concentration of the filtrate
in vacuo afforded the title compound.
Step 2:
N-(tert-Butoxycarbonyl)-O-[2-(2,6-dichloro-4-methylphenoxy)ethyl]t-
yrosine
[0473] Methyl
N-(tert-butoxycarbonyl)-O-[2-(2,6-dichloro-4-methylphenoxy)ethyl]tyrosina-
te from the previous step (1 eq.) was dissolved in a 2:1 (v/v)
THF:MeOH solution (0.07 M). To this was then added lithium
hydroxide (1.0 M aqueous solution, 5 eq.) and the resulting
solution was stirred at RT for 16 h. The volatiles were then
removed in vacuo. Following careful acidification of the resulting
residue with 10% aq. HCl, the mixture was extracted with EtOAc. The
combined organic extracts were washed with H.sub.2O and brine,
dried over MgSO.sub.4 and filtered. Concentration of the filtrate
in vacuo afforded the title compound.
Step 3:
N-(tert-Butoxycarbonyl)-N-cyclopropyl-N-(2,3-dichlorobenzyl)-O-[2--
(2,6-dichloro-4-methylphenoxy)ethyl]tyrosinamide
[0474]
N-(tert-Butoxycarbonyl)-O-[2-(2,6-dichloro-4-methylphenoxy)ethyl]ty-
rosine from the previous step (1 eq.) was combined with Hunig's
base (3 eq.) and Amine 2 (1.2 eq.) in anhydrous DMF (0.04 M). To
this was then added portionwise
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.5 eq.). The resulting solution was stirred
at RT for 16 h. The reaction was quenched with 1 N aq. HCl and
extracted with EtOAc. The combined organic extracts were washed
with sat. aq. NaHCO.sub.3 and brine, dried over MgSO.sub.4,
filtered and the filtrate concentrated in vacuo. Purification of
the crude product thus obtained by way of flash chromatography
(SiO.sub.2, 10:1 (v/v) Hex:EtOAc.fwdarw.EtOAc) afforded the title
compound as a viscous oil.
Step 4:
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-O-[2-(2,6-dichloro-4-methylph-
enoxy)ethyl]tyrosinamide
[0475] To a CH.sub.2Cl.sub.2 solution (0.03 M) of
N-(tert-butoxycarbonyl)-N-cyclopropyl-N-(2,3-dichlorobenzyl)-O-[2-(2,6-di-
chloro-4-methylphenoxy)ethyl]tyrosinamide from the previous step (1
eq.) was added HCl (4.0 M dioxane solution, 10 eq.). The resulting
solution was stirred at RT for 5 h. Following the removal of the
volatiles in vacuo, the resulting residue was directly loaded onto
a SiO.sub.2 column packed with 95:5 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH. Elution with the same solvent system furnished
the title compound as a white froth. MS (ESI+): 581.3.
Example 29
Methyl
(2R)-2-{2-[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{4-[2-[2-(2,-
6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopronyl)amino]ethyl}-3-methy-
lbutanoate
##STR00113##
[0477] A mixture of
3-amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}propanamide (Example 2, 1 eq.) and methyl
(2R)-3-methyl-2-(2-oxoethyl)butanoate (1.2 eq.) were combined in
toluene (0.1 M). To this was then added a few crystals of
p-toluenesulfonic acid monohydrate and the resulting solution was
azeotroped for 3 h. The reaction mixture was then cooled to RT and
added sodium cyanoborohydride (1.2 eq.) was added portionwise.
After 1 h of stirring, the reaction mixture was quenched with 10%
aq. Na.sub.2CO.sub.3 and extracted with EtOAc. The combined organic
extracts were then washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo afforded a brown
residue. Purification of the crude product thus obtained by way of
flash chromatography (SiO.sub.2, 97:3:1 (v/v/v)
CH.sub.2Cl.sub.2:Acetone:2.0 M NH.sub.3 in MeOH) afforded the title
compound as a colorless oil. MS (ESI+): 739.1.
Example 30
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}-3-[(3R)-3-isopropyl-2-oxopyrrolidin-1-yl]propanamide
##STR00114##
[0479] To a solution of methyl
(2R)-2-{2-[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{-4-[2-[2-(2,6-dic-
hloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]ethyl}-3-methylbuta-
noate (Example 29, 1 eq.) in MeOH (0.1 M) was added KOH (8.0 M aq.
solution, 2 eq.). The resulting solution was then stirred at RT for
2 h. Removal of the volatiles in vacuo and purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, 3:2 (v/v) Hex:EtOAc) afforded the title compound as a
colorless oil. MS (ESI+): 707.2.
Example 31
Methyl
(2S)-2-{2-[(3-[cyclopropyl(2,3-dichlorobenzyl)amino]-2-{-4-[2-[2-(2-
,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)amino]ethyl}-3-meth-
ylbutanoate
##STR00115##
[0481] A mixture of
3-amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}propanamide (Example 2, 1 eq.) and methyl
(2S)-3-methyl-2-(2-oxoethyl)butanoate (1.3 eq.) were combined in
toluene (0.2 M). To this was then added a few crystals of
p-toluenesulfonic acid monohydrate and the resulting solution was
azeotroped for 3 h. The reaction mixture was then cooled to RT,
concentrated in vacuo and the resulting residue taken up in THF
(0.2 M). At 0.degree. C., sodium borohydride (1.3 eq.) was added.
After 0/N of stirring, the reaction mixture was quenched with 10%
aq. NH.sub.4Cl and extracted with EtOAc. The combined organic
extracts were then washed with brine, dried over MgSO.sub.4 and
filtered. Concentration of the filtrate in vacuo and purification
of the crude product thus obtained by way of flash chromatography
(SiO.sub.2, 95:4:1 (v/v/v) CH.sub.2Cl.sub.2:Acetone:2.0 M NH.sub.3
in MeOH) afforded the title compound as a colorless oil. MS (ESI+):
739.2.
Example 32
N-Cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}-3-{[2-(2-napthyl)ethyl]amino}propanamide
##STR00116##
[0483] A mixture of
3-amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}propanamide (Example 2, 1 eq.),
2-(2-bromoethyl)naphthalene (1 eq.) and sodium hydride (60% w/w
dispersion in oil, 1 eq.) were combined at 0.degree. C. in DMF (0.2
M). The cooling bath was removed and the reaction mixture was
allowed to stir at RT 0/N. The resulting cloudy suspension was
diluted with EtOAc and quenched with 10% aq. NH.sub.4Cl. The
organic layer was separated, washed further with water and brine,
dried over MgSO.sub.4 and filtered. Concentration of the filtrate
in vacuo and purification of the crude product thus obtained by way
of flash chromatography (SiO.sub.2, 97:3 (v/v) CH.sub.2Cl.sub.2:
2.0 M NH.sub.3 in MeOH) afforded the title compound as a pale
yellow oil. MS (ESI+): 750.1.
Example 33
2-(Aminomethyl)-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]phenyl}-N-(2,3-dimethylbenzyl)-4-pyridin-2-ylbutanamide
##STR00117##
[0484] Step 1:
2-Cyano-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl-
}-N-(2,3-dimethylbenzyl)-4-pyridin-2-ylbutanamide
[0485] To a THF solution (0.5 M) of 2-bromopyridine (2.8 eq.) was
added, at -78.degree. C., n-butyl lithium (1.6 M hexane solution,
2.8 eq.) dropwise over 15 min. The resulting yellow suspension was
stirred at -78.degree. C. for a further 15 min before an ether
solution (0.5 M) of cuprous iodide (1.4 eq.) and dibutyl sulfide
(2.8 eq.) was added over 15 min. The resulting reaction mixture was
allowed to stir at -78.degree. C. for 15 min and then at 0.degree.
C. for 15 min. Finally, to this was added dropwise at 0.degree. C.,
a THF solution (0.1 M) of
(2E)-2-cyano-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]p-
henyl}-N-(2,3-dimethylbenzyl)acrylamide (Example 1, Step 2, 1 eq.).
The resulting emerald green suspension was stirred at 0.degree. C.
for 15 min and then at RT for 2 h. The reaction was quenched with
3:1 (v:v) sat. aq. NH.sub.4Cl:conc. aq. NH.sub.4OH solution and
extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. The crude product thus obtained was purified
by way of column chromatography (SiO.sub.2, 10:1.fwdarw.1:1 (v/v)
Hex:EtOAc). The title compound was isolated as a mixture of
diastereomers.
Step 2: tert-Butyl
(2-{[cyclopropyl(2,3-dimethylbenzyl)amino]carbonyl}-3-{4-[2-(2,6-dichloro-
-4-methylphenoxy)ethoxy]phenyl}-4-pyridin-2-ylbutyl)carbamate
[0486]
2-Cyano-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]-
phenyl}-N-(2,3-dimethylbenzyl)-4-pyridin-2-ylbutanamide from the
previous step (1 eq.) and cobalt(II) chloride hexahydrate (1 eq.)
were combined in MeOH (0.06 M). To this mixture was then added
sodium borohydride (3 eq.) slowly and portionwise. The resulting
black suspension was stirred at RT for 1 h. The reaction mixture
was then diluted with 95:5 (v/v) CH.sub.2Cl.sub.2:MeOH and quenched
with 1 N aq. NaOH. The resulting emulsion was then filtered through
a bed of celite and the insolubles were rinsed with 95:5 (v/v)
CH.sub.2Cl.sub.2:MeOH. The organic layer was separated and washed
further with 1 N aq. NaOH, H.sub.2O and brine. Drying over
MgSO.sub.4, filtration and concentration of the filtrate in vacuo
afforded the crude amine as a white froth. This residue was then
taken up in CH.sub.2Cl.sub.2 (0.03 M) and added di-tert-butyl
dicarbonate (1 eq.). Finally, sodium hydroxide (1.0 N aqueous
solution, 3 eq.) was added and the resulting biphasic mixture was
vigorously stirred for 4 h. The aqueous layer was separated and
back extracted with ether. The combined organic extracts were then
washed H.sub.2O and brine, dried over MgSO.sub.4 and filtered.
Concentration of the filtrate in vacuo afforded a yellow oil.
Purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, 10:1 (v/v) Hex:EtOAc.fwdarw.EtOAc)
afforded the title compound as a mixture of diastereomers.
Step 3:
2-(Aminomethyl)-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenox-
y)ethoxy]phenyl}-N-(2,3-dimethylbenzyl)-4-pyridin-2-ylbutanamide
[0487] To a CH.sub.2Cl.sub.2 solution (0.03 M) of tert-butyl
(2-{[cyclopropyl(2,3-dimethylbenzyl)amino]carbonyl}-3-{4-[2-(2,6-dichloro-
-4-methylphenoxy)ethoxy]phenyl}-4-pyridin-2-ylbutyl)carbamate from
the previous step (1 eq.) was added HCl (4.0 M dioxane solution, 30
eq.). The resulting solution was stirred at RT for 4 h. Following
the removal of the volatiles in vacuo, the resulting residue was
directly loaded onto a SiO.sub.2 column packed with 95:5 (v/v)
CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH. Elution with the same
solvent system furnished the title compound as a white froth.
Diastereomer A: MS (ESI+): 646.0. Diastereomer B: MS (ESI+):
646.0.
Example 34
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-d-
ichloro-4-methylphenoxy)ethoxy]benzyl}butanamide
##STR00118##
[0488] Step 1:
{4-[2-(2,6-Dichloro-4-methylphenoxy)ethyoxy]phenyl}methanol
[0489] At 0.degree. C., sodium borohydride (1.5 eq.) was added
portionwise to a MeOH solution (0.2 M) of Aldehyde 1 (1 eq.). The
resulting mixture was stirred at 0.degree. C. for 15 min and then
at RT for 30 min. Following the removal of the volatiles in vacuo,
the resulting residue was partitioned between ether and 1 N aq.
NaOH. The aqueous layer was separated and back extracted with
ether. The combined organic extracts were washed with H.sub.2O and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded the title compound as a colorless
oil.
Step 2:
1,3-Dichloro-2-{2-[4-(iodomethyl)phenoxy]ethoxy}-5-methylbenzene
[0490] To a solution of triphenylphosphine (1.2 eq.) in
dichloromethane (0.09 M) was added iodine (1.2 eq.) and the
resulting reddish-orange mixture was stirred at RT for 15 min. At
0.degree. C., a dichloromethane solution (0.1 M) of
{4-[2-(2,6-dichloro-4-methylphenoxy)ethyoxy]phenyl}methanol
prepared in the previous step (1 eq.) and imidazole (3 eq.) was
then added dropwise over 15 min. The resulting orange-yellow
suspension was stirred at 0.degree. C. for 1 h and then at RT for
15 min. The reaction was quenched with 10% (w/w) aq. NaHSO.sub.3
and extracted with ether. The organic extracts were combined,
washed with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. The resulting residue was triturated in a
10:1 (v/v) Hex:ether solution and filtered through a pad of
SiO.sub.2. The filtrate was concentrated in vacuo to afford the
title compound as a white solid.
Step 3: Methyl
2-{4-[2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxobutanoate
[0491] Methyl 3-oxobutanoate (1.2 eq.) in THF (0.1 M) was added, at
-78.degree. C., potassium bis(trimethylsilyl)amide (15% w/w toluene
solution, 1.2 eq.). The resulting yellow suspension was stirred at
-78.degree. C. for 15 min and at -40.degree. C. for 15 min.
1,3-Dichloro-2-{2-[4-(iodomethyl)phenoxy]ethoxy}-5-methylbenzene
from the previous step (1 eq.) was then added, at -78.degree. C.,
as a 0.6 M THF solution over a period of 15 min. The resulting pale
yellow mixture was allowed to warm slowly to RT over 15 h. The
reaction was quenched with sat. aq. NH.sub.4Cl and extracted with
ether. The combined organic extracts were washed with H.sub.2O and
brine, dried over MgSO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded a viscous yellow oil. Purification of
the crude product thus obtained by way of column chromatography
(SiO.sub.2, Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title
compound as a colorless oil.
Step 4: Methyl
2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-hydroxybutanoate
[0492] Methyl
2-{-4-[2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxobutanoate
from the previous step (1 eq.) in 2:1 (v:v) THF:MeOH (0.1 M) was
added sodium borohydride (1.2 eq.) in one rapid portion. After 30
min of stirring at RT, the volatiles were removed in vacuo and the
resulting residue partitioned ether and 1 N aq. NaOH. The aqueous
layer was separated and back extracted with ether. The combined
ethereal extracts were then washed further with water and brine,
dried over MgSO.sub.4 and filtered. Concentration of the filtrate
in vacuo afforded a pale yellow oil. Purification of the crude
product thus obtained by way of column chromatography (SiO.sub.2,
Hex.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title compound as a
colorless oil.
Step 5:
2-{4-[2-(2,6-Dichloro-4-methylphenoxy)ethoxy]benzyl}-3-hydroxybuta-
noic acid
[0493] Methyl
2-{-4-[2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-hydroxybutanoate
from the previous step (1 eq.) in 1:1 (v:v) THF:MeOH (0.1 M) was
added lithium hydroxide (1.0 M aqueous solution, 2 eq.). The
resulting solution was stirred at RT for 12 h. Following the
removal of the volatiles in vacuo, the resulting residue was
carefully acidified to pH .about.2 with 1 N aq. HCl and extracted
with EtOAc. The combined organic extracts were washed further with
water and brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo to afford the title compound as a a white
froth.
Step 6:
N-[2-Chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-d-
ichloro-4-methylphenoxy)ethoxy]benzyl}-3-hydroxybutanamide
[0494]
2-{4-[2-(2,6-Dichloro-4-methylphenoxy)ethoxy]benzyl}-3-hydroxybutan-
oic acid from the previous step (1 eq.) was combined with Hunig's
base (3 eq.) and Amine 7 (1.2 eq.) in anhydrous DMF (0.06 M). To
this was then added portionwise
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.2 eq.). The resulting solution was stirred
at RT for 18 h. The reaction was quenched with 1 N aq. HCl and
extracted with EtOAc. The combined organic extracts were washed
with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 10:1 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a viscous
oil.
Step 7:
N-[2-Chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-d-
ichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxobutanamide
[0495]
N-[2-Chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-di-
chloro-4-methylphenoxy)ethoxy]benzyl}-3-hydroxybutanamide from the
previous step (1 eq.) in dichloromethane (0.05 M) was added at
0.degree. C. Dess-Martin periodinane (1.2 eq.). The resulting
solution was allowed to warm to RT over 2 h before the reaction was
quenched with methanol and diluted with ether. This was then washed
sequentially with sat. aq. NaHCO.sub.3, water and brine. Drying of
the organic layer over MgSO.sub.4, filtration and concentration of
the filtrate in vacuo afforded the crude product as a colorless
oil. Further purification by way of flash chromatography
(SiO.sub.2, Hex.fwdarw.10:1 (v/v) Hex:EtOAc) afforded the title
compound as a viscous oil.
Step 8:
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[-
2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}butanamide
[0496]
N-[2-Chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-di-
chloro-4-methylphenoxy)ethoxy]benzyl}-3-oxobutanamide from the
previous step (1 eq.) and ammonium acetate (10 eq.) were combined
in MeOH (0.06 M). After the addition of sodium cyanoborohydride
(1.2 eq.), the resulting reaction mixture was heated at reflux for
2 h. The volatiles were then removed in vacuo and the resulting
residue partitioned between EtOAc and 1 N aq. NaOH. The aqueous
wash was separated and back extracted with EtOAc. The combined
organic extracts were then washed further with water and brine,
dried over MgSO.sub.4, filtered and the filtrate concentrated in
vacuo. The crude product thus obtained was purified further by way
of flash chromatography (SiO.sub.2, 96:4 (v/v) CH.sub.2Cl.sub.2:
2.0 M NH.sub.3 in MeOH) to reveal the title compound as a white
froth. MS (ESI+): 635.3.
Example 35
3-Amino-N-[2-chloro-5-(3-hydroxypropyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00119##
[0498] Prepared according to the procedure described in Example 9
but using instead Amine 11 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 620.8.
Example 36
3-Amino-N-[2-chloro-5-(2-methoxyethoxy)benzyl]-N-cyclopropyl-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00120##
[0500] Prepared according to the procedure described in Example 9
but using instead Amine 12 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 635.
Example 37
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{[6-(pyridin-4-ylmethyl)quinoline-8-yl]methyl}propanamide
##STR00121##
[0502] Prepared according to the procedure described in Example 9
but using instead Amine 13 as starting material. The title compound
was obtained as a pale yellow oil. MS (ESI+): 669.2.
Example 38
3-Amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethyl]benzyl}propanamide
##STR00122##
[0504] Prepared according to the procedure described in Example 9
but using instead Aldehyde 4 as starting material in step 1 and
Amine 6 as starting material in step 4. The title compound was
obtained as a pale yellow oil. MS (ESI+): 617.1.
Example 39
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-d-
ichloro-4-methylphenoxy)ethyl]benzyl}propanamide
##STR00123##
[0506] Prepared according to the procedure described in Example 9
but using instead Aldehyde 4 as starting material in step 1 and
Amine 7 as starting material in step 4. The title compound was
obtained as a pale yellow oil. MS (ESI+): 603.2.
Example 40
3-Amino-N-{2-chloro-5-[3-(dimethylamino)propyl)benzyl}-N-cyclopropyl-2-{4--
[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00124##
[0508] Prepared according to the procedure described in Example 9
but using instead Amine 14 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 646.1.
Example 41
3-Amino-N-cyclopropyl-N-[2,3-dichloro-5-[3-methoxypropyl)benzyl}-2-{4-[2-(-
2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00125##
[0510] Prepared according to the procedure described in Example 9
but using instead Amine 15 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 667.0.
Example 42
3-Amino-N-cyclopropyl-N-[2,3-dichloro-5-[3-methoxypropyl)benzyl}-2-{4-[2-(-
2,6-dichloro-4-methylphenoxy)ethyl]benzyl}propanamide
##STR00126##
[0512] Prepared according to the procedure described in Example 9
but using instead Aldehyde 4 as starting material in step 1 and
Amine 15 as starting material in step 4. The title compound was
obtained as a colorless oil. MS (ESI+): 652.2.
Example 43
3-Amino-N-{[6-(cyanomethyl)quinoline-8-yl]methyl}-N-cyclopropyl]-2-{4-[2-(-
2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00127##
[0514] Prepared according to the procedure described in Example 9
but using instead Amine 16 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 617.1.
Example 44
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{[2-(3-methoxypropyl)quinoline-4-yl]methyl}propanamide
##STR00128##
[0516] Prepared according to the procedure described in Example 9
but using instead Amine 17 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 650.2.
Example 45
3-Amino-N-[2-chloro-5-(2-cyano
ethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]-
benzyl}propanamide
##STR00129##
[0518] Prepared according to the procedure described in Example 9
but using instead Amine 18 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 616.1.
Example 46
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[5-(3-methoxypropyl)-2-methylbenzyl]propanamide
##STR00130##
[0520] Prepared according to the procedure described in Example 9
but using instead Amine 19 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 613.0.
Example 47
3-Amino-N-[2-chloro-5-(2-cyanomethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-di-
chloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00131##
[0522] Prepared according to the procedure described in Example 9
but using instead Amine 20 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 601.4.
Example 48
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[5-(3-methoxyethyl)-2-methylbenzyl]propanamide
##STR00132##
[0524] Prepared according to the procedure described in Example 9
but using instead Amine 21 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 599.1
Example 49
3-Amino-N-[2,5-bis(trifluoromethyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-dich-
loro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00133##
[0526] Prepared according to the procedure described in Example 9
but using instead Amine 22 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 702.3.
Example 50
3-Amino-N-{[6-(1-cyano-1-methylethyl)quinoline-8-yl]methyl}-N-cyclopropyl--
2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00134##
[0528] Prepared according to the procedure described in Example 9
but using instead Amine 23 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 645.2.
Example 51
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-(1-phenylethyl)propanamide
##STR00135##
[0530] Prepared according to the procedure described in Example 9
but using instead Amine 24 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 541.3.
Example 52
3-Amino-N-benzyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-me-
thylpropanamide
##STR00136##
[0532] Prepared according to the procedure described in Example 9
but using instead N-methyl-1-phenylmethanamine as starting
material. The title compound was obtained as a colorless oil. MS
(ESI+): 501.4.
Example 53
3-Amino-N-benzyl-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethox-
y]benzyl}propanamide
##STR00137##
[0534] Prepared according to the procedure described in Example 9
but using instead Amine 25 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 527.1.
Example 54
3-Amino-N-benzyl-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethox-
y]benzyl}-N-(2-phenylethyl)propanamide
##STR00138##
[0536] Prepared according to the procedure described in Example 9
but using instead Amine 26 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 541.4.
Example 55
3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-methyl-N-(2-
-phenylethyl)propanamide
##STR00139##
[0538] Prepared according to the procedure described in Example 9
but using instead N-methyl-2-phenylethanamine as starting material.
The title compound was obtained as a colorless oil. MS (ESI+):
515.1.
Example 56
3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-methyl-N-(1-
-phenylethyl)propanamide
##STR00140##
[0540] Prepared according to the procedure described in Example 9
but using instead N-methyl-1-phenylethanamine as starting material.
The title compound was obtained as a colorless oil. MS (ESI+):
515.2.
Example 57
3-Amino-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethox-
y]phenyl}-N-(2,2,2-trifluoroethyl)propanamide
##STR00141##
[0541] Step 1:
(2E)-2-Cyano-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}acrylic
acid
[0542] To a 2:1 (v/v) THF:MeOH solution (0.1 M) of methyl
(2E)-2-cyano-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}acrylate
from Example 9, Step 1 (1 eq.) was added sodium hydroxide (1.0 M
aq. solution, 3 eq.). The resulting solution was stirred at RT for
18 h before the volatiles were removed in vacuo. Following careful
acidification of the resulting mixture to pH .about.1 with 10% aq.
HCl, the solution was extracted with EtOAc. The combined organic
extracts were washed further with water and brine, dried over
MgSO.sub.4 and filtered. Concentration of the filtrate in vacuo
afforded the title compound as a yellow semi-solid.
Step 2:
(2E)-2-Cyano-N-(2,3-dichlorobenzyl)-3-{4-[2-(2,6-dichloro-4-methyl-
phenoxy)ethoxy]phenyl}-N-(2,2,2-trifluoroethyl)acrylamide
[0543] To a solution of
(2E)-2-cyano-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}acrylic
acid from the previous step (1 eq.) in dichloromethane (0.02 M) was
added oxalyl chloride (1.2 eq.). Then, several drops of neat DMF
were added dropwise. After no further gaseous evolution could be
discerned, the crude reaction mixture was diluted with toluene and
the volatiles were removed in vacuo. The resulting residue was
taken up in dichloromethane (0.02 M) and added sequentially Amine
27 (2 eq.), triethylamine (2 eq.) and a few crystals of DMAP. After
16 h of stirring at RT, the reaction was quenched with sat. aq.
NH.sub.4Cl and then extracted with EtOAc. The combined organic
extracts were washed with water and brine, dried over MgSO.sub.4,
filtered and the filtrate concentrated in vacuo. Purification of
the crude product thus obtained by way of column chromatography
(SiO.sub.2, Hex.fwdarw.7:3 (v/v) Hex:EtOAc) afforded the title
compound as a white foam.
Step 3: tert-Butyl
(3-[(2,3-dichlorobenzyl)(2,2,2-trifluoroethyl)amino]-2-{4-[2-(2,6-dichlor-
o-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
[0544]
(2E)-2-Cyano-N-(2,3-dichlorobenzyl)-3-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethoxy]phenyl}-N-(2,2,2-trifluoroethyl)acrylamide from the
previous step (1 eq.) and cobalt(II) chloride hexahydrate (2 eq.)
were combined in a 7:3 (v/v) THF:MeOH solution (0.003 M). To this
mixture was then added sodium borohydride (10 eq.) slowly and
portionwise. The resulting black suspension was stirred at RT for 2
h. The reaction mixture was then carefully quenched with 10% aq.
HCl and extracted with ether. The combined organic extracts were
washed further with H.sub.2O and brine. Drying over MgSO.sub.4,
filtration and concentration of the filtrate in vacuo afforded the
crude amine. This residue was combined with di-tert-butyl
dicarbonate (1 eq.), Hunig's base (1.5 eq.) and a few crystals of
4-(dimethylamino)pyridine in CH.sub.2Cl.sub.2 (0.06 M). The
resulting solution was stirred at RT for 3 h. The volatiles were
then removed in vacuo and purification of the crude product thus
obtained by way of column chromatography (SiO.sub.2, Hex.fwdarw.7:3
(v/v) Hex:EtOAc) afforded the title compound as a pale yellow
oil.
Step 4:
3-Amino-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylpheno-
xy)ethoxy]benzyl}-N-(2,2,2-trifluoroethyl)propanamide
[0545] To a CH.sub.2Cl.sub.2 solution (0.05 M) of tert-butyl
(3-[(2,3-dichlorobenzyl)(2,2,2-trifluoroethyl)amino]-2-{4-[2-(2,6-dichlor-
o-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from the
previous step (1 eq.) was added HCl (4 M dioxane solution, 20 eq.).
The resulting solution was stirred at RT for 13 h. Following the
removal of the volatiles in vacuo, the resulting residue was
directly loaded onto a SiO.sub.2 column packed with 95:5 (v/v)
CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH. Elution with the same
solvent system furnished the title compound as a colorless oil. MS
(ESI+): 638.2.
Example 58
3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-methyl-N-(1-
-methyl-1-phenylethyl)propanamide
##STR00142##
[0547] Prepared according to the procedure described in Example 9
but using instead Amine 28 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 529.1.
Example 59
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-(cyclopropyl)methyl)-2-{4--
[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00143##
[0549] Prepared according to the procedure described in Example 9
but using instead Amine 29 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 633.2.
Example 60
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}-N-methylpropanamide
##STR00144##
[0551] Prepared according to the procedure described in Example 9
but using instead Amine 30 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 593.2.
Example 61
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-(cyclobutylmethyl)-2-{4-[2-
-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00145##
[0553] Prepared according to the procedure described in Example 9
but using instead Amine 31 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 647.3.
Example 62
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}-N-isopropylpropanamide
##STR00146##
[0555] Prepared according to the procedure described in Example 9
but using instead Amine 32 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 621.1.
Example 63
[0556]
N-Allyl-3-amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00147##
[0557] Prepared according to the procedure described in Example 9
but using instead Amine 33 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 619.2.
Example 64
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-N-cyclobutyl-2-{4-[2-(2,6-di-
chloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00148##
[0559] Prepared according to the procedure described in Example 9
but using instead Amine 34 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 633.2
Example 65
3-Amino-N-[2-chloro-5-(2-methoxyethyl)benzyl]-2-{4-[2-(2,6-dichloro-4-meth-
ylphenoxy)ethoxy]benzyl}-N-ethylpropanamide
##STR00149##
[0561] Prepared according to the procedure described in Example 9
but using instead Amine 35 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 607.2
Example 66
3-{[Amino(imino)methyl]amino}-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyc-
lopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00150##
[0562] Step 1:
Di-tert-butyl{(Z)-[(3-[[2-chloro-5-(3-methoxypropyl)benzyl](cyclopropyl)a-
mino]-N-2-{-4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)-
amino]methylylidene)bis carbamate
[0563] To a solution of
3-amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-
-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide (Example 6, 1
eq.) in DMF (0.04 M) was added sequentially O,O-di-tert-butyl
diimidothiocarbonate (1.2 eq.), triethylamine (2.2. eq.) and EDCI
(1.2 eq.). sodium hydroxide (1.0 M aq. solution, 3 eq.). The
resulting solution was stirred at RT for 18 h. The reaction mixture
was diluted with water and then extracted with ether. The combined
organic extracts were washed further with water and brine, dried
over MgSO.sub.4, filtered and the filtrate concentrated in vacuo.
Purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, Hex.fwdarw.EtOAc) afforded the title
compound.
Step 2:
3-{[Amino(imino)methyl]amino}-N-[2-chloro-5-(3-methoxypropyl)benzy-
l]-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
namide
[0564] To a CH.sub.2Cl.sub.2 solution (0.04 M) of
di-tert-butyl{(z)-[(3-[[2-chloro-5-(3-methoxypropyl)benzyl](cyclopropyl)a-
mino]-N-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)a-
mino]methylylidene)biscarbamate from the previous step (1 eq.) was
added trifluoroacetic acid (190 eq.). The resulting solution was
stirred at RT for 3 h. Following the removal of the volatiles in
vacuo, the resulting residue was directly loaded onto a SiO.sub.2
column packed with 90:10 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in
MeOH. Elution with the same solvent system furnished the title
compound as a white solid. MS (ESI+): 675.3.
Example 67
2-{[Amino(imino)methyl]amino}-N-cyclopropyl-N-(2,3-dichlorobenzyl)-3-{4-[2-
-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00151##
[0566] Prepared according to the procedure described in Example 66
but using instead
N-cyclopropyl-N-(2,3-dichlorobenzyl)-O-[2-(2,6-dichloro-4-methylphenoxy)e-
thyl]tyrosinamide (Example 28) as starting material. The title
compound was obtained as a colorless oil. MS (ESI+): 625.0.
Example 68
2-Amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-3-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00152##
[0568] Prepared according to the procedure described in Example 28
but using instead Amine 6 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 619.5.
Example 69
2-{[Amino(imino)methyl]amino}-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyc-
lopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00153##
[0570] Prepared according to the procedure described in Example 66
but using instead
2-amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-3-{4-[2-(2,6-
-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide (Example 68) as
starting material. The title compound was obtained as a colorless
oil. MS (ESI+): 661.1.
Example 70
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-hydroxy-5-(3-methoxypropyl)benzyl]propanamide
##STR00154##
[0571] Step 1: tert-Butyl
(3-[[3-{[tert-butyl(dimethyl)silyl]oxy}-5-(3-methoxypropyl)benzyl](cyclop-
ropyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopro-
pyl)carbamate
[0572]
3-[tert-Butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}propanoic acid from Example 9, Step 3 (1 eq.) was
combined with Hunig's base (3 eq.) and Amine 36 (1 eq.) in
anhydrous DMF (0.5 M). To this was then added portionwise
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.2 eq.). The resulting yellow solution was
stirred at RT for 18 h. The now reddish solution was diluted with
ether and washed with H.sub.2O. The aqueous washes were back
extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 3:1 (v/v)
Hex:EtOAc) afforded the title compound as a colorless oil.
Step 2: tert-Butyl
(3-{cyclopropyl[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
[0573] To a solution of tert-butyl
(3-[[3-{[tert-butyl(dimethyl)silyl]oxy}-5-(3-methoxypropyl)benzyl](cyclop-
ropyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopro-
pyl)carbamate from the previous step (1 eq.) in THF (0.05 M) was
added tetrabutylammonium fluoride (1.0 M THF solution, 1.5 eq.).
The resulting golden yellow solution was stirred at RT for 8 h. The
reaction mixture was quenched with sat. aq. NH.sub.4Cl and then
extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 2:1 (v/v)
Hex:EtOAc.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title compound
as a white semisolid.
Step 3:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-[3-hydroxy-5-(3-methoxypropyl)benzyl]propanamide
[0574] To a CH.sub.2Cl.sub.2 solution (0.08 M) of tert-butyl
(3-{cyclopropyl[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from the previous step (1 eq.) was added HCl (4.0 M dioxane
solution, 20 eq.). The resulting solution was stirred at RT for 3
h. Following the removal of the volatiles in vacuo, the resulting
residue was directly loaded onto a SiO.sub.2 column packed with
92:8 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH. Elution with
the same solvent system furnished the title compound as a white
froth. MS (ESI+): 615.0.
Example 71
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)-5-(2-pyrrolidin-1-ylethoxy)benzyl]propanamide
##STR00155##
[0575] Step 1: tert-Butyl
(3-{cyclopropyl[3-(3-methoxypropyl)-5-(2-pyrrolidin-1-ylethoxy)benzyl]ami-
no}-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carba-
mate
[0576] To a solution of tert-butyl
(3-{cyclopropyl[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Example 70, Step 2 (1 eq.) in DMF (0.05 M) was added
1-(2-chloroethyl)pyrrolidine (1.2 eq.) and cesium carbonate (1.3
eq.). The resulting suspension was heated at 60.degree. C. for 5 h.
The reaction mixture was quenched sat. aq. NaHCO.sub.3 and then
extracted with ether. The combined organic extracts were washed
with water and brine, dried over MgSO.sub.4, filtered and the
filtrate concentrated in vacuo. Purification of the crude product
thus obtained by way of flash chromatography (SiO.sub.2,
CH.sub.2Cl.sub.2.fwdarw.95:5 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3
in MeOH) afforded the title compound as a colorless oil.
Step 2:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-[3-(3-methoxypropyl)-5-(2-pyrrolidin-1-ylethoxy)benzyl]propanam-
ide
[0577] To a CH.sub.2Cl.sub.2 solution (0.03 M) of tert-butyl
(3-{cyclopropyl[3-(3-methoxypropyl)-5-(2-pyrrolidin-1-ylethoxy)benzyl]ami-
no}-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carba-
mate from the previous step (1 eq.) was added HCl (4.0 M dioxane
solution, 20 eq.). The resulting solution was stirred at RT for 3
h. Following the removal of the volatiles in vacuo, the resulting
residue was directly subjected to column chromatography (SiO.sub.2,
CH.sub.2Cl.sub.2.fwdarw.90:10 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH) to afford the title compound. MS (ESI+):
712.2.
Example 72
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)-5-(pyridin-2-ylmethoxy)benzyl]propanamide
##STR00156##
[0579] Prepared according to the procedure described in Example 71
but using instead 2-(chloromethyl)pyridine as starting material.
The title compound was obtained as a colorless oil. MS (ESI+):
706.4.
Example 73
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl]propanamide
##STR00157##
[0581] Prepared according to the procedure described in Example 71
but using instead 2-bromoethyl methyl ether as starting material.
The title compound was obtained as a colorless oil. MS (ESI+):
673.2.
Example 74
3-Amino-N-[3-(3-cyanopropoxy)-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2-{-
4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00158##
[0583] Prepared according to the procedure described in Example 71
but using instead 4-bromobutanenitrile as starting material. The
title compound was obtained as a colorless oil. MS (ESI+):
682.2.
Example 75
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{3-(3-methoxypropyl)-5-[(3-methylthio)propoxy]benzyl}propanamide
##STR00159##
[0584] Step 1: 3-(Methylthio)propyl methanesulfonate
[0585] To a solution of 3-(methylthio)propan-1-ol in
dichloromethane (0.2 M) was added sequentially at -78.degree. C.
Hunig's base (1.3 eq.) and methanesulfonyl chloride (1.3 eq.). The
resulting reaction mixture was stirred at -78.degree. C. for 1 h
and then warmed slowly to RT. The reaction was quenched with sat.
aq. NH.sub.4Cl and then extracted with ether. The combined organic
extracts were washed with water and brine, dried over MgSO.sub.4,
and filtered. Concentrated of the filtrate in vacuo afforded the
title compound as a yellow oil.
Step 2: tert-Butyl (3-{cyclopropyl
{3-(3-methoxypropyl)-5-[3-(methylthio)propoxy]benzyl}amino)-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
[0586] To a solution of tert-butyl
(3-{cyclopropyl[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Example 70, Step 2 (1 eq.) in DMF (0.05 M) was added
3-(methylthio)propyl methanesulfonate from the previous step (1.4
eq.) and cesium carbonate (1.4 eq.). The resulting suspension was
heated at 60.degree. C. for 12 h. The reaction mixture was quenched
sat. aq. NaHCO.sub.3 and then extracted with ether. The combined
organic extracts were washed with water and brine, dried over
MgSO.sub.4, filtered and the filtrate concentrated in vacuo.
Purification of the crude product thus obtained by way of flash
chromatography (SiO.sub.2, 3:2 (v/v) Hex:EtOAc.fwdarw.2:3 (v/v)
Hex:EtOAc) afforded the title compound as a colorless oil.
Step 3:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-{3-(3-methoxypropyl)-5-[(3-methylthio)propoxy]benzyl}propanamid-
e
[0587] To a CH.sub.2Cl.sub.2 solution (0.08 M) of tert-butyl
(3-{cyclopropyl
{3-(3-methoxypropyl)-5-[3-(methylthio)propoxy]benzyl}amino)-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from
the previous step (1 eq.) was added HCl (4.0 M dioxane solution, 20
eq.). The resulting solution was stirred at RT for 3 h. Following
the removal of the volatiles in vacuo, the resulting residue was
directly subjected to column chromatography (SiO.sub.2,
CH.sub.2Cl.sub.2.fwdarw.95:5 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3
in MeOH) to afford the title compound. MS (ESI+): 703.0.
Example 76
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{3-(3-methoxypropyl)-5-[(3-methylsulfonyl)propoxy]benzyl}propanamide
##STR00160##
[0588] Step 1: tert-Butyl (3-{cyclopropyl
{3-(3-methoxypropyl)-5-[3-(methylsulfonyl)propoxy]benzyl}amino)-2-{4-[2-(-
2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
[0589] To tert-butyl (3-{cyclopropyl
{3-(3-methoxypropyl)-5-[3-(methylthio)propoxy]benzyl}amino)-2-{4-[2-(2,6--
dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from
Example 75, Step 2 (1 eq.) in a 1:1 (v/v) methanol:water solution
(0.05 M) was added Oxone.TM. (2.5 eq.) and sodium bicarbonate (10
eq.). The reaction mixture was stirred at RT for 1 h. The volatiles
were then removed in vacuo and the result residue was extracted
with ether. The combined organic extracts were washed with water
and brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 3:2 (v/v)
Hex:EtOAc.fwdarw.1:3 (v/v) Hex:EtOAc) afforded the title compound
as a colorless oil.
Step 2:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-{3-(3-methoxypropyl)-5-[(3-methylsulfonyl)propoxy]benzyl}propan-
amide
[0590] To a CH.sub.2Cl.sub.2 solution (0.08 M) of tert-butyl
(3-{cyclopropyl
{3-(3-methoxypropyl)-5-[3-(methylsulfonyl)propoxy]benzyl}amino)-2-{4-[2-(-
2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from the previous step (1 eq.) was added HCl (4.0 M dioxane
solution, 20 eq.). The resulting solution was stirred at RT for 4
h. Following the removal of the volatiles in vacuo, the resulting
residue was directly subjected to column chromatography (SiO.sub.2,
CH.sub.2Cl.sub.2.fwdarw.92:8 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3
in MeOH) to afford the title compound. MS (ESI+): 734.8.
Example 77
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)-5-(pyridin-3-ylmethoxy)benzyl]propanamide
##STR00161##
[0592] Prepared according to the procedure described in Example 71
but using instead 3-(chloromethyl)pyridine as starting material.
The title compound was obtained as a pale yellow oil. MS (ESI+):
706.4.
Example 78
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)-5-(pyridin-4-ylmethoxy)benzyl]propanamide
##STR00162##
[0594] Prepared according to the procedure described in Example 71
but using instead 4-(chloromethyl)pyridine as starting material.
The title compound was obtained as a pale yellow oil. MS (ESI+):
706.4.
Example 79
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{3-(3-methoxypropyl)-5-[(1-oxidopyridin-2-yl)methoxy]benzyl}propanamide
##STR00163##
[0595] Step 1: tert-Butyl
(3-(cyclopropyl}3-(3-methoxypropyl)-5-[(1-oxidopyridin-2-yl)methoxy]benzy-
l}amino)-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)-
carbamate
[0596] To a solution of tert-butyl
(3-{cyclopropyl[3-[3-methoxypropyl)-5-(pyridin-2-ylmethoxy)benzyl]amino}--
2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Example 72, Step 1 (1 eq.) in dichloromethane (0.02 M) was
added 3-chloroperoxybenzoic acid (2 eq.). The reaction mixture was
stirred at RT for 1 h. The reaction was quenched with sat. aq.
NaHCO.sub.3 and then extracted with ether. The combined organic
extracts were washed with water and brine, dried over MgSO.sub.4,
filtered and the filtrate concentrated in vacuo. Purification of
the crude product thus obtained by way of flash chromatography
(SiO.sub.2, CH.sub.2Cl.sub.2.fwdarw.97:3 (v/v) CH.sub.2Cl.sub.2:
2.0 M NH.sub.3 in MeOH) afforded the title compound.
Step 2:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-{3-(3-methoxypropyl)-5-[(1-oxidopyridin-2-yl)methoxy]benzyl}pro-
panamide
[0597] To a CH.sub.2Cl.sub.2 solution (0.03 M) of tert-butyl
(3-(cyclopropyl
{3-(3-methoxypropyl)-5-[(1-oxidopyridin-2-yl)methoxy]benzyl}amino)-2-{4-[-
2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from the previous step (1 eq.) was added HCl (4.0 M dioxane
solution, 20 eq.). The resulting solution was stirred at RT for 24
h. Following the removal of the volatiles in vacuo, the resulting
residue was directly subjected to column chromatography (SiO.sub.2,
98:2 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH.fwdarw.90:10
(v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH) to afford the title
compound. MS (ESI+): 721.8.
Example 80
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{3-(3
methoxypropyl)-5-[(1-oxidopyridin-3-yl)methoxy]benzyl}propanamide
##STR00164##
[0599] Prepared according to the procedure described in Example 79
but using instead tert-butyl
(3-{cyclopropyl[3-(3-methoxypropyl)-5-(pyridin-3-ylmethoxy)benzyl]amino}--
2-{-4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamat-
e from Example 77, Step 1 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 721.8.
Example 81
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{3-(3-methoxypropyl)-5-[(1-oxidopyridin-4-yl)methoxy]benzyl}propanamide
##STR00165##
[0601] Prepared according to the procedure described in Example 79
but using instead tert-butyl
(3-{cyclopropyl[3-(3-methoxypropyl)-5-(pyridin-4-ylmethoxy)benzyl]amino}--
2-{-4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamat-
e from Example 78, Step 1 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 721.8.
Example 82
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)-5-(2-pyridin-2-ylethoxy)benzyl]propanamide
##STR00166##
[0602] Step 1: tert-Butyl
(3-{cyclopropyl[3-(3-methoxypropyl)-5-(2-pyridin-2-ylethoxy)benzyl]amino}-
-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamat-
e
[0603] To a solution of tert-butyl
(3-{cyclopropyl[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Example 70, Step 2 (1 eq.) in toluene (0.1 M) was added
2-pyridin-2-ylethanol (1.2 eq.) and
1,1'-(azodicarbonyl)-dipiperidine (1.2 eq.). The resulting orange
solution was deoxygenated before tributylphosphine (1.2 eq.) was
added. The now yellow-orange solution was heated at 100.degree. C.
for 14 h. The reaction mixture was cooled to RT, diluted with
ether, and washed with 1 N aq. NaOH. The aqueous wash was back
extracted with ether and the combined organic extracts were dried
over MgSO.sub.4. Filtration and concentration of the filtrate in
vacuo afforded a red oil. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 4:1 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a pale
yellow oil.
Step 2:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-[3-(3-methoxypropyl)-5-(2-pyridin-2-ylethoxy)benzyl]propanamide
[0604] To a CH.sub.2Cl.sub.2 solution (0.03 M) of tert-butyl
(3-{cyclopropyl[3-(3-methoxypropyl)-5-(2-pyridin-2-ylethoxy)benzyl]amino}-
-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamat-
e from the previous step (1 eq.) was added HCl (4.0 M dioxane
solution, 30 eq.). The resulting solution was stirred at RT for 12
h. Following the removal of the volatiles in vacuo, the resulting
residue was directly subjected to column chromatography (SiO.sub.2,
90:10 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH) to afford the
title compound as a white froth. MS (ESI+): 720.0.
Example 83
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{3-(3-methoxypropyl)-5-[2-(1-oxidopyridin-2-yl)ethoxy]benzyl}propanamid-
e
##STR00167##
[0606] Prepared according to the procedure described in Example 79
but using instead tert-butyl
(3-{cyclopropyl[3-(3-methoxypropyl)-5-(2-pyridin-2-ylethoxy)benzyl]amino}-
-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamat-
e from Example 82, Step 1 as starting material. The title compound
was obtained as a white froth. MS (ESI+): 735.9.
Example 84
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)-5-(2-morpholin-4-ylmethoxy)benzyl]propanamide
##STR00168##
[0608] Prepared according to the procedure described in Example 71
but using instead 4-(2-chloroethyl)morpholine as starting material.
The title compound was obtained as a colorless oil. MS (ESI+):
728.0.
Example 85
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)-5-{4-(methylsulfonyl)benzyl]oxy}benzyl)propanamide
##STR00169##
[0610] Prepared according to the procedure described in Example 71
but using instead 4-(chloromethyl)phenyl methyl sulfone as starting
material. The title compound was obtained as a colorless oil. MS
(ESI+): 782.8.
Example 86
Ethyl
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}propanoyl)
(cyclopropyl)amino]methyl-5-(3-methoxyProPyl)Phenoxy]methyl
cyclopropanecarboxylate
##STR00170##
[0611] Step 1: Ethyl 2-(hydroxymethyl)cyclopropanecarboxylate
[0612] To a solution of ethyl 2-formylcyclopropanecarboxylate in
methanol (0.7 M) was added at -0.degree. C. sodium borohydride
portionwise. The resulting reaction mixture was stirred at
0.degree. C. for 30 min and then at RT for 1.5 h. The reaction was
quenched with sat. aq. NH.sub.4Cl and then extracted with ether.
The combined organic extracts were washed with water and brine,
dried over MgSO.sub.4, and filtered. Concentrated of the filtrate
in vacuo afforded the title compound as a colorless oil.
Step 2: Ethyl
2-{[3-{[(3-tert-butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylpheno-
xy)ethoxy]benzyl}propanoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)p-
henoxy]methyl}cyclopropanecarboxylate
[0613] To a solution of tert-butyl
(3-{cyclopropyl[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Example 70, Step 2 (1 eq.) in toluene (0.06 M) was added ethyl
2-(hydroxymethyl)cyclopropanecarboxylate from the previous step (2
eq.) and 1,1'-(azodicarbonyl)-dipiperidine (2.4 eq.). The resulting
orange solution was deoxygenated before tributylphosphine (2.4 eq.)
was added. The now yellow-orange solution was heated at 80.degree.
C. for 24 h. The reaction mixture was cooled to RT, quenched with
water and diluted with EtOAc. The biphasic mixture was vigorously
stirred at RT for 16 h. The organic layer was then separated and
washed sequentially with water, 5% aq. HCl, sat. aq. NaHCO.sub.3
and brine. The organic layer was dried over MgSO.sub.4, filtered
and the filtrate concentrated in vacuo. Purification of the crude
product thus obtained by way of flash chromatography (SiO.sub.2,
10:1 (v/v) toluene:acetone) afforded the title compound as a
colorless oil.
Step 3: Ethyl
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}prop-
anoyl)
(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclop-
ropanecarboxylate
[0614] To a CH.sub.2Cl.sub.2 solution (0.03 M) of ethyl
2-{[3-[(3-[tert-butoxycarbonyl)amino]-2-{-4-[2-(2,6-dichloro-4-methylphen-
oxy)ethoxy]benzyl}propanoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)-
phenoxy]methyl}cyclopropanecarboxylate from the previous step (1
eq.) was added HCl (4.0 M dioxane solution, 25 eq.). The resulting
solution was stirred at RT for 3 h. Following the removal of the
volatiles in vacuo, the resulting residue was directly subjected to
column chromatography (SiO.sub.2, 95:5 (v/v) CH.sub.2Cl.sub.2: 2.0
M NH.sub.3 in MeOH) to afford the title compound as a colorless
oil. MS (ESI+): 741. .sup.1H NMR (acetone-d.sub.6): 0.31 (m, 1H),
0.65-0.69 (m, 2H), 0.88 (m, 1H), 1.05 (m, 1H), 1.18 (m, 1H), 1.24
(t, J=6.9 Hz, 3H), 1.74 (m, 1H), 1.75-1.9 (m, 3H), 2.33 (s, 3H),
2.41 (m, 1H), 2.61 (t, J=7.5 Hz, 2H), 2.74-2.83 (m, 4H), 2.90 (t,
J=10.7 Hz, 1H), 3.28 (s, 3H), 3.30-3.34 (m, 2H), 3.59 (t, J=10.6
Hz, 1H), 3.83 (t, J=7.4 Hz, 1H), 3.95-4.07 (m, 2H), 4.09-4.12 (m,
2H), 4.26 (d, J=14.9 Hz, 1H), 4.37-4.40 (m, 4H), 4.67 (d, J=14.9
Hz, 1H), 6.65 (br s, 3H), 6.86 (d, J=7.1 Hz, 2H), 7.16 (d, J=7.1
Hz, 2H), 7.27 (s, 2H).
Example 87
Sodium
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzy-
l}propanoyl)
(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclopropane-
carboxylate
##STR00171##
[0616] To a ethanol solution (0.03 M) of ethyl
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}prop-
anoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclopr-
opanecarboxylate from Example 86 was added sodium hydroxide (1 N
aqueous solution, 2.2 eq.). The resulting solution was stirred at
80.degree. C. for 18 h. The volatiles were removed in vacuo and the
resulting solid residue was suspended in dichloromethane. The
insolubles were then filtered off and the filtrate was concentrated
in vacuo to afford the title compound as a white solid. MS for the
corresponding free acid (ESI+): 713.2. .sup.1H NMR
(methanol-d.sub.4): 0.41 (m, 1H), 0.70-0.83 (m, 4H), 1.11 (m, 1H),
1.52 (m, 1H), 1.72 (m, 1H), 1.80-1.87 (m, 2H), 2.24 (m, 1H), 2.31
(s, 3H), 2.59-2.62 (m, 2H), 2.75-2.80 (m, 2H), 2.84 (dd, J=13.2,
9.5 Hz, 1H), 2.95 (dd, J=12.7, 7.5 Hz, 1H), 3.31 (s, 3H), 3.37 (t,
J=6.4 Hz, 2H), 3.73 (m, 1H), 3.85 (d, J=6.7 Hz, 2H), 4.22-4.45 (m,
4H), 4.48 (d, J=14.6 Hz, 1H), 4.58 (d, J=14.8 Hz, 1H), 6.58 (s,
1H), 6.62 (s, 1H), 6.65 (s, 1H), 6.78 (d, J=8.6 Hz, 2H), 7.08 (d,
J=8.5 Hz, 2H), 7.22 (s, 2H).
Example 88
Ethyl
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}propanoyl)
(cyclopropyl)amino]methyl}-2-chloro-5-(3-methoxypropyl)phenoxy]methyl}cyc-
lopropanecarboxylate
##STR00172##
[0618] Prepared according to the procedure described in Example 9
but using instead Amine 37 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 777.2.
Example 89
Sodium
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzy-
l}propanoyl)
(cyclopropyl)amino]methyl}-2-chloro-5-(3-methoxypropyl)phenoxy]methyl}cyc-
lopropanecarboxylate
##STR00173##
[0620] Prepared according to the procedure described in Example 87
but using instead ethyl
2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}prop-
anoyl)(cyclopropyl)amino]methyl}-2-chloro-5-(3-methoxypropyl)phenoxy]methy-
l}cyclopropanecarboxylate from Example 88 as starting material. The
title compound was obtained as a white solid. MS for the
corresponding free acid (ESI+): 747.3.
Example 90
Ethyl
2-[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
propanoyl)
(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]-2-methyl-
propanoate
##STR00174##
[0622] Prepared according to the procedure described in Example 71
but using instead ethyl 2-bromo-2-methylpropanoate as starting
material. The title compound was obtained as a colorless oil. MS
(ESI+): 729.
Example 91
Sodium
2-[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}propanoyl)
(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]-2-methylpropanoate
##STR00175##
[0624] Prepared according to the procedure described in Example 87
but using instead ethyl
2-[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
noyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]-2-methylpropan-
oate from Example 90 as starting material. The title compound was
obtained as a white foam. MS for the corresponding free acid
(ESI+): 700.
Example 92
3-Amino-N-[3,5-bis(2-methoxyethoxy)benzyl]-N-cyclopropyl-2-{4-[2-(2,6-dich-
loro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00176##
[0626] Prepared according to the procedure described in Example 9
but using instead Amine 38 as starting material. The title compound
was obtained as a colorless oil. MS (ESI+): 672.0.
Example 93
3-Amino-N-[3,5-bis(4,4,4-trifluorobutoxy)benzyl]-N-cyclopropyl-2-{4-[2-(2,-
6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00177##
[0628] Prepared according to the procedure described in Example 9
but using instead Amine 39 as starting material. The title compound
was obtained as a pale yellow oil. MS (ESI+): 779.1.
Example 94
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl
{3-(3-methoxypropyl)-5-[3-(1H-tetrazol-5-yl)propoxy]benzyl}propanamide
##STR00178##
[0630] To a solution of tert-butyl
(3-[[3-(3-cyanopropoxy)-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]-2-{-
4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Example 74 in dichlorobenzene (0.08 M) was added
azidotributyltin (2 eq.). The resulting mixture was heated to
150.degree. C. for 22 h. The reaction was quenched with glacial
acetic acid (6 eq.) and directly loaded onto a silica gel column
packed with 85:15 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH.
Elution with the same solvent system afforded the title compound as
a yellow oil. MS (ESI+): 725.4.
Example 95
3-Amino-N-{[5-chloro-2-(3-methoxypropyl)pyridin-4-yl]methyl}-N-cyclopropyl-
-2-{-4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00179##
[0632] Prepared according to the procedure described in Example 9
but using instead Amine 40 as starting material. The title compound
was obtained as a pale yellow oil. MS (ESI+): 779.1.
Example 96
3-Amino-N-{[5-chloro-2-(3-methoxypropyl)-1-oxidopyridin-4-yl]methyl}-N-cyc-
lopropyl-2-{-4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00180##
[0633] Step 1: tert-Butyl
(3-[{[5-chloro-2-(methoxypropyl)-1-oxidopyridin-4-yl]methyl}(cyclopropyl)-
amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)ca-
rbamate
[0634] To a solution of tert-butyl
(3-[{[5-chloro-2-(methoxypropyl)pyridin-4-yl]methyl}(cyclopropyl)amino]-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Experiment 94, Step 4 in dichloromethane (0.03 M) was added
3-chloroperoxybenzoic acid. The reaction mixture was stirred at RT
for 16 h. The reaction was quenched with water and then extracted
with EtOAc. The combined organic extracts were washed with 10% aq.
HCl and brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 1:1 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound.
Step 2:
3-Amino-N-{[5-chloro-2-(methoxypropyl)-1-oxidopyridin-4-yl]methyl}-
-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy]ethoxy}benzyl]propana-
mide
[0635] To a CH.sub.2Cl.sub.2 solution (0.07 M) of tert-butyl
(3-[{[5-chloro-2-(methoxypropyl)-1-oxidopyridin-4-yl]methyl}(cyclopropyl)-
amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)ca-
rbamate from the previous step (1 eq.) was added HCl (4.0 M dioxane
solution, 30 eq.). The resulting solution was stirred at RT for 16
h. Following the removal of the volatiles in vacuo, the resulting
residue was directly subjected to column chromatography (SiO.sub.2,
95:5 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH) to afford the
title compound as an oil. MS (ESI+): 651.
Example 97
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[2-methoxy-6-(3-methoxypropyl)pyridin-4-yl]methyl}propanamide
##STR00181##
[0637] Prepared according to the procedure described in Example 9
but using instead Amine 41 as starting material. The title compound
was obtained as a pale yellow oil. MS (ESI+): 630.0.
Example 98
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[2-hydroxy-6-(3-methoxypropyl)pyridin-4-yl]methyl}propanamide
##STR00182##
[0638] Step 1: tert-Butyl
(3-[{[2-{[tert-butyl(dimethyl)silyl]oxy}-6-(3-methoxypropyl)pyridin-4-yl]-
methyl}(cyclopropyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]be-
nzyl}-3-oxopropyl)carbamate
[0639]
3-[tert-Butoxycarbony)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)-
ethoxy]benzyl}propanoic acid from Example 9, Step 3 (1 eq.) was
combined with Hunig's base (3 eq.) and Amine 42 (1.2 eq.) in
anhydrous DMF (0.5 M). To this was then added portionwise
O-7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.2 eq.). The resulting yellow solution was
stirred at RT for 48 h. The now reddish solution was diluted with
ether and washed with H.sub.2O. The aqueous washes were back
extracted with ether. The combined organic extracts were washed
with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 3:1 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound as a colorless
oil.
Step 2:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-{[2-hydroxy-6-(3-methoxypropyl)pyridin-4-yl]methyl}propanamide
[0640] To a CH.sub.2Cl.sub.2 solution (0.03 M) of tert-butyl
(3-[{[2-{[tert-butyl(dimethyl)silyl]oxy}-6-(3-methoxypropyl)pyridin-4-yl]-
methyl}(cyclopropyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]be-
nzyl}-3-oxopropyl)carbamate from the previous step (1 eq.) was
added HCl (4.0 M dioxane solution, 60 eq.). The resulting solution
was stirred at RT for 3 h and the volatiles were removed in vacuo.
The resulting residue was recrystallized from ether-dichloromethane
to afford the title compound as a white solid. MS (ESI+):
616.1.
Example 99
3-Amino-N-{[2,6-bis(3-methoxypropyl)pyridin-4-yl]methyl}-N-cyclopropyl-2-{-
4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00183##
[0642] Prepared according to the procedure described in Example 9
but using instead Amine 43 as starting material. The title compound
was obtained as a pale yellow oil. MS (ESI+): 672.
Example 100
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-({2-(3-methoxypropyl)-6-[3-(methylthio)propoxylpyridin-4-yl]methyl}prop-
anamide
##STR00184##
[0643] Step 1: tert-Butyl
(3-[cyclopropyl({2-(3-methoxypropyl)-6-[3-(methylthio)propoxy]pyridin-4-y-
l]methyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxo-
propyl)carbamate
[0644]
3-[tert-Butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}propanoic acid from Example 9, Step 3 (1 eq.) was
combined with Hunig's base (3 eq.) and Amine 44 (1.1 eq.) in
anhydrous DMF (0.15 M). To this was then added portionwise
O-7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.2 eq.). The resulting yellow solution was
stirred at RT for 18 h. The now reddish solution was diluted with
EtOAc and washed with H.sub.2O. The aqueous washes were back
extracted with EtOAc. The combined organic extracts were washed
with brine, dried over Na.sub.2SO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 7:3 (v/v)
Hex:EtOAc.fwdarw.1:1 (v/v) Hex:EtOAc) afforded the title compound
as a colorless oil.
Step 2:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-({2-(3-methoxypropyl)-6-[3-(methylthio)propoxy]pyridin-4-yl]met-
hyl}propanamide
[0645] To a CH.sub.2Cl.sub.2 solution (0.04 M) of tert-butyl
(3-[cyclopropyl({2-(3-methoxypropyl)-6-[3-(methylthio)propoxy]pyridin-4-y-
l]methyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxo-
propyl)carbamate from the previous step (1 eq.) was added HCl (4.0
M dioxane solution, 30 eq.). The resulting solution was stirred at
RT for 1 h and the volatiles were removed in vacuo. Purification of
the crude product thus obtained by way of column chromatography
(SiO.sub.2, 94:6 (v/v) CH.sub.2Cl.sub.2: 2.0 M NH.sub.3 in MeOH)
afforded the title compound as an oil. MS (ESI+): 704.
Example 101
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]pyridin-4-yl]methyl}-
propanamide
##STR00185##
[0646] Step 1: tert-Butyl
(3-[cyclopropyl({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]pyridin-
-4-yl]methyl)amino}-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-
-oxopropyl)carbamate
[0647] To a 2:1:1 (v/v/v) THF:MeOH:water solution (0.1 M) of
tert-butyl
(3-[cyclopropyl({2-(3-methoxypropyl)-6-[3-(methylthio)propoxy]pyridin-4-y-
l]methyl)amino}-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxo-
propyl)carbamate from Example 100, Step 1 (1 eq.) was added
Oxone.TM. (2.2 eq.) The resulting solution was stirred at RT for 2
h. The reaction was quenched with sat. aq. NaHCO.sub.3 and then
extracted with EtOAc. The combined organic extracts were washed
with brine, dried over Na.sub.2SO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 95:5 (v/v)
CH.sub.2Cl.sub.2:EtOH) afforded the title compound as a colorless
oil.
Step 2:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]pyridin-4-yl-
}methyl}propanamide
[0648] To a CH.sub.2Cl.sub.2 solution (0.04 M) of tert-butyl
(3-[cyclopropyl({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]pyridin-
-4-yl]methyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-
-oxopropyl)carbamate from the previous step (1 eq.) was added HCl
(4.0 M dioxane solution, 30 eq.). The resulting solution was
stirred at RT for 1.5 h and the volatiles were removed in vacuo.
Purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, 94:6 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH.fwdarw.90:10 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH) afforded the title compound as an oil. MS (ESI+):
736.
Example 102
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-({2-(3-methoxypropyl)-6-[3-(methylsulfonyl]propoxy]-1-oxidopyridin-4-yl-
}methyl}propanamide
##STR00186##
[0649] Step 1: tert-Butyl
(3-[cyclopropyl({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy)-1-oxid-
opyridin-4-yl]methyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]b-
enzyl}-3-oxopropyl)carbamate
[0650] To a dichloromethane solution (0.06 M) of tert-butyl
(3-[cyclopropyl({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]pyridin-
-4-yl]methyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-
-oxopropyl)carbamate from Example 101, Step 1 (1 eq.) was added
3-chloroperoxybenzoic acid (3.6 eq.). The resulting solution was
stirred at RT for 18 h. The reaction was quenched with sat. aq.
NaHCO.sub.3 and then extracted with EtOAc. The combined organic
extracts were washed with brine, dried over Na.sub.2SO.sub.4,
filtered and the filtrate concentrated in vacuo. Purification of
the crude product thus obtained by way of flash chromatography
(SiO.sub.2, 90:10 (v/v) CH.sub.2Cl.sub.2:EtOH.fwdarw.85:15 (v/v)
CH.sub.2Cl.sub.2:EtOH) afforded the title compound.
Step 2:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]-1-oxidopyri-
din-4-yl]methyl}propanamide
[0651] To a CH.sub.2Cl.sub.2 solution (0.04 M) of tert-butyl
(3-[cyclopropyl({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]-1-oxid-
opyridin-4-yl]methyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]b-
enzyl}-3-oxopropyl)carbamate from the previous step (1 eq.) was
added HCl (4.0 M dioxane solution, 20 eq.). The resulting solution
was stirred at RT for 1 h and the volatiles were removed in vacuo.
Purification of the crude product thus obtained by way of column
chromatography (SiO.sub.2, 95:5 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH.fwdarw.90:10 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH) afforded the title compound as an oil. MS (ESI+):
752.
Example 103
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-{[2-(3-methoxypropyl)-6-(2-morpholin-4-ylethoxy)pyridin-4-yl]methyl}pro-
panamide
##STR00187##
[0653] Prepared according to the procedure described in Example 9
but using instead Amine 45 as starting material. The title compound
was obtained as a pale yellow oil. MS (ESI+): 729.2.
Example 104
3-Amino-N-[3-(2-amino-2-oxoethoxy)-5-(3-methoxypropyl)benzyl]-N-cyclopropy-
l-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanamide
##STR00188##
[0655] Prepared according to the procedure described in Example 71
but using instead 2-bromoacetamide as starting material. The title
compound was obtained as an off-white solid. MS (ESI+): 672.
Example 105
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoyl-
)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
ethylcarbamate
##STR00189##
[0656] Step 1:
3-{[(3-[(tert-Butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}propanoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phe-
nyl ethylcarbamate
[0657] To a solution of tert-butyl
(3-{cyclopropyl[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Example 70, Step 2 (1 eq.) in dichloromethane (0.08 M) was
added ethyl isocyanate (3 eq.), triethylamine (3 eq.) and a few
crystals of DMAP. The resulting solution was stirred at RT for 1.5
h. The reaction mixture was concentrated in vacuo and directly
subjected to purification by way of column chromatography
(SiO.sub.2, 3:2 (v/v) Hex:EtOAc.fwdarw.2:3 (v/v) Hex:EtOAc). The
title compound was isolated as a colorless oil.
Step 2:
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}p-
ropanoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
ethylcarbamate
[0658] To a CH.sub.2Cl.sub.2 solution (0.07 M) of
3-{[(3-[(tert-butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}propanoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phe-
nyl ethylcarbamate from the previous step (1 eq.) was added HCl
(4.0 M dioxane solution, 35 eq.). The resulting solution was
stirred at RT for 3 h. Following the removal of the volatiles in
vacuo, the resulting residue was directly subjected to column
chromatography (SiO.sub.2, 94:6 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH) to afford the title compound. MS (ESI+): 686.
Example 106
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoyl-
)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
morpholine-4-carboxylate
##STR00190##
[0660] Prepared according to the procedure described in Example 105
but using instead morpholine-4-carbonyl chloride as starting
material. The title compound was obtained as colorless oil. MS
(APCI+): 728.
Example 107
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoyl-
)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)pheny
4-methylpiperazine-1-carboxylate
##STR00191##
[0662] Prepared according to the procedure described in Example 105
but using instead 4-methylpiperazine-1-carbonyl chloride as
starting material. The title compound was obtained as colorless
oil. MS (APCI+): 741.
Example 108
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoyl-
)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
(3-amino-2,2-dimethyl-3-oxopropyl)carbamate
##STR00192##
[0663] Step 1:
3-{[(3-[(tert-Butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}propanoyl)(cyclopropyl)amino]methyl]-5-(3-methoxypropyl)phe-
nyl (3-amino-2,2-dimethyl-3-oxopropyl)carbamate
[0664] To a solution of tert-butyl
(3-{cyclopropyl[3-hydroxy-5-(3-methoxypropyl)benzyl](cyclopropyl)amino}-2-
-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
from Example 70, Step 2 (1 eq.) in dichloromethane (0.13 M) was
added triphosgene (0.3 eq.) and then sodium hydroxide (1 M aq.
solution, 3 eq.). The resulting mixture was stirred at RT for 2 h.
The reaction was quenched with brine. The organic phase was
separated and then added 3-amino-2,2-dimethylpropanamide (4 eq.).
The resulting suspension was allowed to stir at RT for 16 h. The
reaction was quenched with water and then extracted with EtOAc. The
combined organic extracts were washed with brine, dried over
MgSO.sub.4, filtered, and the filtrate concentrated in vacuo. The
crude product thus obtained was purified further by way of column
chromatography (SiO.sub.2, 1:1 (v/v) Hex:EtOAc.fwdarw.EtOAc) to
afford the title compound as a colorless oil.
Step 2:
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}p-
ropanoyl)(cyclopropyl) amino]methyl}-5-(3-methoxypropyl)phenyl
(3-amino-2,2-dimethyl-3-oxopropyl)carbamate
[0665] To a CH.sub.2Cl.sub.2 solution (0.07 M) of
3-{[(3-[(tert-butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}propanoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phe-
nyl ethylcarbamate from the previous step (1 eq.) was added HCl
(4.0 M dioxane solution, 35 eq.). The resulting solution was
stirred at RT for 3 h. Following the removal of the volatiles in
vacuo, the resulting residue was directly subjected to column
chromatography (SiO.sub.2, 95:5 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH.fwdarw.90:10 (v/v) CH.sub.2Cl.sub.2: 2.0 M
NH.sub.3 in MeOH) to afford the title compound as a white solid. MS
(ESI+): 757.
Example 109
3-{[(3-Amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoyl-
)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl
(2-hydroxypropyl)carbamate
##STR00193##
[0667] Prepared according to the procedure described in Example 108
but using instead 1-aminopropan-2-ol as starting material. The
title compound was obtained as colorless oil. MS (ESI+): 716.
Example 110
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-(pyridin-4-ylmethyl)propanamide
##STR00194##
[0668] Step 1: tert-Butyl
(3-[cyclopropyl(pyridin-4-ylmethyl)amino]-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
[0669]
3-[tert-Butoxycarbonyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy-
)ethoxy]benzyl}propanoic acid from Example 9, Step 3 (1 eq.) was
combined with 1-hydroxybenzotriazole hydrate (1.5 eq.) and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide HCl salt (1.5 eq.)
in chloroform (0.08 M). To this yellow solution was then added
Amine 46 (4 eq.) and triethylamine (1.5 eq.). The resulting brown
solution was stirred at RT for 48 h. The reaction solution was
diluted with EtOAc and washed with H.sub.2O. The aqueous washes
were back extracted with EtOAc. The combined organic extracts were
washed with brine, dried over MgSO.sub.4, filtered and the filtrate
concentrated in vacuo. Purification of the crude product thus
obtained by way of flash chromatography (SiO.sub.2, 2:3 (v/v)
Hex:EtOAc.fwdarw.EtOAc) afforded the title compound.
Step 1:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-(pyridin-4-ylmethyl)propanamide
[0670] To a CH.sub.2Cl.sub.2 solution (0.09 M) of tert-butyl
(3-[cyclopropyl(pyridin-4-ylmethyl)amino]-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from the previous step
(1 eq.) was added HCl (4.0 M dioxane solution, 46 eq.). The
resulting solution was stirred at RT for 5 h. The reaction was
quenched with 2.0 M NH.sub.3 in MeOH and concentrated in vacuo. The
resulting residue was directly loaded onto a SiO.sub.2 column
packed with 90:9:1 (v/v) CH.sub.2Cl.sub.2:MeOH:conc. NH.sub.4OH.
Elution with the same solvent system furnished the title compound.
MS (ESI+): 527.9.
Example 111
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-(pyridin-3-ylmethyl)propanamide
##STR00195##
[0672] Prepared according to the procedure described in Example 110
but using instead Amine 47 as starting material. The title compound
was obtained as colorless oil. MS (ESI+): 527.9.
Example 112
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-(pyridin-2-ylmethyl)propanamide
##STR00196##
[0674] Prepared according to the procedure described in Example 110
but using instead Amine 48 as starting material. The title compound
was obtained as colorless oil. MS (ESI+): 527.9.
Example 113
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[(1-oxidopyridin-4-yl)methyl]propanamide
##STR00197##
[0675] Step 1:
tert-Butyl(3-{cyclopropyl[(1-oxidopyridin-4-yl)methyl]amino}-2-{4-[2-(2,6-
-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate
[0676] To a solution of tert-butyl
(3-[cyclopropyl(pyridin-4-ylmethyl)amino]-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from Example 110, Step
1 (1 eq.) in dichloromethane (0.12 M) was added
3-chloroperoxybenzoic acid (1.3 eq.). The reaction mixture was
stirred at RT for 1.5 h. The reaction was then quenched with 10%
aq. Na.sub.2S.sub.2O.sub.3 and sat. aq. NaHCO.sub.3. The organic
layer was separated and the aqueous layer were back extracted with
ether. The combined organic extracts were washed with water, dried
over Na.sub.2SO.sub.4, filtered and the filtrate concentrated in
vacuo. Purification of the crude product thus obtained by way of
flash chromatography (SiO.sub.2, EtOAc.fwdarw.4:1 (v/v) EtOAc:MeOH)
afforded the title compound.
Step 1:
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy-
]benzyl}-N-[(1-oxidopyridin-4-yl)methyl]propanamide
[0677] To a CH.sub.2Cl.sub.2 solution (0.1 M) tert-butyl
(3-{cyclopropyl[(1-oxidopyridin-4-yl)methyl]amino}-2-{4-[2-(2,6-dichloro--
4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from the
previous step (1 eq.) was added HCl (4.0 M dioxane solution, 40
eq.). The resulting solution was stirred at RT for 5 h. The
reaction was quenched with 2.0 M NH.sub.3 in MeOH and concentrated
in vacuo. The resulting residue was directly loaded onto a
SiO.sub.2 column packed with 86:13:1 (v/v)
CH.sub.2Cl.sub.2:MeOH:conc. NH.sub.4OH. Elution with the same
solvent system furnished the title compound. MS (ESI+): 543.9.
Example 114
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[(1-oxidopyridin-3-yl)methyl]propanamide
##STR00198##
[0679] Prepared according to the procedure described in Example 113
but using instead tert-butyl
(3-[cyclopropyl(pyridin-3-ylmethyl)amino]-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from Example 111, Step
1 as starting material. The title compound was obtained as
colorless oil. MS (ESI+): 543.9.
Example 115
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[(1-oxidopyridin-2-yl)methyl]propanamide
##STR00199##
[0681] Prepared according to the procedure described in Example 113
but using instead tert-butyl
(3-[cyclopropyl(pyridin-2-ylmethyl)amino]-2-{4-[2-(2,6-dichloro-4-methylp-
henoxy)ethoxy]benzyl}-3-oxopropyl)carbamate from Example 112, Step
1 as starting material. The title compound was obtained as
colorless oil. MS (ESI+): 543.9.
Example 116
Ethyl
3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}pro-
panoyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)acetate
##STR00200##
[0683] Prepared according to the procedure described in Example 9
but using instead Amine 49 as starting material. The title compound
was obtained as colorless oil. MS (ESI+): 708.9.
Example 117
Ethyl
3-(3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
propanoyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)propanoate
##STR00201##
[0685] Prepared according to the procedure described in Example 9
but using instead Amine 50 as starting material. The title compound
was obtained as colorless oil. MS (ESI+): 722.9.
Example 118
Ethyl
5-(3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
propanoyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)pentanoate
##STR00202##
[0687] Prepared according to the procedure described in Example 9
but using instead Amine 51 as starting material. The title compound
was obtained as colorless oil. MS (ESI+): 750.9.
Example 119
Sodium
3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}pr-
opanoyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)acetate
##STR00203##
[0689] Prepared according to the procedure described in Example 87
but using instead ethyl
(3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propano-
yl)(cyclopropyl)amino]methyl}-2-bromophenoxy)acetate from Example
116 as starting material. The title compound was obtained as
colorless oil. MS for the corresponding free acid (ESI+):
681.3.
Example 120
Sodium
5-(3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl-
}propanoyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)pentanoate
##STR00204##
[0691] Prepared according to the procedure described in Example 87
but using instead ethyl
3-(3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propa-
noyl)(cyclopropyl)amino]methyl}-2-bromophenoxy)pentanoate from
Example 118 as starting material. The title compound was obtained
as colorless oil. MS (ESI+): 723.2.
Example 121
3-Amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-
-N-[3-(3-methoxypropyl)-5-(2-morpholin-4-yl-2-oxoethoxy)benzyl]propanamide
##STR00205##
[0693] Prepared according to the procedure described in Example 71
but using instead 4-(chloroacetyl)morpholine as starting material.
The title compound was obtained as an off-white solid. MS (ESI+):
742.3.
Example 122
2-{4-[2-(4-Allyl-2,6-dichlorophenoxy)ethoxy]benzyl}-3-amino-N-[2-chloro-5--
(3-methoxypropyl)benzyl]-N-cyclopropanamide
##STR00206##
[0694] Step 1: Ethyl
2-cyano-3-[4-(hydroxyethoxy)phenyl]acrylate
[0695] Ethyl cyanoacetate (1.1 eq.) and
4-(2-hydroxyethoxy)benzaldehyde (1 eq.) were combined in ethanol
(1.2 M). The reaction mixture was stirred at RT for 48. To this was
then added an equal volume of hexane and the title compound was
isolated by filtration as a pale yellow solid.
Step 2: Ethyl
3-[(tert-butoxycarbonyl)amino]-2-[4-(2-hydroxyethoxy)benzyl]propanoate
[0696] Ethyl 2-cyano-3-[4-(hydroxyethoxy)phenyl]acrylate was
combined with di-tert-butyl dicarbonate (1.2 eq.) and platinum(IV)
oxide (20% loading) were combined in EtOH (0.18 M). The resulting
suspension was shaken on a Parr apparatus under 50 psi of hydrogen
gas for one week. The mixture was diluted with dichloromethane and
filtered through a bed of celite. The filtrate was concentrated in
vacuo to afford a viscous pale yellow oil.
Step 3:
3-[(tert-Butoxycarbonyl)amino]-2-[4-(2-hydroxyethoxy)benzyl]propan-
oic acid
[0697] To a 5:3 (v/v) solution of EtOH and THF (0.2 M) of ethyl
3-[(tert-butoxy
carbonyl)amino]-2-[4-(2-hydroxyethoxy)benzyl]propanoate from the
previous step (1 eq.) was added LiOH (1 M aqueous solution, 2 eq.).
The resulting mixture was stirred at RT for 48 h. Following the
removal of the volatiles in vacuo, the resulting residue was
partitioned between ether and 1 N aq. NaOH. The aqueous layer was
separated and washed further with ether. The aqueous layer was then
acidified to pH .about.2 with conc. HCl and the resulting
suspension extracted with dichloromethane. The combined
dichloromethane extracts was concentrated in vacuo. The crude
product thus obtained was recrystallized from EtOAc-hexane to
afford the title compound as a white solid.
Step 4: tert-Butyl
{(3-{[2-chloro-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]-2-[4-(2-hydr-
oxyethoxy)benzyl]-3-oxopropyl)carbamate
[0698]
3-[(tert-Butoxycarbonyl)amino]-2-[4-(2-hydroxyethoxy)benzyl]propano-
ic acid from the previous step (1 eq.) was combined with Hunig's
base (3 eq.) and Amine 6 (1 eq.) in anhydrous DMF (0.7 M). To this
was then added portionwise
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (1.2 eq.). The resulting yellow solution was
stirred at RT for 18 h. The reaction solution was diluted with
ether and washed with water. The aqueous washes were back extracted
with ether. The combined organic extracts were washed with brine,
dried over MgSO.sub.4, filtered and the filtrate concentrated in
vacuo. Purification of the crude product thus obtained by way of
flash chromatography (SiO.sub.2, 5:1 (v/v) Hex:EtOAc.fwdarw.EtOAc)
afforded the title compound pale yellow oil.
Step 5: tert-Butyl
{2-{4-[2-(4-allyl-2,6-dichlorophenoxy)ethoxy]benzyl}-3-{[2-chloro-5-(3-me-
thoxypropyl)benzyl](cyclopropyl)amino}-3-oxopropyl)carbamate
[0699] To a solution of 2,6-dichlorophenol (1.2 eq.) in acetone
(1.4 M) was added allyl bromide (1.2 eq.) and potassium carbonate
(1.4 eq). The resulting suspension was heated to reflux for 4 h.
The insolubles were removed via filtration and the filtrate was
concentrated in vacuo. The resulting residue was heated at
160.degree. C. for 17 h. This was then taken up in toluene (0.13 M)
and added tert-butyl
{(3-[[2-chloro-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]-2-[4-(2-hydr-
oxyethoxy)benzyl]-3-oxopropyl)carbamate from the previous step (1
eq.) and 1,1'-(azodicarbonyl)dipiperidine (1.2 eq.). The resulting
reaction mixture was deoxygenated and then added tributylphosphine
(3 eq.). After 3 h of heating at 80.degree. C., the reaction was
quenched with 1 N NaOH and diluted with EtOAc. The aqueous layer
was separated and back extracted with EtOAc. The combined organic
extracts were washed further with 1 N aq. HCl, water and brine,
dried over Na.sub.2SO.sub.4 and filtered. Concentration of the
filtrate in vacuo afforded a brown oil that, following flash
chromatography (SiO.sub.2, 5:1 (v/v) Hex:EtOAc.fwdarw.1:1 (v/v)
Hex:EtOAc), revealed the title compound as a pale yellow oil.
Step 6:
2-{4-[2-(4-Allyl-2,6-dichlorophenoxy)ethoxy]benzyl}-3-amino-N-[2-c-
hloro-5-(3-methoxypropyl)benzyl]-N-cyclopropanamide
[0700] To a CH.sub.2Cl.sub.2 solution (0.1 M) of tert-butyl
{2-{4-[2-(4-allyl-2,6-dichlorophenoxy)ethoxy]benzyl}-3-[[2-chloro-5-(3-me-
thoxypropyl)benzyl](cyclopropyl)amino]-3-oxopropyl)carbamate from
the previous step (1 eq.) was added HCl (4.0 M dioxane solution, 35
eq.). The resulting solution was stirred at RT for 4 h. Removal of
the volatiles in vacuo afforded the title compound. MS (ESI+):
661.8.
Example 123
3-Amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2-(4-{2-[2,6--
dichloro-4-(3-hydroxypropyl)phenoxy]ethoxy}benzyl}propanamide
##STR00207##
[0701] Step 1:
tert-Butyl[3-{[2-chloro-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]-2-(-
4-{2-[2,6-dichloro-4-(3-hydroxypropyl)phenoxy]ethoxy}benzyl]-3-oxopropyl]c-
arbamate
[0702] To a THF solution (0.04 M) of tert-butyl
{2-{4-[2-(4-allyl-2,6-dichlorophenoxy)ethoxy]benzyl}-3-[[2-chloro-5-(3-me-
thoxypropyl)benzyl](cyclopropyl)amino]-3-oxopropyl)carbamate from
Example 122, Step 5 (1 eq.) was added 9-borabicyclo[3.3.1]nonane
(0.5 M THF solution, 2.6 eq.) dropwise at 0.degree. C. The
resulting solution was warmed slowly to RT over 16 h. The reaction
was quenched at 0.degree. C. with the dropwise addition of ethanol.
Then, NaOH (1 N aqueous solution, 4 eq.) and H.sub.2O.sub.2 (30%
w/w aqueous solution, 12 eq.) were added. After 1 h of stirring at
0.degree. C. and another 4 h of stirring at RT, the reaction
mixture was diluted with EtOAc. The organic layer was separated,
washed with water, dried over Na.sub.2SO.sub.4 and filtered.
Concentration of the filtrate in vacuo and purification of the
crude product thus obtained by way of flash chromatography
(SiO.sub.2, 3:1 (v/v) Hex:EtOAc.fwdarw.EtOAc), revealed the title
compound.
Step 2:
3-Amino-N-[2-chloro-5-(3-methoxypropyl)benzyl]-N-cyclopropyl-2-(4--
{2-[2,6-dichloro-4-(3-hydroxypropyl)phenoxy]ethoxy}benzyl]propanamide
[0703] To a CH.sub.2Cl.sub.2 solution (0.1 M) of
tert-butyl[3-[[2-chloro-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]-2-(-
4-{2-[2,6-dichloro-4-(3-hydroxypropyl)phenoxy]ethoxy 1
benzyl}-3-oxopropyl]carbamate from the previous step (1 eq.) was
added HCl (4.0 M dioxane solution, 35 eq.). The resulting solution
was stirred at RT for 4 h. The reaction was quenched with 2.0 M
NH.sub.3 in MeOH and concentrated in vacuo. The resulting residue
was directly loaded onto a SiO.sub.2 column packed with 90:9:1
(v/v) CH.sub.2Cl.sub.2:MeOH:conc. NH.sub.4OH. Elution with the same
solvent system furnished the title compound. MS (ESI+): 677.2.
* * * * *